Screening & Prevention — MCQs

Q: A 66-year-old man attends after receiving an NHS AAA screening result showing an infrarenal aortic diameter of 4.8 cm. He is asymptomatic. He smokes 15 cigarettes daily, has hypertension treated with ramipril, and his BP is 138/82 mmHg. What is the most appropriate surveillance and management plan?

Repeat ultrasound in 3 months and refer to vascular surgery. ***Repeat ultrasound in 3 months and refer to vascular surgery***- Aneurysms between **4.5 cm and 5.4 cm** are classified as medium-sized and require **3-monthly ultrasound surveillance** according to NICE and NHS guidelines.- Patients with a medium AAA must be **referred to vascular surgery** for assessment, risk factor management, and to establish a pathway if the aneurysm reaches the surgical threshold.*Repeat ultrasound in 12 months and reinforce smoking cessation*- **Annual surveillance** is only indicated for small aneurysms measuring between **3.0 cm and 4.4 cm**.- While **smoking cessation** is vital for all AAA patients, 12-month monitoring is insufficient for a 4.8 cm aneurysm.*Immediate referral to vascular surgery for consideration of intervention*- Surgical intervention is generally only considered when the aneurysm is **asymptomatic and ">=5.5 cm"**, or if there is rapid growth ( ">1 cm per year" ).- This patient is **asymptomatic** and measures 4.8 cm, meaning the risks of elective surgery currently outweigh the risk of rupture.*Repeat ultrasound in 6 months and optimize cardiovascular risk factors*- **6-monthly surveillance** is not a standard interval in the UK AAA screening program; intervals are either 12 months (small) or 3 months (medium).- While **blood pressure control** (target " =5.5 cm" ) has been made.- **Urgent referral** (within 2 weeks) is required for large aneurysms ( ">=5.5 cm" ), whereas a medium-sized aneurysm follows a standard referral pathway.

Q: A 46-year-old man attends for cardiovascular risk assessment. He drinks 6 pints of beer (4.5% ABV) on Friday and Saturday nights. He works in construction and is physically active. BMI is 27 kg/m², BP 134/84 mmHg. He asks about reducing his drinking. According to current UK Chief Medical Officers' guidelines, how many units of alcohol does he consume weekly?

30.6 units. ***30.6 units***- Alcohol units are calculated using the formula: **Volume (ml) × ABV (%) / 1000**. One UK pint is **568 ml**, making one 4.5% ABV beer equal to **2.556 units**.- The patient consumes 12 pints per week (6 on Friday and 6 on Saturday), so total consumption is **12 × 2.556 = 30.672 units**, which is significantly above the **UK Chief Medical Officers' low-risk limit of 14 units** weekly.*14 units*- This represents the **maximum recommended weekly limit** for both men and women in the UK to keep health risks low.- While a target for reduction for this patient, it does not reflect his current actual intake of **12 pints** per week.*24 units*- This value would imply that each pint contains exactly **2 units**, which is not accurate for a 4.5% ABV beer.- A pint of 4.5% ABV beer is actually **2.556 units**, making 12 pints total **30.6 units**.*36 units*- This figure would suggest an incorrect calculation where each pint is assumed to be **3 units**, which is typically associated with stronger beers (around 5.3% ABV).- Using the precise **4.5% ABV** given, the correct calculation yields **30.6 units**.*42 units*- This value would result from assuming approximately **3.5 units per pint**, which is characteristic of much stronger lagers or ciders (around 6% ABV).- The accurate calculation based on the specified **4.5% ABV** confirms the patient's intake is **30.6 units**.

A 43-year-old woman presents asking about strategies to reduce her breast cancer risk. Her mother was diagnosed with breast cancer at age 48 and her maternal aunt at age 52. She has no personal history of breast disease. Clinical examination is normal. She takes the combined oral contraceptive pill and drinks 10 units of alcohol weekly. Her BMI is 26 kg/m². After appropriate genetic assessment, she is found not to carry BRCA mutations. Which lifestyle modification would provide the greatest reduction in her breast cancer risk?

A 66-year-old man attends after receiving an NHS AAA screening result showing an infrarenal aortic diameter of 4.8 cm. He is asymptomatic. He smokes 15 cigarettes daily, has hypertension treated with ramipril, and his BP is 138/82 mmHg. What is the most appropriate surveillance and management plan?

A 55-year-old woman with a BMI of 32 kg/m² attends for weight management support. She has tried multiple diets without sustained success. She has no other medical conditions. She asks about pharmacological options for weight loss. According to NICE guidance, what is the threshold for considering orlistat in this patient?

A 71-year-old woman with type 2 diabetes for 18 years attends for review. Her diabetic eye screening report from 2 weeks ago shows 'proliferative diabetic retinopathy with new vessels at disc in left eye'. She reports no visual symptoms. Her HbA1c is 72 mmol/mol, BP 156/88 mmHg. She has not yet received any ophthalmology appointment. What is the most appropriate action?

A 29-year-old woman attends for preconception counselling. She is planning pregnancy with her partner. She had one previous pregnancy 3 years ago with uncomplicated vaginal delivery. She takes no regular medications and has no chronic conditions. Which of the following screening tests should be offered before conception?

A 46-year-old man attends for cardiovascular risk assessment. He drinks 6 pints of beer (4.5% ABV) on Friday and Saturday nights. He works in construction and is physically active. BMI is 27 kg/m², BP 134/84 mmHg. He asks about reducing his drinking. According to current UK Chief Medical Officers' guidelines, how many units of alcohol does he consume weekly?

A 31-year-old woman attends with her cervical screening result showing hrHPV positive with low-grade dyskaryosis. She is 8 weeks pregnant with her second child. She had a normal screening result 3 years ago. What is the most appropriate management?

A 64-year-old man returns for discussion of his NHS bowel cancer screening result. His FIT result is 78 µg Hb/g faeces. He has no symptoms, no family history of colorectal cancer, and examination is unremarkable. He takes aspirin 75 mg daily for previous myocardial infarction. What is the most appropriate management?

A 58-year-old woman attends for NHS Health Check. She has a BMI of 28 kg/m², BP 128/82 mmHg, and smokes 10 cigarettes daily. Bloods show total cholesterol 5.2 mmol/L, HDL 1.4 mmol/L, HbA1c 39 mmol/mol. Her QRISK3 score is 8.5%. She is motivated to improve her health. What is the most evidence-based lifestyle intervention to offer?

Q10

A 67-year-old man with type 2 diabetes for 15 years attends for review. His diabetic retinopathy screening report shows 'moderate non-proliferative diabetic retinopathy with diabetic maculopathy' in both eyes. His HbA1c is 68 mmol/mol and BP 142/86 mmHg. What is the most appropriate action regarding his eye care?

Screening & Prevention UK Medical PG Practice Questions and MCQs

Question 1: A 43-year-old woman presents asking about strategies to reduce her breast cancer risk. Her mother was diagnosed with breast cancer at age 48 and her maternal aunt at age 52. She has no personal history of breast disease. Clinical examination is normal. She takes the combined oral contraceptive pill and drinks 10 units of alcohol weekly. Her BMI is 26 kg/m². After appropriate genetic assessment, she is found not to carry BRCA mutations. Which lifestyle modification would provide the greatest reduction in her breast cancer risk?

A. Stopping the combined oral contraceptive pill
B. Reducing alcohol intake to below 5 units per week (Correct Answer)
C. Achieving and maintaining BMI <25 kg/m² through weight loss
D. Undertaking regular vigorous physical activity 150 minutes weekly
E. Adopting a plant-based Mediterranean diet low in processed foods

Explanation: ***Reducing alcohol intake to below 5 units per week*** - There is a well-established **dose-response relationship** between alcohol consumption and breast cancer risk, where each unit consumed per day increases risk by approximately **7-10%**. - Reducing consumption from 10 units to below 5 units per week represents a significant risk reduction that is more impactful than other lifestyle changes in a **pre-menopausal** woman with a modest BMI and moderate alcohol intake. *Stopping the combined oral contraceptive pill* - While the **combined oral contraceptive pill (COCP)** is associated with a small relative risk increase (RR ~1.2), this risk is transient and **returns to baseline** 10 years after cessation. - The absolute risk reduction from stopping the pill in a 43-year-old is generally lower than that achieved through significant **alcohol modification**. *Achieving and maintaining BMI <25 kg/m² through weight loss* - Elevated **BMI** is primarily a significant risk factor for **post-menopausal** breast cancer due to peripheral aromatization of androgens in adipose tissue. - In **pre-menopausal** women like this patient, the association between obesity and breast cancer is less pronounced, and her current BMI of 26 kg/m² is only **borderline overweight**. *Undertaking regular vigorous physical activity 150 minutes weekly* - **Physical activity** provides a modest reduction in risk (approx. 10-20%), largely mediated through secondary effects like **weight management** and hormonal regulation. - While beneficial for overall health, the magnitude of specific breast cancer risk reduction is typically less than that achieved by **halving alcohol intake**. *Adopting a plant-based Mediterranean diet low in processed foods* - Although a **Mediterranean diet** is associated with lower overall cancer mortality and improved cardiovascular health, its specific impact on breast cancer risk is less clinically proven than **alcohol restriction**. - Dietary changes are often recommended as part of a holistic approach but do not show the same **linear correlation** with risk reduction as limiting alcohol.

Question 2: A 66-year-old man attends after receiving an NHS AAA screening result showing an infrarenal aortic diameter of 4.8 cm. He is asymptomatic. He smokes 15 cigarettes daily, has hypertension treated with ramipril, and his BP is 138/82 mmHg. What is the most appropriate surveillance and management plan?

A. Repeat ultrasound in 12 months and reinforce smoking cessation
B. Repeat ultrasound in 3 months and refer to vascular surgery (Correct Answer)
C. Immediate referral to vascular surgery for consideration of intervention
D. Repeat ultrasound in 6 months and optimize cardiovascular risk factors
E. CT angiography for surgical planning and urgent vascular referral

Explanation: ***Repeat ultrasound in 3 months and refer to vascular surgery***- Aneurysms between **4.5 cm and 5.4 cm** are classified as medium-sized and require **3-monthly ultrasound surveillance** according to NICE and NHS guidelines.- Patients with a medium AAA must be **referred to vascular surgery** for assessment, risk factor management, and to establish a pathway if the aneurysm reaches the surgical threshold.*Repeat ultrasound in 12 months and reinforce smoking cessation*- **Annual surveillance** is only indicated for small aneurysms measuring between **3.0 cm and 4.4 cm**.- While **smoking cessation** is vital for all AAA patients, 12-month monitoring is insufficient for a 4.8 cm aneurysm.*Immediate referral to vascular surgery for consideration of intervention*- Surgical intervention is generally only considered when the aneurysm is **asymptomatic and ">=5.5 cm"**, or if there is rapid growth ( ">1 cm per year" ).- This patient is **asymptomatic** and measures 4.8 cm, meaning the risks of elective surgery currently outweigh the risk of rupture.*Repeat ultrasound in 6 months and optimize cardiovascular risk factors*- **6-monthly surveillance** is not a standard interval in the UK AAA screening program; intervals are either 12 months (small) or 3 months (medium).- While **blood pressure control** (target "<140/90 mmHg" ) and statins are necessary, the monitoring timeline here is clinically inappropriate for the aneurysm size.*CT angiography for surgical planning and urgent vascular referral*- **CT angiography** is reserved for pre-operative planning once the decision to intervene (threshold ">=5.5 cm" ) has been made.- **Urgent referral** (within 2 weeks) is required for large aneurysms ( ">=5.5 cm" ), whereas a medium-sized aneurysm follows a standard referral pathway.

Question 3: A 55-year-old woman with a BMI of 32 kg/m² attends for weight management support. She has tried multiple diets without sustained success. She has no other medical conditions. She asks about pharmacological options for weight loss. According to NICE guidance, what is the threshold for considering orlistat in this patient?

A. BMI ≥25 kg/m² with commitment to dietary changes
B. BMI ≥28 kg/m² with obesity-related comorbidities
C. BMI ≥30 kg/m² with commitment to dietary and lifestyle changes (Correct Answer)
D. BMI ≥32 kg/m² after failed conservative management
E. BMI ≥35 kg/m² or BMI ≥30 kg/m² with comorbidities

Explanation: ***BMI ≥30 kg/m² with commitment to dietary and lifestyle changes*** - According to **NICE guidelines**, orlistat is indicated for adults with a **BMI of 30 kg/m² or more** as a primary threshold, even in the absence of comorbidities. - The prescription of orlistat must always be part of a comprehensive weight management program that includes **dietary modification**, increased physical activity, and **behavioral support**. *BMI ≥25 kg/m² with commitment to dietary changes* - A **BMI of 25 kg/m²** signifies **overweight**, for which pharmacological interventions like orlistat are not typically recommended by NICE. - Management at this stage primarily focuses on **lifestyle modifications**, including diet and exercise, without drug therapy. *BMI ≥28 kg/m² with obesity-related comorbidities* - Orlistat can be considered at a **BMI of 28 kg/m² or more** but specifically requires the presence of **obesity-related comorbidities**, such as type 2 diabetes or hypertension. - The patient in this scenario has **no other medical conditions**, meaning this specific threshold does not apply to her. *BMI ≥32 kg/m² after failed conservative management* - While the patient's BMI is 32 kg/m², this specific value is not the **minimum NICE threshold** for initiating orlistat, which is **BMI ≥30 kg/m²**. - Adhering to the established guidelines ensures appropriate and timely access to pharmacological support for eligible individuals. *BMI ≥35 kg/m² or BMI ≥30 kg/m² with comorbidities* - This threshold is generally more aligned with the criteria for referral to **bariatric surgery** rather than the initial prescription of orlistat. - Applying this higher criterion would unnecessarily delay pharmacological intervention for patients who meet the lower, more appropriate threshold for orlistat.

Question 4: A 71-year-old woman with type 2 diabetes for 18 years attends for review. Her diabetic eye screening report from 2 weeks ago shows 'proliferative diabetic retinopathy with new vessels at disc in left eye'. She reports no visual symptoms. Her HbA1c is 72 mmol/mol, BP 156/88 mmHg. She has not yet received any ophthalmology appointment. What is the most appropriate action?

A. Contact ophthalmology to confirm urgent referral has been received and processed (Correct Answer)
B. Reassure that ophthalmology will contact her within 2 weeks of screening report
C. Arrange repeat diabetic eye screening in 3 months to monitor progression
D. Refer urgently to ophthalmology via GP pathway in case screening referral was missed
E. Optimize glycaemic and blood pressure control and wait for screening programme referral

Explanation: ***Contact ophthalmology to confirm urgent referral has been received and processed***- **Proliferative diabetic retinopathy (PDR)** with **new vessels at the disc (NVD)** is a sight-threatening condition that requires an **urgent referral** and treatment within **2 weeks**.- Since the patient has not received an appointment after 2 weeks, active verification is necessary to prevent **permanent vision loss** due to potential administrative or system failures.*Reassure that ophthalmology will contact her within 2 weeks of screening report*- Passive reassurance is unsafe because the **2-week target** for assessment has already been reached without the patient being contacted.- Relying solely on the screening program's automation may lead to delays in treating high-risk **neovascularization**.*Arrange repeat diabetic eye screening in 3 months to monitor progression*- Repeat screening is contraindicated once **referable retinopathy** is identified; the screening process has already served its purpose of detection.- Delayed treatment of PDR increases the risk of **vitreous hemorrhage** and **tractional retinal detachment**.*Refer urgently to ophthalmology via GP pathway in case screening referral was missed*- Sending a duplicate referral via the GP pathway can cause **administrative confusion** and may not be as direct as contacting the department regarding the existing screening referral.- The priority is to confirm the status of the **integrated screening-to-treatment pathway** specifically designed for these cases.*Optimize glycaemic and blood pressure control and wait for screening programme referral*- While **HbA1c** and **blood pressure optimization** are vital for long-term management, they do not replace the need for immediate **panretinal photocoagulation** or other specialist interventions.- Waiting indefinitely for a system-triggered referral when a critical deadline has passed places the patient at significant risk of **sudden blindness**.

Question 5: A 29-year-old woman attends for preconception counselling. She is planning pregnancy with her partner. She had one previous pregnancy 3 years ago with uncomplicated vaginal delivery. She takes no regular medications and has no chronic conditions. Which of the following screening tests should be offered before conception?

A. Rubella immunity only, as other infections are tested in pregnancy (Correct Answer)
B. No infectious disease screening needed as she had testing in previous pregnancy
C. Rubella immunity, HIV, hepatitis B, and syphilis serology
D. Full sexually transmitted infection screen including chlamydia and gonorrhoea
E. HIV and syphilis testing only if high-risk factors identified

Explanation: ***Rubella immunity only, as other infections are tested in pregnancy*** - Identifying **rubella immunity status** preconception is vital because the **MMR vaccine** is a live vaccine and cannot be administered during pregnancy due to potential teratogenic risks. - Routine screening for HIV, hepatitis B, and syphilis is standard practice at the **antenatal booking appointment** (usually in the first trimester), rather than preconception, as infection status can change. *No infectious disease screening needed as she had testing in previous pregnancy* - **Immunity** or **infection status** can change over time; for instance, rubella immunity can wane, and new exposures to other pathogens may have occurred since the last delivery. - National guidelines recommend reassessment of **vaccination history** and immunity for every planned pregnancy to ensure optimal fetal protection. *Rubella immunity, HIV, hepatitis B, and syphilis serology* - While all are important, testing for HIV, hepatitis B, and syphilis is specifically timed for the **first trimester** to align with established antenatal management pathways and optimize timing for interventions. - Universal preconception screening for all these infections is not typically recommended unless specific **clinical risk factors** are identified during the consultation, whereas rubella is universally recommended. *Full sexually transmitted infection screen including chlamydia and gonorrhoea* - Broad STI screening for **chlamydia and gonorrhoea** is not a universal preconception requirement for asymptomatic women in low-risk groups, as this patient appears to be. - These tests are generally reserved for patients presenting with **symptoms** or those with a high-risk sexual history, rather than being part of routine preconception screening. *HIV and syphilis testing only if high-risk factors identified* - This option incorrectly omits **rubella screening**, which is the primary infectious disease intervention universally recommended for all women seeking preconception care. - Regardless of identified high-risk factors, HIV and syphilis are still offered to all pregnant women as part of the **routine antenatal screening program** once pregnancy is confirmed.

Question 6: A 46-year-old man attends for cardiovascular risk assessment. He drinks 6 pints of beer (4.5% ABV) on Friday and Saturday nights. He works in construction and is physically active. BMI is 27 kg/m², BP 134/84 mmHg. He asks about reducing his drinking. According to current UK Chief Medical Officers' guidelines, how many units of alcohol does he consume weekly?

A. 14 units
B. 24 units
C. 30.6 units (Correct Answer)
D. 36 units
E. 42 units

Explanation: ***30.6 units***- Alcohol units are calculated using the formula: **Volume (ml) × ABV (%) / 1000**. One UK pint is **568 ml**, making one 4.5% ABV beer equal to **2.556 units**.- The patient consumes 12 pints per week (6 on Friday and 6 on Saturday), so total consumption is **12 × 2.556 = 30.672 units**, which is significantly above the **UK Chief Medical Officers' low-risk limit of 14 units** weekly.*14 units*- This represents the **maximum recommended weekly limit** for both men and women in the UK to keep health risks low.- While a target for reduction for this patient, it does not reflect his current actual intake of **12 pints** per week.*24 units*- This value would imply that each pint contains exactly **2 units**, which is not accurate for a 4.5% ABV beer.- A pint of 4.5% ABV beer is actually **2.556 units**, making 12 pints total **30.6 units**.*36 units*- This figure would suggest an incorrect calculation where each pint is assumed to be **3 units**, which is typically associated with stronger beers (around 5.3% ABV).- Using the precise **4.5% ABV** given, the correct calculation yields **30.6 units**.*42 units*- This value would result from assuming approximately **3.5 units per pint**, which is characteristic of much stronger lagers or ciders (around 6% ABV).- The accurate calculation based on the specified **4.5% ABV** confirms the patient's intake is **30.6 units**.

Question 7: A 31-year-old woman attends with her cervical screening result showing hrHPV positive with low-grade dyskaryosis. She is 8 weeks pregnant with her second child. She had a normal screening result 3 years ago. What is the most appropriate management?

A. Refer for colposcopy after delivery and postnatal period (Correct Answer)
B. Refer for colposcopy within 6 weeks
C. Refer for immediate colposcopy before 12 weeks gestation
D. Repeat cervical screening at 28 weeks gestation
E. Defer all cervical screening until 12 weeks postpartum

Explanation: ***Refer for colposcopy after delivery and postnatal period*** - In the UK screening program, **low-grade dyskaryosis** and **hrHPV positivity** during pregnancy are managed by deferring colposcopy until at least **12 weeks postpartum**. - This delay is appropriate as **CIN1** (low-grade) carries a very low risk of progression to malignancy during gestation, and physiological changes like **cervical eversion** make interpretation difficult and increase risks. *Refer for colposcopy within 6 weeks* - Immediate or urgent referral within 6 weeks is reserved for **high-grade dyskaryosis** or clinical suspicion of **invasive cancer** where a timely biopsy is necessary. - For low-grade changes, the physical changes of the cervix in pregnancy increase the risk of **procedural bleeding** and diagnostic inaccuracy without significant clinical benefit. *Refer for immediate colposcopy before 12 weeks gestation* - There is no clinical indication for immediate colposcopy for **low-grade cytological abnormalities** in a pregnant patient, especially with a previously normal screening history. - Avoiding invasive procedures in the **first trimester** is generally preferred unless life-threatening pathology, such as suspected **invasive carcinoma**, is present. *Repeat cervical screening at 28 weeks gestation* - Repeating cervical screening during pregnancy is generally not recommended because **hormonal influences** and **decidualization** of the stroma can often lead to difficulty in cytological interpretation. - A repeat test would likely yield ambiguous results and would not alter the management plan, which is to await the **postpartum period** for definitive assessment. *Defer all cervical screening until 12 weeks postpartum* - This option is incorrect because the patient has **already had the test** and received an abnormal result; the question concerns the management of this specific **abnormal finding**. - While women are often advised to defer a *routine* screen until postpartum, an abnormal result requires management according to the appropriate **clinical pathway**, not just general deferral.

Question 8: A 64-year-old man returns for discussion of his NHS bowel cancer screening result. His FIT result is 78 µg Hb/g faeces. He has no symptoms, no family history of colorectal cancer, and examination is unremarkable. He takes aspirin 75 mg daily for previous myocardial infarction. What is the most appropriate management?

A. Reassure and repeat FIT in 2 years as part of routine screening
B. Stop aspirin for 2 weeks and repeat FIT test
C. Refer for colonoscopy via the screening programme (Correct Answer)
D. Arrange urgent suspected cancer (2-week wait) referral to gastroenterology
E. Arrange faecal calprotectin test to exclude inflammatory bowel disease

Explanation: ***Refer for colonoscopy via the screening programme*** - A **FIT result of 78 µg Hb/g faeces** is above the threshold for a positive screening result within the **NHS Bowel Cancer Screening Programme**, requiring urgent investigation. - A positive screening test mandates referral for a **colonoscopy** directly through the dedicated **screening programme pathway** to identify or exclude colorectal cancer or significant polyps. *Reassure and repeat FIT in 2 years as part of routine screening* - Reassurance is inappropriate given the **positive FIT result**, which indicates potential gastrointestinal bleeding that requires immediate investigation. - Delaying investigation for two years would constitute a **missed opportunity** to diagnose and treat early-stage colorectal cancer or high-risk adenomas. *Stop aspirin for 2 weeks and repeat FIT test* - **Aspirin** typically does not need to be stopped before a FIT test; while it can cause bleeding, a positive result still necessitates investigation for more serious pathology. - Stopping aspirin and repeating the test would introduce an **unnecessary delay** and does not reliably exclude underlying colorectal cancer or significant polyps. *Arrange urgent suspected cancer (2-week wait) referral to gastroenterology* - The **2-week wait (2WW) pathway** is primarily designed for symptomatic patients with a GP-initiated suspicion of cancer, not for asymptomatic individuals with a positive screening test. - Patients with positive screening results are managed through the **dedicated Bowel Cancer Screening Programme pathway**, which provides its own specific and timely colonoscopy referral system. *Arrange faecal calprotectin test to exclude inflammatory bowel disease* - **Faecal calprotectin** is used to differentiate between inflammatory bowel disease and irritable bowel syndrome in symptomatic patients, and has no role in the workup of a **positive FIT screening result**. - Pursuing a calprotectin test would be a **diagnostic misdirection** and would delay the crucial investigation for colorectal cancer or polyps.

Question 9: A 58-year-old woman attends for NHS Health Check. She has a BMI of 28 kg/m², BP 128/82 mmHg, and smokes 10 cigarettes daily. Bloods show total cholesterol 5.2 mmol/L, HDL 1.4 mmol/L, HbA1c 39 mmol/mol. Her QRISK3 score is 8.5%. She is motivated to improve her health. What is the most evidence-based lifestyle intervention to offer?

A. Smoking cessation support with varenicline or combination NRT (Correct Answer)
B. Exercise programme targeting 150 minutes moderate activity per week
C. Weight loss programme targeting 5-10% body weight reduction
D. Mediterranean diet advice with emphasis on reducing saturated fat
E. Combined lifestyle intervention addressing all modifiable risk factors

Explanation: ***Smoking cessation support with varenicline or combination NRT***- Smoking cessation provides the **single greatest reduction** in cardiovascular risk and overall mortality compared to any other modifiable risk factor intervention.- According to **NICE guidelines (NG92)**, the gold standard for smoking cessation is combining **behavioral support** with pharmacotherapy like varenicline or combination NRT, which significantly reduces CV risk. *Exercise programme targeting 150 minutes moderate activity per week*- While physical activity improves metabolic health and reduces **QRISK3 profiles**, it does not match the magnitude of **mortality reduction** seen with quitting tobacco.- Physical activity is a foundational recommendation, but it is considered secondary to **direct toxin elimination** in a current smoker. *Weight loss programme targeting 5-10% body weight reduction*- The patient’s BMI (28 kg/m²) is classified as **overweight** rather than obese, making weight loss less clinically urgent than addressing her **smoking status**.- Weight loss primarily targets **HbA1c and BP control**, but her levels of these markers are currently within or near acceptable ranges. *Mediterranean diet advice with emphasis on reducing saturated fat*- A **Mediterranean diet** is recommended for primary prevention of CVD, but it does not address the acute **thrombogenic and inflammatory** risks posed by active smoking.- Her lipid profile (Total Cholesterol 5.2, HDL 1.4) is relatively stable, meaning dietary changes would yield **smaller incremental gains** in survival. *Combined lifestyle intervention addressing all modifiable risk factors*- While all factors are important, evidence-based practice requires **prioritizing the intervention** with the highest impact; splitting focus may dilute the efficacy of **tobacco cessation**.- Smoking cessation is the most **cost-effective and clinically significant** individual intervention for a patient with a QRISK3 score below the 10% statin threshold.

Question 10: A 67-year-old man with type 2 diabetes for 15 years attends for review. His diabetic retinopathy screening report shows 'moderate non-proliferative diabetic retinopathy with diabetic maculopathy' in both eyes. His HbA1c is 68 mmol/mol and BP 142/86 mmHg. What is the most appropriate action regarding his eye care?

A. Increase screening frequency to 6 months
B. Continue annual diabetic eye screening
C. Refer to ophthalmology for assessment within 6 weeks (Correct Answer)
D. Arrange urgent ophthalmology referral within 2 weeks
E. Refer to optometry for visual acuity assessment

Explanation: ***Refer to ophthalmology for assessment within 6 weeks*** - The presence of **diabetic maculopathy** on screening is a "referable" condition that requires specialist assessment by an **ophthalmologist** within a 6-week timeframe. - **Maculopathy** is identified by features such as exudates or retinal thickening within **one disc diameter** of the fovea and can lead to severe central vision loss if not addressed with treatments like **anti-VEGF injections**. *Increase screening frequency to 6 months* - Increasing screening frequency is typically reserved for cases of **pre-proliferative (moderate/severe) retinopathy** without maculopathy, but it is insufficient when macroscopic macular changes are present. - Once **maculopathy** is detected, the patient moves out of the standard screening program and into the **Hospital Eye Service** for management. *Continue annual diabetic eye screening* - **Annual screening** is appropriate for patients with no or only mild non-proliferative retinopathy (background retinopathy) without macular involvement. - Maintaining a yearly schedule in this patient would risk permanent vision loss due to the failure to treat active **macular edema** or exudation. *Arrange urgent ophthalmology referral within 2 weeks* - A **2-week urgent referral** is reserved for **proliferative diabetic retinopathy** (new vessel formation), vitreous hemorrhage, or sudden, unexplained loss of vision. - **Moderate non-proliferative retinopathy** with maculopathy is considered serious but typically does not meet the criteria for emergency/urgent 2-week fast-track unless vision-threatening proliferative changes are noted. *Refer to optometry for visual acuity assessment* - While visual acuity is important, an **optometrist** cannot provide the specialized medical treatments (like laser or intravitreal drugs) required for **diabetic maculopathy**. - Clinical guidelines mandate a direct referral to **Ophthalmology** (secondary care) rather than optometry for any patient identified with referable retinopathy on screening.

Question 11: A 42-year-old man presents for cardiovascular risk assessment. He has no past medical history, is a non-smoker with BMI 26 kg/m². Blood tests show total cholesterol 7.8 mmol/L, HDL 1.1 mmol/L, non-HDL 6.7 mmol/L, fasting glucose 5.2 mmol/L. His father died of myocardial infarction aged 44 years. What is the most appropriate initial management?

A. Calculate QRISK3 score and consider statin if >10%
B. Start atorvastatin 20 mg without risk calculation
C. Refer to lipid clinic for assessment of familial hypercholesterolaemia (Correct Answer)
D. Arrange genetic testing for familial hypercholesterolaemia
E. Repeat lipid profile in 3 months with lifestyle advice

Explanation: ***Refer to lipid clinic for assessment of familial hypercholesterolaemia***- This patient meets the **Simon Broome criteria** for suspected **familial hypercholesterolaemia (FH)** due to a **total cholesterol >7.5 mmol/L** and a first-degree relative with **premature coronary heart disease** (MI before age 55 in a male relative).- **NICE guidelines** recommend direct **referral to a specialist lipid clinic** for definitive diagnosis, comprehensive management, and to initiate **cascade testing** for at-risk family members, given the very high lifetime cardiovascular risk.*Calculate QRISK3 score and consider statin if >10%*- Cardiovascular risk scores like **QRISK3** are **not appropriate** for patients with suspected FH as they significantly **underestimate the lifetime risk** of cardiovascular events in these individuals.- **NICE guidelines** explicitly state that a total cholesterol above **7.5 mmol/L** (or LDL-C >4.9 mmol/L) should trigger suspicion of FH, leading to direct referral rather than routine risk calculation.*Start atorvastatin 20 mg without risk calculation*- While statin therapy is essential for FH, starting a standard **primary prevention dose** of 20 mg without specialist assessment may lead to **under-treatment** for an inherited high-risk condition requiring higher intensity lipid lowering.- Specialist referral ensures proper diagnosis, optimal treatment intensity, and crucial **cascade screening** for family members, which is paramount in FH management.*Arrange genetic testing for familial hypercholesterolaemia*- Genetic testing for FH is a specialized investigation that is typically arranged by **specialist lipid services** once a clinical diagnosis is strongly suspected and confirmed by a clinician.- Clinical diagnosis based on **Simon Broome criteria** is usually sufficient for initial referral and management; genetic testing is often used to confirm the diagnosis, identify specific mutations, and aid cascade testing, but it follows clinical assessment.*Repeat lipid profile in 3 months with lifestyle advice*- Given the highly elevated **total cholesterol (7.8 mmol/L)** and strong family history of **premature MI**, a repeat lipid profile after lifestyle advice would inappropriately delay crucial diagnosis and initiation of effective treatment for FH.- Lifestyle interventions alone are generally **insufficient** to achieve target lipid levels in patients with FH due to the underlying genetic defect, and delaying definitive management increases cardiovascular risk.

Question 12: A 35-year-old woman attends with her cervical screening result. The hrHPV test is positive but cytology shows 'inadequate sample'. She had a normal screening result 3 years ago and has had no abnormal vaginal bleeding. What is the most appropriate next step?

A. Repeat cervical sample in 3 months (Correct Answer)
B. Repeat cervical sample immediately
C. Refer for urgent colposcopy within 2 weeks
D. Refer for routine colposcopy
E. Arrange repeat sample in 12 months

Explanation: ***Repeat cervical sample in 3 months*** - When **high-risk HPV (hrHPV)** is detected but the cytology is **inadequate**, a repeat sample is required specifically at a **3-month interval** to allow the cervical epithelium to regenerate. - This follow-up ensures that if a high-grade lesion or **persistent HPV** is present, it can be appropriately triaged after obtaining a readable slide. *Repeat cervical sample immediately* - Repeating the smear immediately is discouraged because the transformation zone needs approximately **3 months** to heal and provide a representative cellular sample. - Re-sampling too early increases the risk of a second **inadequate result** due to insufficient squamous or glandular cells. *Refer for urgent colposcopy within 2 weeks* - Urgent 2-week wait referrals are reserved for patients with clinical suspicion of **cervical cancer** (e.g., suspicious mass or unexplained bleeding), which is not present here. - An **inadequate cytology** result alone is not an indication for an urgent cancer-pathway referral. *Refer for routine colposcopy* - Routine **colposcopy** is indicated after two consecutive **inadequate samples** or if cytology shows abnormalities like **dyskaryosis** alongside a positive hrHPV result. - A single inadequate sample in an asymptomatic patient does not meet the criteria for direct specialist referral. *Arrange repeat sample in 12 months* - A **12-month repeat** is the protocol for patients who are **hrHPV positive with negative cytology**, not for those with inadequate samples. - Waiting 12 months would be inappropriate as it risks a delayed diagnosis of potential underlying pathology that was not assessable on the **inadequate slide**.

Question 13: A 53-year-old woman attends for her first NHS breast screening appointment. She asks how often she will be invited for screening if this mammogram is normal. What is the correct screening interval?

A. Annually
B. Every 2 years
C. Every 3 years (Correct Answer)
D. Every 4 years
E. Every 5 years

Explanation: ***Every 3 years*** - The **NHS Breast Screening Programme** invites women aged **50 to 70 years** for a screening mammogram every 3 years to detect early signs of cancer. - This specific interval is evidence-based, balancing the clinical benefit of **early detection** against risks like **overdiagnosis** and radiation exposure. *Annually* - **Annual screening** is not the standard for the general population as it would significantly increase the risk of **false positives** and unnecessary biopsies. - Yearly mammograms are typically reserved only for certain **high-risk groups**, such as those with specific **BRCA gene mutations**. *Every 2 years* - While some international programs use a biennial (2-year) cycle, the **UK national guidelines** strictly adhere to a triennial (3-year) schedule. - A 2-year interval would lead to higher **cumulative radiation exposure** without a proven significant increase in survival for the average-risk UK population. *Every 4 years* - An interval of 4 years is considered too long, as it increases the likelihood of **interval cancers** developing between screens. - Extending the time beyond 3 years may result in cancers being diagnosed at a **later stage**, reducing the effectiveness of treatment. *Every 5 years* - A 5-year gap is not clinically recommended as the **doubling time** of many breast tumors would allow them to become symptomatic before the next screen. - **Screening efficacy** relies on catching tumors while they are **asymptomatic**, which is less likely with such a prolonged interval.

Question 14: A 40-year-old man attends for an NHS Health Check. He is of South Asian ethnicity, works as an accountant, and is sedentary. His BMI is 26 kg/m², BP 128/78 mmHg, and he is a non-smoker. Fasting blood tests show glucose 6.2 mmol/L and HbA1c 41 mmol/mol. His QRISK3 score is 6.5%. He asks what lifestyle changes would be most effective at reducing his future diabetes risk given his ethnic background. Which advice is most appropriate?

A. Focus on weight reduction to achieve BMI <25 kg/m² as South Asian populations have lower BMI thresholds for metabolic risk
B. Commence metformin for diabetes prevention as he meets criteria for intermediate hyperglycaemia
C. Intensive dietary modification emphasising low glycaemic index foods and reduced refined carbohydrates
D. Structured exercise programme with at least 150 minutes moderate-intensity activity per week combined with dietary advice (Correct Answer)
E. Arrange referral to tier 3 weight management service given his elevated diabetes risk

Explanation: ***Structured exercise programme with at least 150 minutes moderate-intensity activity per week combined with dietary advice***- This patient has **impaired fasting glucose** (IFG), and evidence-based guidelines (like the Diabetes Prevention Programme) show that combined **intensive lifestyle intervention** reduces diabetes risk by approximately 58%.- **South Asian** populations are at higher metabolic risk at lower BMIs; a **structured programme** addressing both physical activity and nutrition is the gold standard for prevention in this demographic.*Focus on weight reduction to achieve BMI <25 kg/m² as South Asian populations have lower BMI thresholds for metabolic risk*- While the BMI threshold for "overweight" is lower in South Asian patients (**23 kg/m²**), weight loss is only one component of the necessary lifestyle shift.- Focusing solely on a BMI number is less effective than the **combination of diet and aerobic exercise** for improving insulin sensitivity.*Commence metformin for diabetes prevention as he meets criteria for intermediate hyperglycaemia*- **Metformin** is generally reserved for patients where lifestyle interventions have failed or for those at exceptionally high risk (e.g., HbA1c 42–47 mmol/mol).- Lifestyle changes have been proven in clinical trials to be significantly **more effective** than metformin (58% vs 31% risk reduction) for diabetes prevention.*Intensive dietary modification emphasising low glycaemic index foods and reduced refined carbohydrates*- Diet is a crucial pillar, but isolated dietary advice without a **structured exercise** component is suboptimal for managing **prediabetes**.- Evidence supports the synergy of **physical activity** and nutrition over a single-focus dietary approach to delay the onset of Type 2 Diabetes.*Arrange referral to tier 3 weight management service given his elevated diabetes risk*- **Tier 3 services** are multidisciplinary teams intended for patients with **BMI ≥40 kg/m²** (or ≥35 kg/m² with comorbidities), which does not apply to this patient.- This patient's needs are best met through **Primary Care** or community-based **National Diabetes Prevention Programmes** (Tier 2 levels).

Question 15: A 72-year-old woman with longstanding type 2 diabetes attends following her diabetic eye screening result, which reports 'ungradable images due to cataracts'. She had a similar result last year. Her visual acuity is 6/12 in both eyes, which she says is unchanged. She manages her diabetes and daily activities independently. Her recent HbA1c is 58 mmol/mol. What is the most appropriate management of this screening result?

A. Refer to ophthalmology for cataract surgery assessment and retinopathy evaluation (Correct Answer)
B. Repeat diabetic eye screening in 12 months as per standard protocol
C. Arrange optical coherence tomography (OCT) imaging to assess for maculopathy
D. Discharge from diabetic eye screening programme as screening is not possible
E. Arrange urgent ophthalmology referral under 2-week wait pathway for possible sight-threatening diabetic retinopathy

Explanation: ***Refer to ophthalmology for cataract surgery assessment and retinopathy evaluation*** - When **diabetic eye screening** images are **ungradable** for two consecutive years due to **cataracts**, it necessitates a referral to **ophthalmology** for a comprehensive slit-lamp examination. - This ensures that **diabetic retinopathy** is not missed and allows for assessment of the need for **cataract surgery** to enable clearer retinal views for future screening. *Repeat diabetic eye screening in 12 months as per standard protocol* - Repeating the standard **diabetic eye screening** is inappropriate as the underlying **cataracts** will likely lead to another **ungradable result**. - This approach would delay proper evaluation and potential management of any underlying **diabetic retinopathy** or the cataracts themselves. *Arrange optical coherence tomography (OCT) imaging to assess for maculopathy* - **OCT** is useful for assessing **macular edema** but would still be compromised by the significant **cataracts** preventing clear imaging of the retina. - The primary issue is a **media opacity**, which requires a clinical **fundoscopic examination** by an ophthalmologist rather than another photographic imaging technique. *Discharge from diabetic eye screening programme as screening is not possible* - All patients with diabetes require continuous **retinal surveillance** to prevent and manage **diabetic retinopathy**, even if standard screening is difficult. - An **ungradable result** prompts a referral to specialists for alternative assessment methods, not discharge from the essential screening program. *Arrange urgent ophthalmology referral under 2-week wait pathway for possible sight-threatening diabetic retinopathy* - A **2-week wait referral** is typically reserved for urgent suspicion of malignancy or rapidly progressive, severe sight-threatening conditions requiring immediate intervention. - The patient's **stable visual acuity** (6/12) and lack of acute symptoms do not warrant an emergency 2-week wait pathway; a routine or urgent (but not 2-week) ophthalmology referral is more appropriate.

Question 16: A 55-year-old man attends for NHS Health Check. He has a BMI of 31 kg/m², BP 138/86 mmHg, and is a non-smoker. Blood tests show HbA1c 43 mmol/mol (non-diabetic range), total cholesterol 5.4 mmol/L, and HDL 0.9 mmol/L. His QRISK3 score is 16%. He works night shifts as a warehouse supervisor and admits to poor sleep quality, often sleeping only 4-5 hours daily. Recent research suggests chronic sleep deprivation is associated with increased cardiovascular risk. How should this information influence his management?

A. Sleep duration is not an established modifiable cardiovascular risk factor in current guidelines and should not alter standard management based on QRISK3
B. Arrange referral to sleep clinic for assessment of possible sleep apnoea before starting other interventions
C. Delay statin therapy until sleep patterns improve as this may reduce his QRISK3 score below treatment threshold
D. Recommend sleep hygiene measures but prioritise evidence-based interventions including statin therapy and lifestyle advice (Correct Answer)
E. Prescribe zopiclone to improve sleep duration as this may provide greater cardiovascular benefit than statins

Explanation: ***Recommend sleep hygiene measures but prioritise evidence-based interventions including statin therapy and lifestyle advice*** - This patient has a **QRISK3 score of 16%**, which, according to **NICE guidelines**, indicates a high cardiovascular risk and warrants initiation of **statin therapy** (e.g., atorvastatin 20mg) for primary prevention. - While chronic sleep deprivation is an emerging risk factor, management should primarily focus on **evidence-based interventions** with proven efficacy in reducing **major adverse cardiovascular events (MACE)**, alongside lifestyle modifications and addressing sleep hygiene. *Sleep duration is not an established modifiable cardiovascular risk factor in current guidelines and should not alter standard management based on QRISK3* - While sleep duration is not formally integrated into **QRISK3** or most current official guidelines for pharmacological intervention thresholds, it is an increasingly recognized **non-traditional cardiovascular risk factor** that should be discussed as part of general lifestyle advice. - Disregarding poor sleep entirely misses an opportunity for **holistic patient care** and lifestyle modification, even if it doesn't directly alter the immediate statin decision. *Arrange referral to sleep clinic for assessment of possible sleep apnoea before starting other interventions* - The patient's poor sleep is primarily attributed to **night shifts** and reported poor sleep quality, not specific symptoms like loud snoring, witnessed apnoeas, or excessive daytime somnolence that would strongly suggest **sleep apnoea**. - Delaying **evidence-based interventions** like statin therapy for a patient with a **16% QRISK3 score** while awaiting a sleep clinic assessment would be inappropriate and increase their cardiovascular risk. *Delay statin therapy until sleep patterns improve as this may reduce his QRISK3 score below treatment threshold* - **Sleep duration** is not a parameter included in the **QRISK3 algorithm**, therefore, improvements in sleep patterns will not mathematically alter the calculated QRISK3 score. - Delaying **statin therapy** for a patient already at high cardiovascular risk (16%) based on an unproven effect on the risk score or an unvalidated intervention would be clinically unsound. *Prescribe zopiclone to improve sleep duration as this may provide greater cardiovascular benefit than statins* - **Zopiclone** and other hypnotics are indicated for short-term management of insomnia and have **no demonstrated cardiovascular benefits** that outweigh or even compare to statins. - Prescribing hypnotics carries risks such as **dependency, falls, and cognitive impairment**, making it an unsuitable primary intervention for cardiovascular risk reduction, especially over proven therapies.

Question 17: A 44-year-old woman attends requesting advice about breast screening. Her sister was recently diagnosed with breast cancer aged 47. Her mother had ovarian cancer aged 52 and died from it. The patient herself is well with no symptoms. She asks when she should start having mammograms. What is the most appropriate initial management?

A. Arrange urgent referral to breast clinic for clinical assessment and mammography
B. Refer to clinical genetics service for family history assessment and possible BRCA testing (Correct Answer)
C. Reassure that she will be invited for routine NHS breast screening from age 50
D. Arrange immediate bilateral mammography in primary care
E. Arrange breast MRI surveillance to commence immediately

Explanation: ***Refer to clinical genetics service for family history assessment and possible BRCA testing*** - This patient has a significant family history featuring a first-degree relative with **breast cancer < 50** and another with **ovarian cancer**, suggesting a potential **BRCA1/BRCA2 mutation**. - Referral to **clinical genetics** or a specialist family history clinic is the correct primary care step to perform a formal **risk assessment** (e.g., using the Tyrer-Cuzick model) and determine eligibility for **genetic testing**. *Arrange urgent referral to breast clinic for clinical assessment and mammography* - Urgent referrals (2-week rule) are indicated for **symptomatic patients** (e.g., breast lumps, skin changes), but this patient is currently **asymptomatic**. - Diagnostic mammography in a symptomatic clinic is not the appropriate pathway for managing **asymptomatic hereditary risk**. *Reassure that she will be invited for routine NHS breast screening from age 50* - Routine screening starting at **age 50** is insufficient for patients at **high or moderate risk** due to family history, who may require surveillance starting as early as age 30 or 40. - Reassurance without formal risk assessment would be inappropriate given the **combination of breast and ovarian cancer** in her immediate family. *Arrange immediate bilateral mammography in primary care* - Primary care practitioners do not typically have the facility to direct-order **screening mammographies** outside of the national program or specialist referral scripts. - Mammography is less sensitive in **younger women** with denser breast tissue, making formal risk-stratified surveillance planning essential before ordering tests. *Arrange breast MRI surveillance to commence immediately* - **Breast MRI** is reserved for specific high-risk groups (like confirmed **BRCA mutation carriers**) and is not the first-line investigation in primary care. - Specialist surveillance schedules are determined by the **clinical genetics** or specialist team only after a comprehensive **pedigree analysis**.

Question 18: A 68-year-old man with a 4.7 cm infrarenal abdominal aortic aneurysm (AAA) detected through NHS screening attends for discussion. He has been under surveillance with 3-monthly scans for 18 months. The most recent scan shows the aneurysm has increased from 4.5 cm to 4.7 cm over the past 3 months. He is asymptomatic. He has COPD with FEV1 65% predicted, type 2 diabetes, and hypertension. He quit smoking 2 years ago. What is the most appropriate management?

A. Continue 3-monthly ultrasound surveillance and refer if aneurysm reaches 5.5 cm (Correct Answer)
B. Refer urgently to vascular surgery for consideration of elective repair
C. Arrange CT angiography and refer to vascular surgery for discussion of repair options
D. Increase surveillance frequency to monthly scans to closely monitor expansion rate
E. Arrange MR angiography to assess suitability for endovascular repair

Explanation: ***Continue 3-monthly ultrasound surveillance and refer if aneurysm reaches 5.5 cm***- According to **NHS AAA screening guidelines**, an asymptomatic infrarenal aneurysm measuring **4.5-5.4 cm** is classified as a medium AAA, requiring **3-monthly ultrasound surveillance**.- Surgical referral is typically indicated when the aneurysm reaches **5.5 cm** in diameter, or if there is rapid expansion, defined as **>1 cm per year** or **>0.5 cm in 6 months**. The current growth of 0.2 cm in 3 months does not meet the rapid expansion criteria for immediate referral.*Refer urgently to vascular surgery for consideration of elective repair*- Urgent referral for elective repair is generally reserved for aneurysms that have reached the **5.5 cm threshold**, are **symptomatic**, or demonstrate **rapid expansion** significantly exceeding the current growth rate.- The patient's current aneurysm size of 4.7 cm and growth rate of 0.2 cm in 3 months (0.4 cm in 6 months) do not meet these criteria, as he remains **asymptomatic**.*Arrange CT angiography and refer to vascular surgery for discussion of repair options*- **CT angiography** is a detailed imaging modality primarily used for **pre-operative planning** and anatomical assessment once surgical intervention is being considered, typically after the 5.5 cm referral threshold is met.- For ongoing surveillance of stable, asymptomatic aneurysms below the surgical threshold, **ultrasound** is the standard, cost-effective, and **radiation-free** method.*Increase surveillance frequency to monthly scans to closely monitor expansion rate*- **National guidelines** for AAA surveillance recommend 3-monthly scans for aneurysms in the 4.5-5.4 cm range; **monthly scans** are not a standard surveillance interval.- Increasing scan frequency beyond established protocols offers no proven clinical benefit for a stable aneurysm and can lead to increased **healthcare burden** and unnecessary patient anxiety.*Arrange MR angiography to assess suitability for endovascular repair*- **MR angiography** (MRA), similar to CTA, provides detailed anatomical information for planning procedures like **EVAR (Endovascular Aneurysm Repair)**.- This is a step in the **surgical workup** and is premature when the patient has not yet met the size or growth criteria for surgical intervention.

Question 19: A 33-year-old woman attends with her cervical screening result showing hrHPV positive with low-grade dyskaryosis. She underwent colposcopy 6 months ago for similar results, and punch biopsy at that time showed CIN1. The colposcopist advised repeat cytology in 6 months, which is the current result. She has no symptoms and is currently 8 weeks pregnant. What is the most appropriate next step in management?

A. Defer further investigation until after pregnancy and arrange colposcopy 3 months postpartum (Correct Answer)
B. Arrange urgent colposcopy now to exclude high-grade disease
C. Arrange large loop excision of transformation zone (LLETZ) after delivery
D. Repeat cervical screening in 12 months
E. Arrange repeat colposcopy and biopsy immediately

Explanation: ***Defer further investigation until after pregnancy and arrange colposcopy 3 months postpartum*** - In pregnant women with **CIN1** or **low-grade dyskaryosis**, the risk of progression to invasive cancer is extremely low, and further review should be delayed until the cervix has recovered from pregnancy-related changes. - **Colposcopy** and biopsies are generally avoided during pregnancy unless **invasive disease** is suspected, specifically to prevent complications like heavy bleeding due to increased **cervical vascularity**. *Arrange urgent colposcopy now to exclude high-grade disease* - Urgent colposcopy is only indicated in pregnancy if there is a suspicion of **malignancy** or **high-grade dyskaryosis** (e.g., severe dyskaryosis or suspicion of invasion). - **Low-grade dyskaryosis** with a known history of **CIN1** does not meet the criteria for urgent intervention during the first trimester. *Arrange large loop excision of transformation zone (LLETZ) after delivery* - **LLETZ** is a treatment for high-grade disease (**CIN2/3**) and is not typically indicated for **CIN1**, which has a high rate of **spontaneous regression**. - A follow-up **colposcopy** must be performed postpartum to reassess the status of the lesion before committing to any surgical treatment. *Repeat cervical screening in 12 months* - Repeating a smear in 12 months is inappropriate because the patient has persistent **low-grade changes** and **hrHPV positivity** following a previous abnormal biopsy. - **Colposcopic evaluation** is required after the 3-month postpartum period to ensure that the **CIN1** has not progressed or persisted. *Arrange repeat colposcopy and biopsy immediately* - Immediate referral for biopsy is unnecessary and poses risks of **bleeding** and **preterm labor** without providing any benefit for managing low-grade disease. - Clinical guidelines recommend waiting until at least **12 weeks postpartum** for repeat colposcopy to ensure accurate visualization and interpretation of the **transformation zone**.

Question 20: A 70-year-old woman attends for cardiovascular risk assessment. She has a BMI of 27 kg/m² and walks her dog daily for 30 minutes. She does not smoke and drinks 6 units of alcohol weekly. Blood tests show total cholesterol 6.8 mmol/L, HDL 1.6 mmol/L, and HbA1c 41 mmol/mol. Her BP is 126/76 mmHg. She asks about starting a statin as her friend was prescribed one. Her QRISK3 score is 8%. What is the most appropriate management?

A. Prescribe atorvastatin 20 mg once daily and review lipids in 3 months
B. Offer lifestyle advice about diet and exercise and reassess in 12 months (Correct Answer)
C. Arrange lipid clinic referral for consideration of specialist lipid-lowering therapy
D. Prescribe atorvastatin 80 mg once daily for primary prevention
E. Request familial hypercholesterolaemia genetic testing

Explanation: ***Offer lifestyle advice about diet and exercise and reassess in 12 months*** - According to **NICE guidelines**, primary prevention with statins should be offered to individuals with a **QRISK3 score of 10% or higher** over 10 years; this patient's score is only **8%**. - The most appropriate initial step for a patient below the treatment threshold is reinforcing **lifestyle modifications** (diet and physical activity) and periodic monitoring. *Prescribe atorvastatin 20 mg once daily and review lipids in 3 months* - **Atorvastatin 20 mg** is a standard dose for primary prevention, but it is not indicated here as the patient's **10-year cardiovascular risk** (QRISK3 8%) is less than the **10% threshold** for statin initiation. - Routine pharmacological intervention is reserved for those who exceed the risk threshold or have specific high-risk comorbidities like **Type 1 Diabetes** or **Chronic Kidney Disease**, which this patient does not have. *Arrange lipid clinic referral for consideration of specialist lipid-lowering therapy* - Specialist referral is typically reserved for patients with **refractory hyperlipidemia**, suspected complex genetic disorders, or those who cannot tolerate standard therapy. - This patient does not meet the criteria for **specialist intervention** as her risk profile and lipid levels can be managed in a primary care setting. *Prescribe atorvastatin 80 mg once daily for primary prevention* - **Atorvastatin 80 mg** is a high-intensity dose used for **secondary prevention** in patients with established cardiovascular disease (e.g., post-MI or stroke) or very high primary prevention risk. - Using this dose for primary prevention in a low-risk (QRISK3 < 10%) patient is inappropriate and significantly increases the risk of **adverse effects** without clear benefit. *Request familial hypercholesterolaemia genetic testing* - Testing for **Familial Hypercholesterolaemia (FH)** is usually considered if total cholesterol is >7.5 mmol/L or if there is a suggestive **family history** of premature CVD, or clinical signs like **tendon xanthomata**. - This patient's total cholesterol of 6.8 mmol/L, while elevated, does not meet the typical **Simon Broome criteria** for immediate genetic testing without additional risk factors.

Question 21: A 56-year-old woman with type 2 diabetes for 12 years attends for annual review. Her HbA1c is 64 mmol/mol. She mentions she received a letter about diabetic eye screening but has not attended for the past 2 years as she has 'perfect vision' and sees no point in screening. Her visual acuity today is 6/6 bilaterally. What is the most important reason to emphasise the need for diabetic retinopathy screening?

A. Diabetic retinopathy can progress to sight-threatening stages without visual symptoms (Correct Answer)
B. Annual screening is a performance indicator that affects practice funding
C. Proliferative retinopathy requires immediate pan-retinal photocoagulation to prevent blindness
D. Visual acuity testing in general practice is insufficient to detect early retinopathy
E. Patients with HbA1c >58 mmol/mol are at particularly high risk of rapid retinopathy progression

Explanation: ***Diabetic retinopathy can progress to sight-threatening stages without visual symptoms*** - Many early and even moderate stages of **diabetic retinopathy**, including **macular edema** or **pre-proliferative changes**, can be asymptomatic, with central vision remaining unaffected. - Screening allows for the **early detection** of these silent changes, enabling timely intervention (e.g., laser treatment, anti-VEGF injections) to prevent irreversible vision loss before symptoms manifest. *Annual screening is a performance indicator that affects practice funding* - While **Quality and Outcomes Framework (QOF)** or similar schemes link screening rates to practice funding, this is an administrative and financial reason, not a primary medical justification for the patient. - Emphasizing **financial incentives** rather than direct patient health outcomes is unethical and unlikely to improve long-term patient compliance. *Proliferative retinopathy requires immediate pan-retinal photocoagulation to prevent blindness* - **Pan-retinal photocoagulation (PRP)** is a critical treatment for **proliferative diabetic retinopathy** to prevent severe vision loss from neovascularization or vitreous hemorrhage. - However, the primary goal of screening is to identify retinopathy at **earlier, treatable stages** *before* it progresses to the sight-threatening, emergent proliferative stage requiring such intensive intervention. *Visual acuity testing in general practice is insufficient to detect early retinopathy* - **Visual acuity** primarily assesses **central macular function**; therefore, it can remain normal (6/6) even if significant **peripheral retinal damage** or early macular edema is present. - While technically true, this and other clinical facts are secondary to the main message that **asymptomatic progression** poses the greatest risk to the patient, highlighting the importance of comprehensive screening. *Patients with HbA1c >58 mmol/mol are at particularly high risk of rapid retinopathy progression* - An elevated **HbA1c** (like 64 mmol/mol in this patient) is indeed a significant **risk factor** for the development and progression of diabetic retinopathy due to poor glycemic control. - However, retinopathy can develop even in patients with seemingly **well-controlled diabetes** or at lower HbA1c levels, meaning screening is crucial for *all* diabetic patients, not just those with high HbA1c.

Question 22: A 61-year-old woman attends following her NHS bowel cancer screening. Her FIT result is 78 μg Hb/g faeces. She has no symptoms, no weight loss, and bowel habit is unchanged. Abdominal examination is normal. She has a history of diverticular disease diagnosed 3 years ago. She takes amlodipine for hypertension. What is the most appropriate next management step?

A. Reassure and advise to complete another FIT test in 2 years
B. Arrange urgent 2-week wait referral for suspected colorectal cancer (Correct Answer)
C. Arrange routine colonoscopy via local colorectal service
D. Request CT colonography
E. Repeat FIT test in 3 months

Explanation: ***Arrange urgent 2-week wait referral for suspected colorectal cancer***- A **Faecal Immunochemical Test (FIT)** result of **78 μg Hb/g** faeces is significantly above the positive threshold (typically ≥10 μg Hb/g) in the NHS screening programme, mandating an **urgent 2-week wait (2WW) referral**.- The presence of **occult blood**, even without symptoms or a history of **diverticular disease**, means that colorectal cancer must be investigated promptly. *Reassure and advise to complete another FIT test in 2 years*- Reassurance is inappropriate as a **positive FIT result** indicates the presence of blood that needs urgent investigation to rule out serious pathology, including **colorectal cancer**.- Waiting for the next routine screening interval would constitute a significant and potentially harmful **diagnostic delay**. *Arrange routine colonoscopy via local colorectal service*- A **routine referral** is not appropriate for a patient with a positive bowel cancer screening result, which triggers the **suspected cancer pathway**.- NICE guidelines and screening protocols require an **urgent 2-week wait referral** to ensure timely investigation and diagnosis. *Request CT colonography*- The primary management step for the GP is to initiate the **formal 2WW referral** to a specialist colorectal service.- The specialist team will then determine the most appropriate diagnostic imaging or endoscopic procedure, with **colonoscopy** typically being the preferred initial investigation if suitable. *Repeat FIT test in 3 months*- Repeating a **positive FIT test** is contraindicated as it causes an unnecessary delay in investigation.- Tumor bleeding can be **intermittent**, meaning a repeat test could yield a false-negative result, further delaying a critical diagnosis.

Question 23: A 47-year-old man attends for advice about reducing his cardiovascular risk. He has a BMI of 32 kg/m², smokes 20 cigarettes daily, and drinks 28 units of alcohol weekly. His BP is 144/88 mmHg. His 10-year QRISK3 score is 18%. He is keen to make lifestyle changes but feels overwhelmed about where to start. Based on evidence for cardiovascular risk reduction, which intervention should be prioritised?

A. Smoking cessation (Correct Answer)
B. Weight reduction to achieve BMI <25 kg/m²
C. Reduction of alcohol intake to <14 units per week
D. Initiation of antihypertensive medication
E. Increasing physical activity to 150 minutes per week

Explanation: ***Smoking cessation*** - **Smoking cessation** is the single most impactful intervention for reducing **cardiovascular risk**, as it significantly lowers the risk of **myocardial infarction** and stroke within a year of quitting. - It provides the most substantial and rapid **absolute risk reduction** compared to other lifestyle modifications, directly addressing the primary driver of atherosclerosis and improving endothelial function. *Weight reduction to achieve BMI <25 kg/m²* - While reducing **BMI** is crucial for long-term cardiovascular health, achieving a BMI <25 kg/m² from 32 kg/m² is a significant, long-term goal that may feel **overwhelming** to start with. - The relative benefit of **weight loss** on immediate cardiovascular outcomes, while important, is not as profound or rapid as the benefit seen from **smoking cessation**. *Reduction of alcohol intake to <14 units per week* - Reducing **alcohol intake** is important for overall health, including **blood pressure** control and reducing stroke risk, but its immediate impact on overall **cardiovascular mortality** is less pronounced than quitting smoking. - Excessive alcohol intake contributes to hypertension and cardiomyopathy, but the **effect size** of its reduction on the 10-year QRISK3 score is typically smaller than that of **smoking cessation**. *Initiation of antihypertensive medication* - While this patient's **blood pressure** of 144/88 mmHg and **QRISK3 score >10%** warrant consideration for medication, **lifestyle changes** are generally the first line of intervention, especially when the patient is motivated. - **Smoking cessation** itself can lead to improvements in blood pressure and vascular function, potentially postponing or reducing the need for immediate **pharmacological intervention**. *Increasing physical activity to 150 minutes per week* - Regular **physical activity** is a vital component of cardiovascular health, improving **lipid profiles** and blood pressure, but its individual impact on **absolute risk reduction** is less than that of quitting smoking. - Although exercise helps with **weight management** and overall well-being, prioritizing **smoking cessation** addresses the most potent and modifiable risk factor in this patient's profile.

Question 24: What is the screening interval for NHS breast screening for women aged 50-70 years in England?

A. Annually
B. Every 2 years
C. Every 3 years (Correct Answer)
D. Every 5 years
E. Every 18 months

Explanation: ***Every 3 years*** - The **NHS Breast Screening Programme** currently invites women aged **50 to 70 years** for a screening **mammogram** once every three years. - This triennial interval is designed to balance the **early detection** of breast cancer with the potential harms of **over-diagnosis** and radiation exposure. *Annually* - **Annual screening** is not the standard for the general population in the UK as it increases the rate of **false positives** without significantly improving mortality outcomes. - Annual mammograms are typically reserved for specific **high-risk groups**, such as those with certain **genetic mutations** like BRCA1 or BRCA2. *Every 2 years* - While some international programs (such as those in the US or some European countries) use a **biennial** (two-year) interval, the **NHS model** remains strictly triennial. - Clinical evidence used by the NHS suggests that a **three-year gap** is sufficient for catching most slow-growing tumors in the target age group. *Every 5 years* - A **five-year interval** is considered too long, as it would likely lead to an increase in **interval cancers** (cancers appearing between screens) that are more advanced at diagnosis. - This frequency would significantly reduce the **sensitivity** of the screening program and fail to provide the necessary diagnostic benefit. *Every 18 months* - There is no clinical guideline within the **Public Health England** screening protocols that recommends an **18-month interval** for routine population screening. - Routine screening follows a **standardized schedule** to ensure efficient resource allocation and manageable **patient recall** systems.

Question 25: A 28-year-old woman attends with her cervical screening result. She is nulliparous and has been in a monogamous relationship for 2 years. The hrHPV test is positive, but cytology shows normal cells (hrHPV positive, cytology negative). She has no symptoms and examination is normal. She is anxious about the result and asks about the likelihood of developing cervical cancer. What is the most appropriate next management step?

A. Repeat hrHPV test and cytology in 12 months (Correct Answer)
B. Refer urgently to colposcopy under 2-week wait pathway
C. Perform immediate colposcopy in primary care
D. Repeat hrHPV test and cytology in 3 months
E. Discharge back to routine 3-yearly screening

Explanation: ***Repeat hrHPV test and cytology in 12 months***- According to current screening guidelines, patients who are **hrHPV positive but cytology negative** should be invited for a repeat screen in **1 year** to allow for spontaneous viral clearance.- Most **HPV infections** in younger women are transient; immediate intervention is deferred because the risk of high-grade disease is low when cytology is normal.*Refer urgently to colposcopy under 2-week wait pathway*- An urgent **2-week wait** referral is reserved for clinical suspicion of **cervical cancer** on examination or severe cytological abnormalities.- Normal cytology with a first-time HPV positive result does not meet the criteria for urgent specialist referral.*Perform immediate colposcopy in primary care*- **Colposcopy** is a specialized procedure performed in a clinical setting by trained specialists, not as a routine **primary care** intervention.- Immediate referral for colposcopy is only indicated after a **positive cytology** result or if HPV persists for several years.*Repeat hrHPV test and cytology in 3 months*- A **3-month interval** is insufficient time for the immune system to clear the **hrHPV infection**, potentially leading to unnecessary anxiety and interventions.- The standard surveillance interval for persistent HPV with normal cytology is **12 months** to ensure clinically significant clearance can be detected.*Discharge back to routine 3-yearly screening*- Patients cannot be discharged to **routine recall** while they remain **hrHPV positive**, as they are at a higher risk of developing future neoplastic changes.- Routine screening is only appropriate if the sample is **HPV negative**, regardless of the cytological findings.

Question 26: A 52-year-old woman attends for discussion about lifestyle modification. She has a BMI of 28 kg/m², drinks 2 glasses of wine on most evenings, and works long hours in a sedentary office job. She wants to reduce her cardiovascular risk. Her father had a myocardial infarction aged 68. On examination, her BP is 132/78 mmHg. Blood tests show total cholesterol 5.2 mmol/L, HDL 1.1 mmol/L, and HbA1c 38 mmol/mol. What single lifestyle intervention would provide the greatest cardiovascular benefit?

A. Increase physical activity to at least 150 minutes of moderate intensity exercise per week (Correct Answer)
B. Reduce alcohol intake to within recommended limits of 14 units per week
C. Reduce BMI to below 25 kg/m² through dietary modification
D. Adopt a Mediterranean-style diet rich in fruits, vegetables, and unsaturated fats
E. Reduce total cholesterol through dietary changes including reducing saturated fat intake

Explanation: ***Increase physical activity to at least 150 minutes of moderate intensity exercise per week*** - Increasing physical activity directly targets the patient's **sedentary lifestyle**, a major modifiable risk factor for cardiovascular disease. - Regular exercise provides broad benefits including improved **endothelial function**, increased **HDL cholesterol**, better **insulin sensitivity**, and reduced **blood pressure**, often independently of weight loss. *Reduce alcohol intake to within recommended limits of 14 units per week* - The patient consumes approximately **10-14 units per week** (2 glasses of wine on most evenings), which is already at or near the current **recommended limits** for women. - While moderation is important, further reduction would likely offer less incremental cardiovascular benefit compared to addressing her significant **physical inactivity**. *Reduce BMI to below 25 kg/m² through dietary modification* - A BMI of 28 kg/m² indicates she is **overweight**, but addressing her complete lack of movement from a **sedentary job** offers a more immediate and impactful cardiovascular benefit. - The metabolic benefits of **exercise** occur even without significant weight loss and often precede substantial BMI reduction. *Adopt a Mediterranean-style diet rich in fruits, vegetables, and unsaturated fats* - While a **Mediterranean-style diet** is excellent for cardiovascular health, the patient's most prominent unaddressed risk factor is her **sedentary lifestyle**. - Initiating regular physical activity provides a more comprehensive and direct impact on multiple cardiovascular risk factors for a previously inactive individual. *Reduce total cholesterol through dietary changes including reducing saturated fat intake* - Her **total cholesterol (5.2 mmol/L)** is only mildly elevated, and dietary changes typically result in modest reductions of around **5-10%**. - Physical activity offers a more holistic benefit by simultaneously improving **blood pressure**, **glucose metabolism**, and the **lipid profile**, making it a more impactful single intervention here.

Question 27: A 65-year-old man attends for his NHS AAA screening appointment. He is asymptomatic and has no significant past medical history. The ultrasound scan shows an infrarenal aortic diameter of 2.8 cm. His blood pressure is 138/82 mmHg, and he is a non-smoker who stopped 10 years ago. What is the most appropriate management for this patient?

A. Discharge from screening programme with no further surveillance required (Correct Answer)
B. Arrange repeat ultrasound surveillance in 12 months
C. Refer to vascular surgery for consideration of surgical repair
D. Arrange CT angiogram to further assess the aneurysm
E. Arrange repeat ultrasound surveillance in 3 months

Explanation: ***Discharge from screening programme with no further surveillance required***- The patient's aortic diameter is **2.8 cm**, which is below the **3.0 cm threshold** used by the **NHS AAA Screening Programme** to define an aneurysm.- When the scan shows an aorta measuring **less than 3.0 cm**, the result is considered **normal**, and no further follow-up or screening is necessary for that individual.*Arrange repeat ultrasound surveillance in 12 months*- This management is reserved for patients with a **small aneurysm**, defined as an aortic diameter between **3.0 cm and 4.4 cm**.- Since this patient's measurement is below 3.0 cm, **annual surveillance** is not indicated as he does not have an abdominal aortic aneurysm.*Refer to vascular surgery for consideration of surgical repair*- Urgent referral for surgical repair is indicated when the aortic diameter is **5.5 cm or larger** (large aneurysm) or if it **expands rapidly**.- Referral is also indicated if the patient is **symptomatic**, but this patient is asymptomatic with a **normal aortic diameter**.*Arrange CT angiogram to further assess the aneurysm*- **CT angiography** is typically used for **pre-operative planning** once an aneurysm reaches the threshold for intervention or if there is diagnostic uncertainty on ultrasound.- It is never the first-line investigation or follow-up for a measurement that falls within the **normal range (<3.0 cm)**.*Arrange repeat ultrasound surveillance in 3 months*- **3-monthly (quarterly) surveillance** is the standard protocol for **medium-sized aneurysms** measuring between **4.5 cm and 5.4 cm**.- This patient's measurement is significantly lower than this threshold, making frequent monitoring clinically unnecessary and not cost-effective.

Question 28: A 48-year-old woman attends for smoking cessation support. She smokes 20 cigarettes daily and has a 30 pack-year history. She has tried nicotine replacement therapy (NRT) patches before without success. She is motivated to quit and asks about varenicline. She has a history of depression treated with sertraline 50 mg daily, which is well-controlled. She has no other medical conditions. What is the most appropriate advice regarding varenicline?

A. Varenicline is contraindicated due to her history of depression
B. Varenicline can be prescribed with close monitoring for neuropsychiatric symptoms (Correct Answer)
C. Varenicline should not be used in combination with any antidepressants
D. She should try combination NRT before considering varenicline
E. Varenicline is only licensed for patients who have failed two attempts with NRT

Explanation: ***Varenicline can be prescribed with close monitoring for neuropsychiatric symptoms*** - **Varenicline** is a highly effective first-line smoking cessation medication that can be used in patients with a history of **stable mental health conditions**, such as well-controlled depression. - While initial concerns existed, the **EAGLES trial** demonstrated that the risk of serious **neuropsychiatric adverse events** with varenicline is comparable to placebo, even in individuals with a psychiatric history, provided they are closely monitored. *Varenicline is contraindicated due to her history of depression* - A history of **well-controlled depression** (especially while on stable medication like **sertraline**) is a **precaution**, not an absolute **contraindication**, for varenicline use. - Patients should be advised to report any **mood changes** or unusual behavior, but the medication can still be prescribed with appropriate monitoring. *Varenicline should not be used in combination with any antidepressants* - There are no clinically significant pharmacokinetic interactions between **varenicline** and **SSRIs** like **sertraline**, making their co-administration generally safe. - The main concern with psychiatric medications during smoking cessation relates to changes in the metabolism of certain drugs (e.g., clozapine) once smoking stops, rather than direct interaction with varenicline. *She should try combination NRT before considering varenicline* - The patient has already tried **NRT patches** without success, indicating a need for a different approach. **NICE guidelines** endorse varenicline as a first-line option, alongside NRT and bupropion. - Given her previous failure with NRT monotherapy and strong motivation, offering a more effective agent like **varenicline** is a clinically appropriate and often preferred next step. *Varenicline is only licensed for patients who have failed two attempts with NRT* - This statement is incorrect; **varenicline** is licensed as a **first-line pharmacotherapy** for smoking cessation and does not require any prior failed attempts with NRT. - It can be offered as the initial treatment option based on patient preference and clinical judgment, given its proven efficacy.

Question 29: A 31-year-old woman attends with her cervical screening result showing hrHPV positive and low-grade dyskaryosis. Colposcopy reveals CIN 1 affecting a small area of the transformation zone. She is otherwise well and has no symptoms. The colposcopist recommends conservative management. What is the most appropriate follow-up strategy?

A. Return to routine 3-yearly cervical screening
B. Repeat cervical screening with hrHPV test in 6 months
C. Repeat cervical screening with hrHPV test in 12 months (Correct Answer)
D. Repeat colposcopy in 6 months
E. Immediate excisional treatment with large loop excision

Explanation: ***Repeat cervical screening with hrHPV test in 12 months*** - For women with **CIN 1** confirmed at colposcopy, the standard management is conservative follow-up because the majority of cases (60-80%) show **spontaneous regression** within a year. - Current guidelines recommend a **repeat hrHPV test at 12 months**; if negative, the patient returns to routine screening, and if positive, further management is dictated by cytology results. *Return to routine 3-yearly cervical screening* - This is inappropriate because the patient currently has **active CIN 1** and is **hrHPV positive**, requiring close monitoring to ensure the lesion resolves. - Routine screening is only resumed once a **test of cure** (negative hrHPV 12 months post-diagnosis) has been achieved. *Repeat cervical screening with hrHPV test in 6 months* - A 6-month interval is generally considered **too short** for the natural clearance of hrHPV and the regression of low-grade dysplasia. - Screening at 12 months provides a more accurate assessment of whether the **immune system** has successfully cleared the virus. *Repeat colposcopy in 6 months* - **Colposcopy** is a diagnostic tool and is not typically used for primary follow-up of CIN 1 unless cytology shows worsening high-grade changes. - Routine follow-up is primarily driven by **hrHPV testing** in a primary care setting rather than repeat invasive procedures. *Immediate excisional treatment with large loop excision* - **LLETZ** is usually reserved for **high-grade dysplasia (CIN 2 or 3)** or persistent CIN 1 (lasting 24 months or more). - Immediate excision for CIN 1 is avoided to prevent **obstetric complications**, such as cervical incompetence and preterm labor, especially in women of childbearing age.

Question 30: A 44-year-old woman with a BMI of 37 kg/m² attends for weight management review. She has lost 4 kg (4% of baseline weight) over the past 3 months following dietary modification and increased physical activity. She asks about adding orlistat. She has no comorbidities. Laboratory results show normal renal and liver function. What advice should be given about continuing weight loss management?

A. Orlistat can be prescribed; continue current lifestyle measures and review in 3 months
B. Increase follow-up intensity and reassess at 6 months before considering orlistat
C. Refer to specialist weight management services as first-line orlistat has not achieved target
D. Prescribe orlistat only if she loses an additional 1% body weight in the next month
E. Continue lifestyle interventions alone and do not prescribe orlistat as target not met (Correct Answer)

Explanation: ***Continue lifestyle interventions alone and do not prescribe orlistat as target not met*** - According to **NICE guidelines**, orlistat should only be prescribed or continued if a patient has lost at least **5% of their initial body weight** through lifestyle changes alone before starting medication. - This patient has achieved a **4% weight loss**, which—while positive—falls short of the required clinical threshold to justify the addition of pharmacological therapy at this review. *Orlistat can be prescribed; continue current lifestyle measures and review in 3 months* - Prescribing orlistat now is premature because the patient has not yet demonstrated the mandatory **5% weight loss** required by clinical criteria for initiation. - **Lifestyle modifications** should remain the primary focus until the specific weight loss targets are met to ensure medication efficacy and patient commitment. *Increase follow-up intensity and reassess at 6 months before considering orlistat* - While increasing support is beneficial, the standard review period for assessing the impact of lifestyle interventions regarding orlistat initiation is typically **3 months**, not 6. - Delaying the reassessment to 6 months may lead to a loss of patient **motivation** and momentum in their current weight loss progress. *Refer to specialist weight management services as first-line orlistat has not achieved target* - **Specialist referral (Tier 3/4 services)** is generally reserved for patients with a **BMI ≥40 kg/m²** or ≥35 kg/m² with significant comorbidities, which this patient does not have. - The patient is currently managed successfully in **primary care**, and there is no evidence that primary care interventions have been exhausted or failed. *Prescribe orlistat only if she loses an additional 1% body weight in the next month* - Guidelines specify a **cumulative 5% weight loss** from baseline, but they do not prescribe a specific "1% per month" additional hurdle for drug initiation. - Artificially setting a one-month deadline is not a standard protocol and does not align with the **long-term behavioral approach** recommended for obesity management.

Question 31: A 55-year-old man with schizophrenia attends for his annual physical health check. He takes olanzapine 20 mg daily. His BMI is 33 kg/m², waist circumference 108 cm, blood pressure 138/86 mmHg, fasting glucose 6.2 mmol/L, HbA1c 43 mmol/mol, total cholesterol 5.4 mmol/L, HDL 0.9 mmol/L, and triglycerides 2.8 mmol/L. Which diagnosis is most likely based on these findings?

A. Impaired glucose tolerance
B. Metabolic syndrome (Correct Answer)
C. Type 2 diabetes mellitus
D. Familial hypercholesterolaemia
E. Isolated hypertriglyceridaemia

Explanation: ***Metabolic syndrome*** - The patient meets five criteria for **metabolic syndrome**: increased **waist circumference** (108 cm > 102 cm), elevated **triglycerides** (2.8 mmol/L > 1.7 mmol/L), low **HDL** (0.9 mmol/L < 1.0 mmol/L), elevated **blood pressure** (138/86 mmHg > 130/85 mmHg), and raised **fasting glucose** (6.2 mmol/L > 5.6 mmol/L).- The use of **olanzapine**, a second-generation antipsychotic, is associated with a significantly increased risk of developing **metabolic syndrome** due to its effects on weight gain, glucose, and lipid metabolism.*Impaired glucose tolerance* - This diagnosis typically requires a **2-hour plasma glucose** between 7.8 and 11.0 mmol/L following a **75g oral glucose tolerance test (OGTT)**, which was not performed in this case.- While the patient has **impaired fasting glucose** (6.1–6.9 mmol/L) and **prediabetes** (HbA1c 43 mmol/mol or 6.1%), these are specific components of glucose dysregulation, not the overarching diagnosis that encompasses all his metabolic abnormalities.*Type 2 diabetes mellitus* - Diagnosis of **Type 2 diabetes** requires a **fasting glucose** ≥ 7.0 mmol/L or an **HbA1c** ≥ 48 mmol/mol (6.5%), and this patient's values (6.2 mmol/L and 43 mmol/mol respectively) fall below these thresholds.- Although he has multiple risk factors and features consistent with **insulin resistance**, he is currently classified as having **prediabetes** rather than established diabetes.*Familial hypercholesterolaemia* - This condition is primarily characterized by significantly elevated **LDL cholesterol** (often > 5.0 mmol/L) from birth, leading to early cardiovascular disease, and typically has a strong family history.- This patient's dyslipidaemia primarily involves **high triglycerides** and **low HDL**, with a total cholesterol of 5.4 mmol/L which is not severely elevated, making a genetic **LDL receptor defect** less likely than metabolically induced dyslipidemia.*Isolated hypertriglyceridaemia* - This diagnosis is inappropriate because the patient presents with a cluster of other significant metabolic abnormalities, including **abdominal obesity**, **hypertension**, **low HDL**, and **impaired fasting glucose**.- The elevated **triglycerides** are part of a broader systemic metabolic dysfunction, most accurately captured by the diagnosis of **metabolic syndrome**, rather than an isolated finding.

Question 32: A 72-year-old woman attends for review. She has a 3.5 cm infrarenal abdominal aortic aneurysm (AAA) detected 18 months ago through the NHS screening programme. Her latest ultrasound shows the aneurysm has grown to 4.8 cm (increase of 1.3 cm in 18 months). She is asymptomatic. What is the most appropriate next step in her management?

A. Continue annual ultrasound surveillance
B. Increase surveillance to 3-monthly intervals
C. Arrange urgent vascular surgery referral for consideration of repair (Correct Answer)
D. Arrange CT angiography and routine vascular surgery referral
E. Reassure that growth is within expected parameters and continue 6-monthly surveillance

Explanation: ***Arrange urgent vascular surgery referral for consideration of repair*** - This patient's aneurysm has shown **rapid expansion**, growing by **1.3 cm in 18 months**. This rate of growth, even if not strictly >1 cm in 12 months, is considered significant and indicates a higher risk of rupture, requiring an **urgent vascular referral** for evaluation of repair. - The current size of **4.8 cm** combined with this rapid growth necessitates immediate specialist assessment rather than continued surveillance, as it approaches the threshold for intervention. *Continue annual ultrasound surveillance* - **Annual surveillance** is typically recommended for smaller **Abdominal Aortic Aneurysms (AAA)**, generally those measuring between **3.0 cm and 4.4 cm**. - This patient's aneurysm, now **4.8 cm** and demonstrating **rapid growth**, falls outside the parameters for annual monitoring. *Increase surveillance to 3-monthly intervals* - While **3-monthly surveillance** is appropriate for asymptomatic AAAs between **4.5 cm and 5.4 cm**, the presence of **rapid expansion** (1.3 cm in 18 months) elevates the risk beyond what can be managed by increased surveillance alone. - The **rate of growth** is a critical factor and, in this case, necessitates a specialist referral for potential intervention. *Arrange CT angiography and routine vascular surgery referral* - The **rapid expansion** observed makes a **routine vascular surgery referral** inappropriate; the situation demands an **urgent assessment** due to the increased risk of rupture. - While **CT angiography** is essential for pre-operative planning, the initial and most critical step is the **urgent referral** to a vascular surgeon who will then guide further diagnostic steps. *Reassure that growth is within expected parameters and continue 6-monthly surveillance* - A growth of **1.3 cm in 18 months** is considered significant and **not within expected benign parameters** for an AAA, particularly when compared to a threshold of >1 cm in 12 months. - **6-monthly surveillance** is not a standard interval in the NHS AAA screening guidelines, which typically use annual or 3-monthly intervals based on size.

Question 33: A 59-year-old man attends for lifestyle advice. He drinks 4 units of alcohol daily (28 units per week), exclusively in the evenings. He has no alcohol-related health problems and scores 8 on the AUDIT questionnaire. According to NICE guidance on alcohol interventions, what is the most appropriate initial management?

A. Reassure and advise to continue current drinking pattern
B. Offer brief intervention focusing on cutting down (Correct Answer)
C. Refer to specialist alcohol services
D. Prescribe acamprosate for alcohol reduction
E. Arrange admission for medically-assisted alcohol withdrawal

Explanation: ***Offer brief intervention focusing on cutting down*** - The patient consumes **28 units per week**, which exceeds the recommended low-risk limit of 14 units, and his **AUDIT score of 8** categorizes him as an **increasing risk drinker** according to NICE guidelines. - For individuals in the increasing risk category, NICE recommends a **brief intervention**, involving structured advice and support to help them reduce their alcohol consumption. *Reassure and advise to continue current drinking pattern* - Reassurance is inappropriate as consuming **28 units per week** significantly exceeds the low-risk guideline, increasing long-term health risks. - An **AUDIT score of 8** indicates a need for active intervention, not simply continuing the current pattern, to mitigate future harm. *Refer to specialist alcohol services* - Referral to specialist alcohol services is generally reserved for individuals with **higher-risk drinking** (AUDIT 16-19) or diagnosed **alcohol dependence** (AUDIT 20+). - This patient's drinking pattern and AUDIT score do not meet the criteria for immediate specialist referral; a primary care intervention is more appropriate. *Prescribe acamprosate for alcohol reduction* - **Acamprosate** is a medication used to help maintain **abstinence** in patients with a history of **alcohol dependence** who have already undergone withdrawal. - It is not indicated for **increasing risk drinkers** who are not dependent and whose primary need is to reduce consumption through behavioral changes. *Arrange admission for medically-assisted alcohol withdrawal* - Medically-assisted alcohol withdrawal is necessary for individuals with significant **physical alcohol dependence** at risk of severe withdrawal symptoms like seizures or delirium tremens. - The patient exhibits no signs of physical dependence or withdrawal symptoms that would necessitate acute medical detoxification or hospital admission.

Question 34: A 36-year-old woman attends with her cervical screening result showing hrHPV positive with normal cytology. She asks about HPV vaccination. She was too old to receive the HPV vaccine in school but wonders if vaccination now would be helpful. What is the most appropriate advice regarding HPV vaccination in this situation?

A. Vaccination is recommended and will clear her current HPV infection
B. Vaccination may provide protection against other HPV types but will not clear existing infection (Correct Answer)
C. Vaccination is contraindicated in women with positive hrHPV results
D. Vaccination should be delayed until her next cervical screening in 12 months
E. Vaccination is only effective if given before first sexual contact

Explanation: ***Vaccination may provide protection against other HPV types but will not clear existing infection*** - The HPV vaccine is **prophylactic**, not therapeutic; it helps prevent new infections from the types covered by the vaccine (e.g., **Gardasil 9**) that the patient has not yet encountered. - While it cannot treat or **clear existing hrHPV**, it remains beneficial for adult women to prevent future infection with different **oncogenic strains**. *Vaccination is recommended and will clear her current HPV infection* - Clinical trials have conclusively shown that HPV vaccines have **no therapeutic effect** on pre-existing HPV infections or related **cervical lesions**. - Advising that it will clear her current infection is medically incorrect and may provide a **false sense of security** regarding her follow-up. *Vaccination is contraindicated in women with positive hrHPV results* - A positive **hrHPV test** is not a contraindication; the vaccine is safe to administer to individuals already exposed to or infected with the virus. - There is no evidence of **increased adverse effects** or worsened disease progression when vaccinating HPV-positive individuals. *Vaccination should be delayed until her next cervical screening in 12 months* - There is no clinical requirement to delay vaccination based on **cytology** or **HPV status**, as the vaccine's utility is independent of current infection. - The patient's management plan (repeat testing in 12 months) remains the same regardless of whether she chooses to receive the vaccine now. *Vaccination is only effective if given before first sexual contact* - While **maximum efficacy** is achieved when administered prior to **sexual debut**, the vaccine still offers significant protection to sexually active adults. - It is unlikely an individual has been exposed to all **nine strains** covered by modern vaccines, making it effective for prevention of other types.

Question 35: A 68-year-old man with type 2 diabetes attends following his diabetic eye screening. The report states 'R1M1S0' for the right eye and 'R1M0S0' for the left eye. What action should be taken based on these grading results?

A. Routine annual screening in 12 months
B. Accelerated screening in 6 months
C. Urgent ophthalmology referral within 2 weeks
D. Routine ophthalmology referral within 13 weeks (Correct Answer)
E. Immediate same-day ophthalmology referral

Explanation: ***Routine ophthalmology referral within 13 weeks***- The **M1 grading** in the right eye signifies **maculopathy**, indicating diabetic changes affecting the **macula**.- **Maculopathy (M1)** necessitates a **routine ophthalmology referral** for further assessment and potential treatment, typically within **13 weeks**, to prevent vision loss.*Routine annual screening in 12 months*- This interval is appropriate for patients with **R0M0** (no retinopathy) or **R1M0** (background retinopathy without maculopathy).- The presence of **M1 (maculopathy)** requires prompt specialist evaluation, as annual screening would delay necessary intervention for a condition threatening central vision.*Accelerated screening in 6 months*- **Accelerated screening** (e.g., 6 months) is typically recommended for **R2 (pre-proliferative retinopathy)** without maculopathy, where close monitoring is indicated.- **Maculopathy (M1)** warrants a direct **specialist referral** rather than just a shorter screening interval, due to the direct impact on central vision.*Urgent ophthalmology referral within 2 weeks*- An **urgent referral** (within 2 weeks) is usually reserved for **R3 (proliferative diabetic retinopathy)** with high-risk features like new vessels, or severe active maculopathy with rapid vision changes.- While M1 is significant, it generally follows a **routine referral pathway** unless accompanied by acute severe symptoms or proliferative features.*Immediate same-day ophthalmology referral*- **Same-day referral** is reserved for true ophthalmic emergencies, such as **retinal detachment**, acute angle-closure glaucoma, or sudden severe vision loss potentially from vitreous hemorrhage due to R3.- **R1M1** describes established diabetic retinopathy and maculopathy, which, while serious, does not typically constitute a same-day emergency unless acute, rapid changes are noted.

Question 36: A 42-year-old woman with a BMI of 34 kg/m² attends for weight management advice. She has tried multiple diets without sustained success. She asks about orlistat. Her blood pressure is 142/88 mmHg and HbA1c is 41 mmol/mol. According to NICE guidance, what is the minimum BMI threshold at which orlistat can be prescribed for this patient?

A. BMI ≥25 kg/m²
B. BMI ≥28 kg/m² (Correct Answer)
C. BMI ≥30 kg/m²
D. BMI ≥32 kg/m²
E. BMI ≥35 kg/m²

Explanation: ***BMI ≥28 kg/m²*** - According to **NICE guidelines**, orlistat may be prescribed for patients with a **BMI ≥28 kg/m²** if they have associated **co-morbidities**, such as hypertension or type 2 diabetes. - This patient qualifies at this lower threshold because she has **hypertension** (142/88 mmHg), making orlistat a valid pharmacological option. *BMI ≥25 kg/m²* - A **BMI ≥25 kg/m²** is the threshold for being classified as **overweight**, but it does not meet the pharmacological intervention criteria for orlistat. - **Weight management** at this level typically focuses exclusively on diet, exercise, and lifestyle modifications rather than medication. *BMI ≥30 kg/m²* - This is the standard threshold for prescribing orlistat in patients who have **no co-morbidities**. - While this patient’s BMI of 34 exceeds this, the **minimum threshold** is lower (28) because of her existing clinical risk factor (hypertension). *BMI ≥32 kg/m²* - This is not a standard NICE diagnostic threshold for initiating orlistat therapy in the general population. - However, lower thresholds (starting at **BMI 27.5 kg/m²**) may be considered for individuals from **South Asian** or other minority ethnic groups due to increased metabolic risk. *BMI ≥35 kg/m²* - This threshold is often used in the context of referring patients for **Tier 3 specialist weight management** services or considering **bariatric surgery** if co-morbidities exist. - Orlistat is available much earlier in the treatment pathway to prevent progression to this level of obesity.

Question 37: A 65-year-old woman attends for her NHS breast screening mammogram. She mentions that her sister was diagnosed with ovarian cancer at age 58, and her maternal aunt had breast cancer at age 52. She asks whether she should have genetic testing. Which criterion from the NICE guidelines would indicate referral to genetic services for possible BRCA testing?

A. One first-degree relative with breast cancer under 60 years
B. Two relatives on the same side of the family with ovarian cancer at any age (Correct Answer)
C. One second-degree relative with breast cancer under 50 years
D. One first-degree relative with ovarian cancer over 50 years
E. Three relatives on different sides of the family with breast cancer

Explanation: ***Two relatives on the same side of the family with ovarian cancer at any age***- According to **NICE guidelines (NG164)**, having two or more relatives on the **same side of the family** diagnosed with **ovarian cancer** at any age is a specific criterion for specialist genetic referral.- This reflects the high probability of a **BRCA1** or **BRCA2** mutation within the family, as ovarian cancer is a potent indicator of hereditary breast and ovarian cancer syndrome.*One first-degree relative with breast cancer under 60 years*- A single first-degree relative with breast cancer typically requires the diagnosis to be under **age 40** (not 60) for referral, or the presence of other associated cancers.- Under the age of 60, NICE usually requires **two first-degree relatives** or one first-degree and one second-degree relative to warrant referral.*One second-degree relative with breast cancer under 50 years*- Family history criteria generally prioritize the **number of relatives** and their degree of relatedness; a lone second-degree relative does not meet the threshold for referral regardless of age.- Clinical concern increases if there are multiple second-degree relatives or if the cancer occurs in a **male relative**.*One first-degree relative with ovarian cancer over 50 years*- While ovarian cancer is a significant risk marker, a **single case** (unless the individual has both breast and ovarian cancer) is insufficient for genetic service referral under standard guidelines.- Referral for a single relative with ovarian cancer is usually only considered if they were diagnosed at a **very young age** in specific population groups or if combined with other family history.*Three relatives on different sides of the family with breast cancer*- To meet NICE criteria for genetic risk, the affected relatives must be on the **same side of the family** (either maternal or paternal) to track a single inherited mutation.- Cancer cases on **different sides of the family** are usually treated as separate, lower-risk clusters unless they are individual high-risk cases on both sides.

Question 38: A 47-year-old man attends for advice about physical activity. He has a BMI of 29 kg/m², hypertension controlled on ramipril, and works a sedentary office job. He currently does no regular exercise. According to UK Chief Medical Officers' physical activity guidelines, what is the minimum recommended amount of moderate-intensity aerobic activity per week for adults?

A. 75 minutes per week
B. 100 minutes per week
C. 150 minutes per week (Correct Answer)
D. 200 minutes per week
E. 300 minutes per week

Explanation: ***150 minutes per week*** - The **UK Chief Medical Officers'** guidelines recommend that adults accumulate at least **150 minutes** of **moderate-intensity aerobic activity** per week to maintain health. - This activity should ideally be spread across the week and can be combined with **muscle-strengthening** activities on at least two days. *75 minutes per week* - This is the minimum recommended duration for **vigorous-intensity aerobic activity**, such as running or fast cycling, rather than moderate-intensity. - Engaging in **vigorous activity** provides similar health benefits in half the time compared to moderate activity. *100 minutes per week* - While performing **100 minutes** of activity is better than being sedentary, it falls short of the evidence-based **150-minute threshold** for optimal health outcomes. - There is no specific UK guideline designating 100 minutes as a primary target for **aerobic exercise**. *200 minutes per week* - While exceeding the minimum 150 minutes provides **additional health benefits**, it is not the standard "minimum" recommendation for adults. - Clinicians should encourage increasing activity levels beyond 150 minutes for further **cardiovascular risk reduction**. *300 minutes per week* - This level is often cited for more significant **weight loss** or specific metabolic improvements but is not the baseline public health requirement. - For a sedentary patient starting out, aiming for **300 minutes** initially may be unrealistic compared to the standard 150-minute goal.

Question 39: A 51-year-old woman attends for discussion about her NHS breast screening invitation. She has read online about overdiagnosis and wants to understand what this means. Which statement best explains the concept of overdiagnosis in breast cancer screening?

A. Detection of breast cancers that are too advanced to treat effectively
B. False positive results leading to unnecessary biopsies
C. Detection of cancers that would never have caused symptoms or death in the woman's lifetime (Correct Answer)
D. Missing breast cancers due to limitations of mammography
E. Detecting breast cancers in women outside the screening age range

Explanation: ***Detection of cancers that would never have caused symptoms or death in the woman's lifetime*** - **Overdiagnosis** refers specifically to the identification of true histological malignancies through screening that are **indolent** and would not have clinically progressed within the patient's natural lifespan. - It leads to **overtreatment**, where patients undergo surgery, radiotherapy, or chemotherapy for a condition that would never have naturally harmed them. *Detection of breast cancers that are too advanced to treat effectively* - This describes a **poor prognosis** or screening failure where the cancer is detected at a late stage rather than too early. - Overdiagnosis is the opposite; it typically involves detecting **very early-stage** or slow-growing lesions like ductal carcinoma in situ (**DCIS**). *False positive results leading to unnecessary biopsies* - A **false positive** occurs when an initial screening test is abnormal, but subsequent diagnostic tests prove that **no cancer** is present. - In overdiagnosis, the woman **actually has cancer** cells present, but the cancer lacks the biological potential to cause clinical disease. *Missing breast cancers due to limitations of mammography* - This refers to **false negatives**, where a malignancy is present but not detected by the screening tool. - These cases often present as **interval cancers**, which appear in the time period between scheduled screening rounds. *Detecting breast cancers in women outside the screening age range* - The **NHS Breast Screening Programme** typically targets women aged 50 to 71; detecting cancers outside this range refers to **opportunistic screening** or diagnostic testing. - This does not define overdiagnosis, as the concept relates to the **biological behavior** of the tumor rather than the patient's age.

Question 40: A 56-year-old woman with type 2 diabetes attends for her annual diabetic eye screening. The report shows dot and blot haemorrhages in all four quadrants, venous beading in two quadrants, and intraretinal microvascular abnormalities (IRMA) in one quadrant. No neovascularisation is seen. What grade of diabetic retinopathy does this represent?

A. Moderate non-proliferative diabetic retinopathy
B. Severe non-proliferative diabetic retinopathy (Correct Answer)
C. Proliferative diabetic retinopathy
D. Advanced diabetic eye disease
E. Diabetic maculopathy

Explanation: ***Severe non-proliferative diabetic retinopathy***

Question 41: A 54-year-old man attends for his first NHS Health Check. He asks about the cholesterol blood test. What is the primary lipid measurement used to assess cardiovascular risk in the NHS Health Check programme?

A. Total cholesterol
B. Non-HDL cholesterol (Correct Answer)
C. LDL cholesterol
D. HDL cholesterol
E. Triglycerides

Explanation: ***Non-HDL cholesterol***- Per **NICE guidelines** and the **NHS Health Check** protocol, **non-HDL cholesterol** is the preferred lipid parameter for assessing **cardiovascular risk**.- It is calculated as **total cholesterol minus HDL cholesterol** and represents the total amount of **atherogenic lipoproteins** (LDL, VLDL, and IDL) in the blood.*Total cholesterol*- While measured during the check, it is used primarily to calculate the **non-HDL** value and the **total cholesterol:HDL ratio**.- On its own, total cholesterol is less predictive of risk than non-HDL because it includes **"good" HDL cholesterol**.*LDL cholesterol*- LDL cholesterol is a significant risk factor, but its calculation often requires a **fasting sample** to be accurate via the Friedewald formula.- **Non-HDL cholesterol** is favored in primary care because it can be measured accurately in **non-fasting** states, unlike calculated LDL.*HDL cholesterol*- HDL is known as **"good" cholesterol** and is used as a component to determine the overall risk profile rather than a primary target.- A high HDL level is generally **cardioprotective**, but it does not serve as the primary measurement for assessing total lipid-related risk.*Triglycerides*- Triglycerides are highly variable and sensitive to recent food intake, making them unsuitable as a **primary screening** tool in non-fasting checks.- While important for specific cases like **metabolic syndrome**, they are not the primary lipid measurement used in the **QRISK3** calculator for general health checks.

Question 42: A 63-year-old man attends for results of his NHS bowel cancer screening FIT test showing 120 micrograms Hb/g faeces. He underwent colonoscopy which identified a 3cm polyp in the sigmoid colon. Histology confirms a tubulovillous adenoma with high-grade dysplasia, completely excised with clear margins. He asks about his ongoing screening. What is the most appropriate surveillance strategy for this patient?

A. Return to routine NHS bowel cancer screening programme (FIT every 2 years)
B. Colonoscopic surveillance at 3 years
C. Colonoscopic surveillance at 1 year (Correct Answer)
D. Colonoscopic surveillance at 6 months
E. Annual FIT testing for 5 years then return to routine screening

Explanation: ***Colonoscopic surveillance at 1 year*** - According to the **British Society of Gastroenterology (BSG)** guidelines, any adenoma **≥10mm** or with **high-grade dysplasia** (HGD) classifies the patient as high-risk. - This patient's **3cm tubulovillous adenoma** with HGD requires a follow-up colonoscopy at **one year** to ensure clearance and detect early recurrence. *Return to routine NHS bowel cancer screening programme (FIT every 2 years)* - Patients meeting **high-risk criteria** are moved into a dedicated surveillance program rather than continuing with standard **population screening**. - Returning to routine **FIT testing** alone would risk missing metachronous lesions that require direct visual inspection. *Colonoscopic surveillance at 3 years* - While a 3-year interval is appropriate for some lower-risk findings, a **3cm lesion with HGD** is too advanced for this delay. - A **three-year interval** is typically reserved for follow-up *after* the initial one-year clear surveillance colonoscopy has been performed. *Colonoscopic surveillance at 6 months* - A **six-month interval** is generally unnecessary for an adenoma that was **completely excised** with clear margins. - Such frequent surveillance is more commonly associated with **piecemeal excision** of large sessile lesions to check for site recurrence. *Annual FIT testing for 5 years then return to routine screening* - **Annual FIT** is not a substitute for colonoscopic surveillance in patients who have already developed **advanced adenomas**. - Guidelines mandate **visual assessment** (colonoscopy) because FIT has insufficient sensitivity to reliably detect all precancerous polyps during the surveillance period.

Question 43: A 43-year-old woman with a family history of breast cancer asks about risk-reducing strategies. Her mother was diagnosed with breast cancer at age 48 and her maternal aunt at age 52. She has no personal history of breast disease. She does not meet criteria for genetic testing. Which lifestyle modification is supported by the strongest evidence for breast cancer risk reduction in this patient?

A. Maintaining a healthy weight and avoiding obesity, particularly after menopause (Correct Answer)
B. Avoiding all alcohol consumption
C. Taking aspirin 75mg daily as chemoprevention
D. Vitamin D supplementation 4000 IU daily
E. Increasing dietary phytoestrogen intake through soy products

Explanation: ***Maintaining a healthy weight and avoiding obesity, particularly after menopause*** - Obesity is a major modifiable risk factor because **adipose tissue** is the primary source of **estrogen production** via aromatase in postmenopausal women. - High **serum estrogen levels** directly increase the risk of hormone-receptor-positive breast cancers, making weight management a cornerstone of prevention. *Avoiding all alcohol consumption* - While **alcohol consumption** has a dose-dependent relationship with increased breast cancer risk, the overall impact on risk reduction is generally considered less robust than weight management in the population. - Guidelines suggest limiting intake to less than one drink per day, but **complete avoidance** is not supported by stronger evidence than maintaining a healthy weight. *Taking aspirin 75mg daily as chemoprevention* - **Aspirin** and other NSAIDs have shown potential in reducing colorectal cancer risk, but their role in **breast cancer prevention** is not established in clinical guidelines. - Daily use for breast cancer risk reduction is not recommended due to insufficient evidence and the risk of **gastrointestinal bleeding**. *Vitamin D supplementation 4000 IU daily* - Although observational studies suggested a link between **Vitamin D** and cancer, large randomized trials have failed to show a significant reduction in **breast cancer incidence** with supplementation. - High-dose supplementation (4000 IU) is not indicated for cancer prevention and carries risks of **hypercalciuria and hypercalcemia**. *Increasing dietary phytoestrogen intake through soy products* - Evidence regarding **phytoestrogens** (like isoflavones) and breast cancer risk is inconsistent and varies significantly between Western and Asian populations. - Current guidelines do not recommend increasing soy intake specifically for **breast cancer chemoprevention** due to the lack of clear, reproducible evidence.

Question 44: A 71-year-old woman with type 2 diabetes, hypertension, and stage 3a CKD attends for cardiovascular risk assessment. Her medications include metformin, ramipril, and amlodipine. She has never smoked. Her BP is 134/78 mmHg, BMI 29 kg/m², total cholesterol 5.2 mmol/L, LDL 3.1 mmol/L, HDL 1.3 mmol/L. She is not currently on a statin. According to NICE guidelines, what is the most appropriate approach to lipid management?

A. No statin required as her cholesterol levels are acceptable for her age
B. Calculate QRISK3 score; offer statin if ≥10%
C. Offer atorvastatin 20mg as she has type 2 diabetes regardless of cholesterol level (Correct Answer)
D. Offer atorvastatin 80mg as she has established cardiovascular disease
E. Arrange specialist lipid clinic referral for consideration of PCSK9 inhibitor therapy

Explanation: ***Offer atorvastatin 20mg as she has type 2 diabetes regardless of cholesterol level***- **NICE guidelines** (CG181) recommend offering **atorvastatin 20mg** for the **primary prevention** of CVD to all patients with **Type 2 Diabetes** who have a 10% or greater 10-year risk or those over age 40.- This patient also has **Stage 3a CKD**, which is an independent indication for initiating **atorvastatin 20mg** for primary prevention of cardiovascular events.*No statin required as her cholesterol levels are acceptable for her age*- Statin therapy in Type 2 Diabetes is based on **cardiovascular risk profile**, not on reaching a specific "acceptable" baseline cholesterol level.- Her age and comorbidities places her in a high-risk category where **primary prevention** is clinically indicated regardless of current lipid values.*Calculate QRISK3 score; offer statin if ≥10%*- **QRISK3** is not typically required for patients with Type 2 Diabetes to justify a statin, as most meet the threshold for therapy based on **age** or **organ damage** (like CKD).- In clinical practice, adults with Type 2 Diabetes are considered high risk and should be offered a statin if they are **older than 40** or have complications.*Offer atorvastatin 80mg as she has established cardiovascular disease*- High-intensity **atorvastatin 80mg** is reserved for **secondary prevention** in patients with established CVD (e.g., previous MI, stroke, or PAD).- There is no evidence in the presentation that she has **established cardiovascular disease** yet, making 20mg the appropriate starting dose for primary prevention.*Arrange specialist lipid clinic referral for consideration of PCSK9 inhibitor therapy*- **PCSK9 inhibitors** are specialized treatments reserved for patients with **familial hypercholesterolaemia** or those who fail to reach targets on maximum-dose statins and ezetimibe.- This patient has not yet started first-line therapy with a **low-dose statin**, making a specialist referral for advanced biologics inappropriate at this stage.

Question 45: A 55-year-old man with type 2 diabetes for 6 years attends for his annual diabetic retinopathy screening result. The report indicates R1 (background retinopathy) with microaneurysms in both eyes. His HbA1c is 64 mmol/mol, BP 142/86 mmHg. He asks what this result means and what follow-up is needed. What is the most appropriate screening interval for diabetic retinopathy in this patient?

A. Urgent ophthalmology referral within 2 weeks
B. Routine ophthalmology referral for assessment within 6 weeks
C. Repeat retinopathy screening in 6 months
D. Repeat retinopathy screening in 12 months (Correct Answer)
E. Discharge from retinopathy screening as stable findings

Explanation: ***Repeat retinopathy screening in 12 months*** - **R1 (background retinopathy)** is characterized by **microaneurysms** and is considered the earliest stage of diabetic retinopathy without immediate sight-threatening features. - Patients with **R1 changes** and no maculopathy typically follow a **12-month (annual) screening interval**, while emphasizing **HbA1c** and **blood pressure** control to prevent progression. *Urgent ophthalmology referral within 2 weeks* - This referral pathway is reserved for **R3 (proliferative retinopathy)**, which involves **neovascularization** or vitreous hemorrhage, indicating a sight-threatening emergency. - It is also indicated for sudden, severe **visual loss** or rubeosis iridis, which are not described in this patient's R1 report. *Routine ophthalmology referral for assessment within 6 weeks* - Routine ophthalmology referral is typically indicated for **R2 (pre-proliferative retinopathy)**, characterized by signs like cotton wool spots, or **M1 (maculopathy)**. - **Background retinopathy (R1)** without maculopathy is managed within the standard diabetic retinopathy screening program, not via routine ophthalmology referral. *Repeat retinopathy screening in 6 months* - **Six-monthly screening** is usually reserved for specific high-risk scenarios, such as stable **pre-proliferative disease** or for patients managed under a digital surveillance clinic. - For a standard finding of **R1 background retinopathy** without other complications, increasing screening frequency to 6 months is not the standard clinical guideline. *Discharge from retinopathy screening as stable findings* - Patients with type 2 diabetes require lifelong screening because they remain at constant risk for **sight-threatening complications** as long as the underlying disease persists. - **R1 findings** indicate that early retinal damage has begun, necessitating continued monitoring rather than discharge to detect any potential **progression**.

Question 46: A 32-year-old woman attends with her cervical screening result showing hrHPV negative. She mentions that 2 years ago, at her previous screen, the result was hrHPV positive with normal cytology and she was recalled at 12 months, at which time hrHPV was still positive with normal cytology. She asks why she has been told to attend again in 3 years rather than sooner given her previous positive results. What is the most appropriate explanation?

A. The previous hrHPV positive results were false positives and can be disregarded
B. hrHPV clearance has occurred; she returns to routine 3-yearly screening as the current negative result indicates low risk (Correct Answer)
C. She should be recalled in 12 months as previous persistent HPV infection indicates higher risk
D. She needs colposcopy referral as HPV clearance after persistent infection suggests immune suppression
E. She should have annual screening for the next 10 years due to previous HPV persistence

Explanation: ***hrHPV clearance has occurred; she returns to routine 3-yearly screening as the current negative result indicates low risk***- In the NHS cervical screening programme, a woman who becomes **hrHPV negative** after previous persistent infection is considered at **very low risk** for cervical disease.- A negative hrHPV result warrants a return to **routine recall intervals** (every 3 years for those aged 25-49) regardless of previous positive results.*The previous hrHPV positive results were false positives and can be disregarded*- These results were likely **true positives** reflecting a **transient infection** that the immune system has now successfully cleared.- Calling them false positives is medically inaccurate as **HPV clearance** within 1-2 years is a well-documented clinical occurrence.*She should be recalled in 12 months as previous persistent HPV infection indicates higher risk*- A **12-month recall** is only used when the current result is hrHPV positive with **normal cytology** to monitor for persistence.- Since the current test is negative, the short-term risk of developing **CIN3 or cervical cancer** is negligible, making frequent testing unnecessary.*She needs colposcopy referral as HPV clearance after persistent infection suggests immune suppression*- **Colposcopy** is indicated if hrHPV is persistent for 24 months or if there are **cytological abnormalities**, neither of which apply here.- **HPV clearance** is actually a sign of a robust and effective **immune response**, not immune suppression.*She should have annual screening for the next 10 years due to previous HPV persistence*- There is no clinical guideline suggesting **annual screening** for a decade following a single period of HPV persistence that has now resolved.- Excessive screening increases the risk of **over-diagnosis** and unnecessary patient anxiety without providing additional prophylactic benefit.

Question 47: A 67-year-old man with a 4.2 cm infrarenal abdominal aortic aneurysm (AAA) detected through NHS screening attends for review. He is asymptomatic. His BP is 158/92 mmHg. He continues to smoke 10 cigarettes daily despite previous advice. What is the single most important intervention to reduce his risk of AAA rupture?

A. Immediate surgical repair given the aneurysm size
B. Optimising blood pressure control with target <140/90 mmHg
C. Smoking cessation support and intervention (Correct Answer)
D. Commencing statin therapy if not already prescribed
E. Arranging urgent vascular surgery outpatient assessment

Explanation: ***Smoking cessation support and intervention*** - **Smoking** is the single most significant modifiable risk factor for **AAA expansion** and has the strongest association with **rupture risk**. - Evidence confirms that continued tobacco use increases the rate of **aneurysm growth** significantly compared to non-smokers. *Immediate surgical repair given the aneurysm size* - Elective surgical repair for men is generally only indicated when the aneurysm exceeds **5.5 cm** or grows by **>1 cm per year**. - At **4.2 cm**, this is classified as a small aneurysm, where the risks of surgery outweigh the risk of rupture. *Optimising blood pressure control with target <140/90 mmHg* - While **hypertension management** is vital for reducing general **cardiovascular mortality**, its impact on preventing AAA rupture is less potent than smoking cessation. - This patient does require better BP control, but it is not the single most important intervention for **aneurysm-specific stability**. *Commencing statin therapy if not already prescribed* - **Statins** are indicated for all patients with AAA to manage **atherosclerotic risk** and lower the incidence of cardiovascular events. - Although they improve long-term survival, they do not reduce the **rupture risk** as effectively as stopping smoking. *Arranging urgent vascular surgery outpatient assessment* - Under NHS screening protocols, an aneurysm of **4.2 cm** requires surveillance (typically every **3 months**) rather than urgent referral. - Urgent vascular assessment is usually reserved for symptomatic patients or those with a diameter reaching the **5.5 cm threshold**.

Question 48: A 47-year-old woman attends requesting advice about alcohol consumption. She drinks half a bottle of wine (13% ABV, 750ml bottle) most evenings, approximately 5 nights per week. She works as a lawyer and finds it helps her unwind. She has no medical problems and takes no medications. Using the AUDIT-C screening tool, her score is 7. What is the most appropriate initial management approach?

A. Reassure that her drinking is within safe limits and requires no intervention
B. Provide brief advice about reducing alcohol consumption and give information on unit guidelines (Correct Answer)
C. Refer immediately to community alcohol services for specialist assessment
D. Prescribe thiamine and arrange follow-up in 2 weeks
E. Arrange liver function tests and liver ultrasound before discussing reduction

Explanation: ***Provide brief advice about reducing alcohol consumption and give information on unit guidelines*** - An **AUDIT-C score of 7** indicates **increasing risk** drinking (hazardous drinking), for which the primary intervention is **brief advice** or a brief intervention (BI). - The patient consumes roughly **24 units per week**, which significantly exceeds the recommended limit of **14 units per week** for women, necessitating education on **health risks** and reduction strategies. *Reassure that her drinking is within safe limits and requires no intervention* - Reassurance is incorrect because her intake of **24 units per week** is well above the **14-unit threshold** for women, indicating hazardous drinking. - Failing to intervene in a patient with an elevated **AUDIT-C score** (7) neglects the opportunity to prevent progression to **alcohol dependence** or serious health complications. *Refer immediately to community alcohol services for specialist assessment* - Specialist referral is typically reserved for **high-risk/dependent** drinkers (e.g., AUDIT score 20+) or those requiring **supervised detoxification** due to withdrawal symptoms. - This patient, while drinking hazardously, shows no immediate signs of **physical dependence** or severe social dysfunction that would justify immediate **specialist intervention** at this initial stage. *Prescribe thiamine and arrange follow-up in 2 weeks* - **Thiamine supplementation** is indicated for those with **chronic alcohol dependence**, signs of **malnutrition**, or risk of **Wernicke’s encephalopathy**, none of which are explicitly evident here. - This patient does not meet the criteria for **high-risk dependence** or nutrient deficiency based on her clinical profile, and brief advice is the first step. *Arrange liver function tests and liver ultrasound before discussing reduction* - While **LFTs** can be a useful tool for monitoring, the delivery of **brief advice** about alcohol reduction should not be delayed by waiting for diagnostic investigations. - **Liver ultrasound** is not a primary screening tool for hazardous drinking; it is generally reserved for suspected **cirrhosis** or significantly abnormal blood results warranting further investigation.

Question 49: A 29-year-old woman who is 9 weeks pregnant attends for booking. She previously had a termination of pregnancy 4 years ago and declined antenatal screening at that time. She now wishes to have all recommended screening tests. Her booking bloods include screening for infectious diseases. Which combination of infections is routinely screened for in all pregnant women in the UK?

A. HIV, hepatitis B, hepatitis C, syphilis, and toxoplasmosis
B. HIV, hepatitis B, syphilis, and rubella immunity (Correct Answer)
C. HIV, hepatitis B, hepatitis C, and group B streptococcus
D. HIV, syphilis, rubella immunity, and cytomegalovirus
E. Hepatitis B, hepatitis C, syphilis, and chlamydia

Explanation: ***HIV, hepatitis B, syphilis, and rubella immunity*** - In the UK, the **NHS Infectious Diseases in Pregnancy Screening (IDPS)** program routinely offers screening for **HIV**, **hepatitis B**, and **syphilis** at the booking appointment to prevent **vertical transmission**. - Screening for **rubella immunity** is standard practice to identify susceptible women for **postpartum MMR vaccination**, protecting against congenital rubella syndrome. *HIV, hepatitis B, hepatitis C, syphilis, and toxoplasmosis* - **Toxoplasmosis** screening is not routinely recommended in the UK due to its low prevalence and concerns about test **specificity and sensitivity**. - **Hepatitis C** is not universally screened for in all pregnant women, though it may be offered to those at **high risk** or in specific pilot programs. *HIV, hepatitis B, hepatitis C, and group B streptococcus* - **Group B Streptococcus (GBS)** is not routinely screened for in the UK using antenatal swabs; instead, a **risk-based approach** guides intrapartum antibiotic prophylaxis. - As mentioned, **Hepatitis C** is not part of the national universal antenatal screening program. *HIV, syphilis, rubella immunity, and cytomegalovirus* - **Cytomegalovirus (CMV)** is not included in routine screening as there is currently no universally effective **prenatal treatment** or vaccine to prevent congenital infection. - This option incorrectly omits **Hepatitis B**, which is a crucial part of routine screening to ensure timely **neonatal vaccination** and immunoglobulin administration if needed. *Hepatitis B, hepatitis C, syphilis, and chlamydia* - **Chlamydia** screening is part of the **National Chlamydia Screening Programme** for sexually active individuals under 25, but it is not a routine universal booking blood test for all pregnant women. - Critically, **HIV** screening is absent from this list, despite being a fundamental component of antenatal screening for preventing **mother-to-child transmission**.

Question 50: A 66-year-old man with a 50 pack-year smoking history quit smoking 3 months ago using varenicline. He remains abstinent and attends for follow-up. He asks about his ongoing cancer risk now that he has stopped smoking. Which statement most accurately describes his lung cancer risk following smoking cessation?

A. His lung cancer risk returns to that of a never-smoker within 5 years of stopping
B. His lung cancer risk immediately begins to decline but remains elevated compared to never-smokers for at least 20 years (Correct Answer)
C. His lung cancer risk plateaus at current levels and does not decrease after stopping smoking
D. His lung cancer risk decreases by 50% within the first year of stopping smoking
E. His lung cancer risk equals that of a never-smoker once he reaches 10 years of abstinence

Explanation: ***His lung cancer risk immediately begins to decline but remains elevated compared to never-smokers for at least 20 years*** - **Smoking cessation** initiates a progressive decline in lung cancer risk; however, due to **cumulative DNA damage** and cellular changes, it never fully reverts to that of a **never-smoker**. - For a heavy smoker with a **50 pack-year history**, significant residual risk persists, often remaining elevated for **20-25 years or more**, still approximately double that of a never-smoker. *His lung cancer risk returns to that of a never-smoker within 5 years of stopping* - The **carcinogenic effects** of long-term smoking, including **mutations** and tissue damage, are not fully reversible within just **5 years**. - While other health benefits accrue rapidly, a 5-year period is too short for a heavy smoker's lung cancer risk to equalize with that of a **never-smoker**. *His lung cancer risk plateaus at current levels and does not decrease after stopping smoking* - This statement is inaccurate; stopping smoking immediately halts further exposure to **carcinogens**, preventing new damage and allowing some **repair mechanisms** to begin. - Numerous **epidemiological studies** consistently show a **gradual reduction** in lung cancer risk with increased duration of **abstinence**. *His lung cancer risk decreases by 50% within the first year of stopping smoking* - While improvements in **cardiovascular risk** are rapid post-cessation, the reduction in **lung cancer risk** is much more protracted. - It typically takes **10 to 15 years** of sustained abstinence for a former smoker to achieve a **50% reduction** in lung cancer risk compared to someone who continues to smoke. *His lung cancer risk equals that of a never-smoker once he reaches 10 years of abstinence* - Even after **10 years of abstinence**, a former heavy smoker's risk of lung cancer remains **significantly elevated** compared to an individual who has never smoked. - This persistent risk is why **lung cancer screening guidelines** often recommend continued screening for individuals with a substantial smoking history for many years post-cessation.

Question 51: A 54-year-old woman with a BMI of 36 kg/m² attends for weight management support. She has tried multiple diets over the years with temporary success but regains weight. She has no other comorbidities. Her HbA1c is 40 mmol/mol. She is motivated to lose weight but feels she needs additional support beyond lifestyle advice. Which pharmaceutical intervention is most appropriate to offer alongside lifestyle modification?

A. Orlistat 120mg three times daily with meals (Correct Answer)
B. Liraglutide 3mg subcutaneous injection once daily
C. Metformin 500mg twice daily
D. Semaglutide 2.4mg subcutaneous injection once weekly
E. Naltrexone-bupropion combination therapy

Explanation: ***Orlistat 120mg three times daily with meals***- Per **NICE guidelines**, orlistat is the first-line pharmacological treatment for weight loss in adults with a **BMI ≥30 kg/m²** (or ≥28 kg/m² with comorbidities) who have failed lifestyle changes.- It acts as a **lipase inhibitor**, preventing the absorption of approximately 30% of dietary fat in the gastrointestinal tract.*Liraglutide 3mg subcutaneous injection once daily*- This **GLP-1 receptor agonist** is generally considered a second-line option and often requires an assessment of pre-diabetes or specific cardiovascular risk factors under specialist care.- While effective, it is much more **costly** and invasive than oral orlistat, making it less appropriate as the very first pharmaceutical step in primary care for this patient.*Metformin 500mg twice daily*- Metformin is primarily an **antihyperglycemic agent** and is not currently licensed in the UK specifically for weight loss in patients without diabetes.- The patient’s **HbA1c of 40 mmol/mol** is within the non-diabetic range, making this intervention inappropriate for her clinical profile.*Semaglutide 2.4mg subcutaneous injection once weekly*- While a powerful **GLP-1 analogue** for weight management, NICE restricts its use to specialist weight management services for those with a **BMI ≥35 kg/m²** and at least one weight-related comorbidity.- Since this patient has **no other comorbidities**, she does not meet the specific threshold for semaglutide initiation in many clinical pathways over orlistat.*Naltrexone-bupropion combination therapy*- This drug acts on the **reward system** in the brain to reduce cravings, but it is not typically initiated as a first-line therapy in standard primary care settings.- It carries a higher burden of **central nervous system side effects** and contraindications compared to the localized action of orlistat.

Question 52: A 62-year-old man attends following his NHS bowel cancer screening. His faecal immunochemical test (FIT) result shows haemoglobin concentration of 85 micrograms/g faeces. He is asymptomatic with no weight loss or change in bowel habit. His past medical history includes diverticular disease diagnosed 5 years ago. What is the most appropriate next step in his management?

A. Reassure and repeat FIT in 2 years as the result is within normal limits
B. Refer routinely to gastroenterology for colonoscopy within 6 weeks
C. Arrange urgent suspected cancer pathway referral for colonoscopy within 2 weeks (Correct Answer)
D. Prescribe iron supplementation and repeat FIT in 3 months
E. Arrange CT colonography as first-line investigation due to his diverticular disease

Explanation: ***Arrange urgent suspected cancer pathway referral for colonoscopy within 2 weeks***- A **faecal immunochemical test (FIT)** result of **85 micrograms/g** is significantly above the threshold for a positive screening result (usually **≥10-120 μg/g** depending on the regional program).- Regardless of being **asymptomatic**, any positive result in the **NHS bowel cancer screening** program necessitates an **urgent 2-week wait (2WW)** referral for investigation, typically via colonoscopy.*Reassure and repeat FIT in 2 years as the result is within normal limits*- This result is not normal; it is **positive**, and delaying for two years would risk missing an early-stage malignancy.- Routine screening intervals only apply to patients with a **negative FIT** result.*Refer routinely to gastroenterology for colonoscopy within 6 weeks*- A positive screening test requires an **urgent referral** under the suspected cancer pathway rather than a routine referral.- **Routine pathways** are insufficient for managing the high predictive value of colorectal cancer associated with an elevated FIT.*Prescribe iron supplementation and repeat FIT in 3 months*- Repeating the FIT is inappropriate when a test is already positive, as it does not rule out intermittent bleeding from a **malignancy**.- Treating potential **iron deficiency** without investigating the source of bleeding (the bowel) violates standard oncology diagnostic protocols.*Arrange CT colonography as first-line investigation due to his diverticular disease*- **Colonoscopy** remains the gold-standard first-line investigation for a positive screening FIT as it allows for **biopsy** and **polypectomy**.- **CT colonography** is generally reserved for patients who are unfit for colonoscopy or where colonoscopy was incomplete, regardless of a history of **diverticular disease**.

Question 53: A 27-year-old woman attends with her first cervical screening result. The hrHPV test is positive, and cytology shows low-grade dyskaryosis. She is anxious and asks what this means for her risk of cervical cancer. What is the most appropriate explanation regarding her current result?

A. She has early cervical cancer and requires urgent colposcopy within 2 weeks
B. She has pre-cancerous changes that will definitely progress to cancer without treatment
C. She has HPV infection with mild cellular changes that may resolve spontaneously, but requires colposcopy for assessment (Correct Answer)
D. She needs immediate treatment with loop excision to prevent cancer development
E. She has normal cervical cells and can return to routine screening in 3 years

Explanation: ***She has HPV infection with mild cellular changes that may resolve spontaneously, but requires colposcopy for assessment***- A positive **hrHPV** test with **low-grade dyskaryosis** signifies an active HPV infection with mild cellular abnormalities that often **regress spontaneously** without intervention, especially in young women.- Current cervical screening protocols recommend **colposcopy** (typically within 6 weeks in the UK) for these findings to allow for a detailed visual assessment and biopsy if necessary, to rule out higher-grade lesions.*She has early cervical cancer and requires urgent colposcopy within 2 weeks*- **Low-grade dyskaryosis** (equivalent to LSIL or CIN1) indicates **mild cellular changes**, not early cervical cancer. Cervical cancer is a very rare outcome at this stage.- An **urgent 2-week referral** for colposcopy is usually reserved for cytology results indicating **high-grade glandular abnormalities**, suspicious of invasion, or persistent high-grade squamous lesions.*She has pre-cancerous changes that will definitely progress to cancer without treatment*- While **low-grade dyskaryosis** (CIN1) is considered a pre-cancerous change, it has a high rate of **spontaneous regression** (around 60-70%) within 1-2 years, especially in younger women.- Progression to **invasive cancer** is **not definite** and occurs in a small minority of untreated low-grade lesions, typically over many years.*She needs immediate treatment with loop excision to prevent cancer development*- **Loop Electrosurgical Excision Procedure (LEEP/LLETZ)** is generally reserved for confirmed **high-grade cervical intraepithelial neoplasia (CIN2/3)** or persistent low-grade lesions identified at colposcopy.- Immediate treatment for **low-grade dyskaryosis** without colposcopic assessment is not standard practice due to the high regression rate and to avoid potential side effects like **preterm birth** in future pregnancies.*She has normal cervical cells and can return to routine screening in 3 years*- The presence of **low-grade dyskaryosis** and a **positive hrHPV test** clearly indicates abnormal cervical cells, not normal cells.- Routine screening in 3 years would only be appropriate if both the **hrHPV test was negative** and cytology was normal. These results require further investigation.

Question 54: A 58-year-old man attends for NHS Health Check. His BMI is 32 kg/m², BP 136/84 mmHg, total cholesterol 5.8 mmol/L, HDL 1.0 mmol/L, non-smoker. His QRISK3 score is 8.5%. He asks about lifestyle modification to reduce his cardiovascular risk. Which lifestyle intervention would have the most significant impact on reducing his 10-year cardiovascular risk?

A. Reducing dietary salt intake to less than 6g per day
B. Achieving 5-10% weight loss through calorie restriction (Correct Answer)
C. Increasing physical activity to 150 minutes of moderate intensity exercise per week
D. Following a Mediterranean diet rich in fruits, vegetables, and olive oil
E. Limiting alcohol consumption to 14 units per week

Explanation: ***Achieving 5-10% weight loss through calorie restriction*** - In an obese patient (**BMI 32 kg/m²**), weight loss is the most powerful intervention as it concurrently improves **blood pressure**, **lipid profiles**, and **insulin sensitivity**. - A modest reduction of **5-10% of body weight** has been shown to significantly lower the **QRISK3 score** by targeting the underlying metabolic drivers of cardiovascular disease. *Reducing dietary salt intake to less than 6g per day* - While effective for managing **hypertension**, this patient's blood pressure (136/84 mmHg) is only mildly elevated, making the impact of salt reduction secondary to overall weight loss. - This intervention primarily targets **systolic blood pressure** but has a less comprehensive impact on other metabolic markers like lipids compared to weight loss. *Increasing physical activity to 150 minutes of moderate intensity exercise per week* - **Physical activity** is critical for cardiovascular health, but without caloric restriction, it is often insufficient to achieve significant **weight reduction** in obese individuals. - While it improves **HDL cholesterol** and cardiovascular fitness, its independent effect on the 10-year risk score is generally smaller than that of significant weight loss. *Following a Mediterranean diet rich in fruits, vegetables, and olive oil* - The **Mediterranean diet** is highly recommended for cardioprotection, but its benefits are often maximized when used as a tool to achieve **weight loss** in obese patients. - On its own, dietary composition changes provide significant benefits, but **caloric restriction** and weight loss provide a more measurable reduction in global risk for this specific patient profile. *Limiting alcohol consumption to 14 units per week* - Reducing **alcohol intake** helps lower blood pressure and **caloric intake**, but it is a targeted intervention rather than a global metabolic stabilizer. - Unless the patient is currently consuming excessive amounts, limiting intake to **14 units** provides less overall risk reduction than achieving a healthy BMI.

Question 55: A 65-year-old woman attends for her NHS breast screening appointment. She asks about the frequency of mammography in the NHS breast screening programme. What is the standard screening interval for women aged 50-70 years in England?

A. Annually
B. Every 18 months
C. Every 2 years
D. Every 3 years (Correct Answer)
E. Every 5 years

Explanation: ***Every 3 years***- In the **NHS Breast Screening Programme** in England, women aged **50 to 70** are automatically invited for screening every **3 years**.- This frequency is designed to optimize the detection of **early-stage breast cancer** while balancing the cost-effectiveness and risks of **overdiagnosis**.*Annually*- **Annual screening** is not the standard for the general population in the UK, although it may be used for specific **high-risk groups** (e.g., those with genetic mutations like BRCA).- Implementing yearly mammograms for the entire population would significantly increase **false positives** and healthcare resource utilization.*Every 18 months*- An **18-month interval** is not utilized within the British screening framework for any standard age group.- There is no clinical evidence currently suggesting that an 18-month gap offers a better **mortality benefit** compared to the 3-year standard in England.*Every 2 years*- While a **2-year interval** is common in many European countries and the **United States** (USPSTF guidelines), it is not the protocol for the **NHS**.- The UK follows the **Forrest Report** recommendations, which established the 3-yearly interval as the national standard.*Every 5 years*- A **5-year interval** is considered too long, as it would likely lead to an increase in **interval cancers** (cancers appearing between screens).- Screening this infrequently would miss the opportunity for **early intervention**, potentially leading to diagnosis at a more advanced, less treatable stage.

Question 56: A 68-year-old man with type 2 diabetes attends following his routine diabetic eye screening. The report states: 'Proliferative diabetic retinopathy with extensive neovascularization at the optic disc (NVD) in the right eye. Left eye shows pre-proliferative changes. Graded R3 right eye, R2 left eye. Urgent ophthalmology referral recommended.' He is asymptomatic with normal visual acuity. What timeframe is defined as 'urgent' for this ophthalmology referral?

A. Same day referral to emergency eye services
B. Within 1 week (Correct Answer)
C. Within 2 weeks
D. Within 4 weeks
E. Within 6 weeks

Explanation: ***Within 1 week*** - For **Proliferative Diabetic Retinopathy (R3)**, which is characterized by **neovascularization at the disc (NVD)** or elsewhere (NVE), the NHS guidelines mandate an urgent referral to be seen **within 1 week**. - This timeframe is critical to initiate treatments like **panretinal photocoagulation (PRP)** or **anti-VEGF therapy** to prevent catastrophic complications such as **vitreous hemorrhage** or tractional retinal detachment. *Same day referral to emergency eye services* - This is reserved for immediate sight-threatening complications such as **sudden severe vision loss**, **rubeosis iridis**, or acute **retinal detachment**. - Since the patient is currently **asymptomatic** with normal visual acuity, a same-day emergency referral is not clinically indicated over a 1-week urgent referral. *Within 2 weeks* - The **two-week window** is commonly associated with suspected malignancy pathways and is not the standard for **R3 graded** proliferative diabetic retinopathy. - Waiting 14 days increases the risk of **ischaemic triggers** causing further vessel growth and potential hemorrhage in a high-risk patient. *Within 4 weeks* - A **four-week** timeframe is considered too long for active **new vessel formation** (NVD/NVE), which requires more rapid intervention to stabilize the retina. - Prolonged delay at this stage significantly increases the likelihood of progressing to permanent **vision impairment**. *Within 6 weeks* - This timeframe is typically appropriate for **routine referrals**, such as for **maculopathy (M1)** or stable **pre-proliferative (R2)** changes that do not meet the R3 criteria. - While the left eye is graded **R2**, the urgency of the case is dictated by the more severe **R3 grading** in the right eye.

Question 57: A 55-year-old woman attends for cardiovascular risk assessment as part of her NHS Health Check. She is of South Asian ethnicity. Her blood pressure is 132/78 mmHg, BMI 27 kg/m², non-smoker. Fasting lipids show total cholesterol 5.8 mmol/L, HDL 1.1 mmol/L. HbA1c is 39 mmol/mol. When calculating her QRISK3 score, which adjustment should be applied based on her ethnicity?

A. No adjustment is needed as QRISK3 automatically accounts for ethnicity (Correct Answer)
B. Her calculated QRISK3 score should be reduced by 25%
C. Her calculated QRISK3 score should be increased by approximately 40%
D. She should be assessed using the Framingham score instead of QRISK3
E. Her ethnicity only affects risk if she also has type 2 diabetes

Explanation: ***No adjustment is needed as QRISK3 automatically accounts for ethnicity*** - **QRISK3** is a sophisticated multivariable algorithm that includes **ethnicity** as an integrated variable, removing the need for manual multipliers. - It automatically incorporates **ethnicity-specific risk multipliers** based on large UK population datasets to reflect the higher cardiovascular risk in **South Asian** populations. *Her calculated QRISK3 score should be reduced by 25%* - South Asian ethnicity is associated with an **increased baseline risk** of cardiovascular disease, so a reduction in the score would be clinically incorrect and underestimate true risk. - Reductions are not standard for any ethnic group within the **NICE-recommended** risk assessment tools like QRISK3. *Her calculated QRISK3 score should be increased by approximately 40%* - While South Asian ethnicity does confer roughly a **1.4x higher risk** of cardiovascular disease, this adjustment is already **built into the software algorithm** of QRISK3. - Manual adjustments for ethnicity were used in older risk calculators (e.g., JBS2) but are obsolete with the implementation of **QRISK3**. *She should be assessed using the Framingham score instead of QRISK3* - The **Framingham score** is less accurate for UK-specific populations and lacks the comprehensive **ethnicity data** and other contemporary risk factors found in QRISK3. - **NICE guidelines** in the UK specifically recommend QRISK3 for cardiovascular risk assessment in patients between 25 and 84 years of age. *Her ethnicity only affects risk if she also has type 2 diabetes* - Ethnicity is an **independent risk factor** for cardiovascular disease regardless of the patient's glycemic status or **HbA1c** levels. - While the combination of South Asian ethnicity and **diabetes** significantly increases risk, each factor contributes independently to the overall QRISK3 calculation.

Question 58: A 61-year-old man completes his NHS bowel cancer screening FIT kit. The result is 110 micrograms Hb/g faeces (positive). He attends worried and asks about his likelihood of having bowel cancer. Based on NHS bowel screening data, approximately what proportion of people with a positive FIT result are found to have colorectal cancer at colonoscopy?

A. Approximately 2-3%
B. Approximately 8-10% (Correct Answer)
C. Approximately 25-30%
D. Approximately 50-55%
E. Approximately 75-80%

Explanation: ***Approximately 8-10%*** - According to **NHS Bowel Cancer Screening Programme** data, roughly **1 in 10** or **1 in 11** patients with a positive **FIT result** are diagnosed with **colorectal cancer** during colonoscopy. - While the majority are cancer-free, this positive predictive value is high enough to mandate urgent investigation, typically via **colonoscopy** within two weeks. *Approximately 2-3%* - This figure significantly underestimates the risk associated with a positive **FIT result** in the **national screening cohort**. - Prevalence rates this low are more characteristic of asymptomatic populations before any screening kit is applied. *Approximately 25-30%* - This range is more reflective of the detection rate for **high-risk adenomas** (precancerous polyps) rather than confirmed invasive cancer. - Providing this figure to a patient would unnecessarily increase anxiety by overstating the actual likelihood of a **malignant diagnosis**. *Approximately 50-55%* - This would imply a 1-in-2 chance of cancer, which is significantly higher than actual outcomes for **FIT-positive** patients in the **UK screening program**. - Such high predictive values are usually only seen in patients with **extremely high FIT levels** (e.g., >400 μg/g) or overt clinical symptoms. *Approximately 75-80%* - Most patients with a positive **FIT** (e.g., ≥120 μg/g or ≥80 μg/g depending on region) do not have cancer, making this an incorrect assessment. - Screening is designed for **early detection** in a varied population, and while sensitive, it does not achieve this level of **positive predictive value** for cancer.

Question 59: A 33-year-old woman attends for cervical screening. She is 16 weeks pregnant. She mentions she received a letter but wasn't sure if she should attend while pregnant. Her last cervical screen was 3.5 years ago and was normal. What is the most appropriate management?

A. Proceed with cervical screening today as scheduled
B. Defer cervical screening until 12 weeks postpartum (Correct Answer)
C. Defer cervical screening until 3 months postpartum
D. Arrange urgent colposcopy due to pregnancy
E. Perform cervical screening only if she has symptoms

Explanation: ***Defer cervical screening until 12 weeks postpartum*** - In routine cases, **cervical screening** should be delayed until at least **12 weeks (3 months) postpartum** to allow the cervix to recover from physiological changes. - Pregnancy-induced changes like **increased vascularity** and **decidualization** interfere with accurate cytological interpretation, leading to a high rate of **inadequate samples**. *Proceed with cervical screening today as scheduled* - Routine screening is not recommended during pregnancy because the result is likely to be **unreliable** or **inconclusive**. - There is also a slightly increased risk of **minor bleeding** from the hyperemic cervix, which can cause unnecessary patient anxiety. *Defer cervical screening until 3 months postpartum* - While 3 months is equivalent to 12 weeks, the standard clinical guideline specifies waiting until **12 weeks postpartum** for the cervix to return to its non-pregnant state. - This timing ensures that the **transformation zone** has fully regressed and inflammatory changes have resolved for an accurate test. *Arrange urgent colposcopy due to pregnancy* - **Colposcopy** is only indicated during pregnancy if there is a clinical suspicion of **malignancy** or a high-grade abnormal smear prior to conception. - Routine screening intervals or being slightly overdue are not indications for **referral** in the absence of symptoms or previous high-grade dyskaryosis. *Perform cervical screening only if she has symptoms* - If a pregnant woman presents with symptoms like **postcoital bleeding**, she should be referred for **clinical assessment** or colposcopy rather than routine screening. - Routine screening represents a preventive tool for asymptomatic women and should follow the **standard deferral protocol** regardless of pregnancy timing unless pathology is suspected.

Question 60: A 72-year-old man with type 2 diabetes for 20 years attends for review. His diabetic eye screening report states: 'Background diabetic retinopathy with scattered microaneurysms and dot hemorrhages in both eyes. Several hard exudates noted within the temporal arcade of the right macula. No neovascularization. Graded as R2M1 right eye, R1M0 left eye.' What is the most appropriate action?

A. Continue annual diabetic eye screening and routine diabetes care
B. Arrange repeat screening in 6 months to monitor progression
C. Refer urgently (within 1 week) to ophthalmology for assessment
D. Refer routinely to ophthalmology within 6 weeks for assessment (Correct Answer)
E. Reassure patient that no specific action is needed beyond usual care

Explanation: ***Refer routinely to ophthalmology within 6 weeks for assessment*** - The grading **M1** in the right eye indicates the presence of **maculopathy**, specifically noting "several hard exudates within the temporal arcade of the right macula," which is a **sight-threatening** condition. - The **R2 grading** (pre-proliferative retinopathy) also necessitates ophthalmological review due to the increased risk of progression to proliferative disease, and both **M1** and **R2** warrant a **routine referral** for specialist assessment and potential treatment. *Continue annual diabetic eye screening and routine diabetes care* - Annual screening is appropriate for patients with **R0M0 (no retinopathy)** or stable **R1M0 (background retinopathy without maculopathy)**. - Given the presence of **R2 (pre-proliferative retinopathy)** and **M1 (maculopathy)**, this patient requires more urgent and specialized intervention than standard annual screening provides. *Arrange repeat screening in 6 months to monitor progression* - While some stable pre-proliferative cases (R2M0) might warrant closer monitoring, the presence of **M1 maculopathy** is an immediate concern requiring direct specialist ophthalmology assessment, not just another screening. - Delaying to 6 months is inappropriate as prompt assessment and treatment for maculopathy can prevent **irreversible vision loss**. *Refer urgently (within 1 week) to ophthalmology for assessment* - **Urgent referral** is typically reserved for **R3 (proliferative diabetic retinopathy)**, severe or sudden vision loss, **vitreous hemorrhage**, or suspected **retinal detachment**. - While serious, **R2M1** is generally managed via a **routine referral pathway** (e.g., within 4-6 weeks), which is less immediate than an urgent referral. *Reassure patient that no specific action is needed beyond usual care* - This is incorrect as the patient has definite **pre-proliferative retinopathy (R2)** and **maculopathy (M1)**, both of which are **referable conditions** indicating significant diabetic eye disease. - Failing to act on these findings could lead to preventable and **permanent central vision loss**, especially from the maculopathy.

Question 61: A 48-year-old woman with a BMI of 39 kg/m² attends for weight management review. She has been following a calorie-controlled diet and exercising regularly for 6 months but has lost only 3 kg. She has hypertension, type 2 diabetes (HbA1c 64 mmol/mol), and obstructive sleep apnoea. She asks about weight loss medication. What is the most appropriate pharmacological option?

A. Rimonabant 20 mg once daily
B. Orlistat 120 mg three times daily with meals
C. Liraglutide 3.0 mg subcutaneous injection once daily (Correct Answer)
D. Metformin 500 mg twice daily for weight reduction
E. Phentermine 37.5 mg once daily

Explanation: ***Liraglutide 3.0 mg subcutaneous injection once daily*** - **Liraglutide** (a GLP-1 receptor agonist) is indicated for weight management in patients with a **BMI ≥30** (or ≥27 with comorbidities) who have failed lifestyle interventions. - It is particularly beneficial for this patient as it helps manage **weight loss** while simultaneously improving **glycemic control** (HbA1c) and associated comorbidities like **Type 2 Diabetes** and **obstructive sleep apnoea**. *Orlistat 120 mg three times daily with meals* - While licensed for weight loss, it typically results in significantly **less weight reduction** compared to GLP-1 agonists and is often poorly tolerated due to **gastrointestinal side effects** like steatorrhea. - This patient's high BMI and multiple metabolic comorbidities warrant a more potent and effective pharmacological agent like **Liraglutide** as a primary choice. *Metformin 500 mg twice daily for weight reduction* - While **Metformin** is used to treat Type 2 Diabetes and can be weight-neutral or cause modest weight loss, it is not a primary **weight management medication** with robust evidence for significant weight reduction. - It does not provide the clinically significant **weight loss of ≥5%** required to address her severe obesity (BMI 39 kg/m²) and associated comorbidities effectively. *Phentermine 37.5 mg once daily* - **Phentermine** is a sympathomimetic amine that is often not licensed or recommended for long-term use in many regions (including the UK) due to **cardiovascular safety concerns**. - Given the patient's existing **hypertension**, using a stimulant-based appetite suppressant would be contraindicated or high-risk. *Rimonabant 20 mg once daily* - **Rimonabant**, an endocannabinoid receptor antagonist, was **withdrawn from the market** globally due to severe psychiatric side effects, including depression and suicidal ideation. - It is associated with a significantly increased risk of **depression and suicidal ideation**, making it an obsolete and unsafe recommendation.

Question 62: A 52-year-old man attends requesting lifestyle advice. He currently drinks 4-5 pints of lager (4.5% ABV) on Friday and Saturday nights. He wants to reduce his drinking. On calculation, his weekly alcohol consumption is approximately 36 units. He has no features of alcohol dependence. Which intervention strategy has the strongest evidence base for effectiveness in this primary care setting?

A. Provision of written information leaflets about recommended alcohol limits
B. Brief intervention using motivational interviewing techniques (Correct Answer)
C. Referral to community alcohol services for specialist counseling
D. Prescription of disulfiram to support abstinence attempts
E. Recommendation to attend Alcoholics Anonymous meetings

Explanation: ***Brief intervention using motivational interviewing techniques*** - **Brief interventions** (5-10 minutes) delivered in primary care have the strongest evidence base for reducing consumption in **hazardous drinkers** who are not yet dependent. - These techniques, often using the **FRAMES model**, focus on enhancing **self-efficacy** and personal responsibility, which is ideal for a patient already motivated to change. *Provision of written information leaflets about recommended alcohol limits* - **Written materials** alone are significantly less effective than **personalized counseling** or brief face-to-face discussions. - Leaflets are best used as an **adjunct** to a brief intervention rather than a standalone primary strategy. *Referral to community alcohol services for specialist counseling* - **Specialist referral** is generally reserved for patients with complex needs or **alcohol dependence**, rather than uncomplicated hazardous drinking. - Managing the patient in a **primary care setting** is more resource-efficient and appropriate for someone drinking 36 units without dependency signs. *Prescription of disulfiram to support abstinence attempts* - **Disulfiram** is an aversive agent indicated strictly for **alcohol dependence** to maintain abstinence, not for harm reduction in hazardous drinkers. - Given the patient lacks features of **dependence**, pharmacological treatment is contraindicated and carries unnecessary risks of **toxicity**. *Recommendation to attend Alcoholics Anonymous meetings* - **Alcoholics Anonymous (AA)** follows a 12-step model designed for **alcoholics** seeking lifelong sobriety, which may not align with this patient's goal to simply reduce drinking. - While helpful for some, the evidence for **AA** is most robust in populations with established **dependence** rather than non-dependent hazardous drinkers.

Question 63: A 59-year-old woman with type 2 diabetes attends for annual review. She has not attended diabetic eye screening for 3 years despite invitations. She explains she doesn't attend because she can see perfectly well and has no eye symptoms. Her HbA1c is 78 mmol/mol. What is the best approach to encourage screening attendance?

A. Explain that most sight-threatening diabetic retinopathy is asymptomatic until advanced (Correct Answer)
B. Arrange urgent optometry referral for comprehensive eye examination
C. Document her refusal and discharge her from the diabetic eye screening programme
D. Warn her that she may lose her driving licence if she doesn't attend screening
E. Reassure her that absence of symptoms means screening is less urgent

Explanation: ***Explain that most sight-threatening diabetic retinopathy is asymptomatic until advanced*** - Patient education must address the misconception that normal vision excludes pathology; **diabetic retinopathy** is notoriously **asymptomatic** in early stages. - Early detection through **digital photography screening** allows for timely intervention before permanent, irreversible visual loss occurs. *Arrange urgent optometry referral for comprehensive eye examination* - An urgent referral is not clinically indicated as the patient is currently **asymptomatic**, and specialized **diabetic eye screening programs** are the gold standard over routine optometry. - The primary goal at this stage is to fix the **screening gap** and address the patient's health beliefs rather than bypass systematic screening protocols. *Document her refusal and discharge her from the diabetic eye screening programme* - Discharging a patient from a necessary screening program due to a misunderstanding of risk is not **patient-centered care** and increases the risk of **preventable blindness**. - While **autonomy** and documentation are important, the clinician’s role is to ensure the patient makes an **informed decision** by explaining the risks of non-attendance. *Warn her that she may lose her driving licence if she doesn't attend screening* - This approach is coercive and factually incorrect; **DVLA requirements** are based on functional **visual acuity** and fields, not on participation in screening programs. - Using threats can damage the **doctor-patient relationship** and is less effective for long-term health behavior change than positive education. *Reassure her that absence of symptoms means screening is less urgent* - This is medically dangerous advice; her high **HbA1c (78 mmol/mol)** indicates poor glycemic control, which significantly increases the risk of **maculopathy** and proliferative changes. - Clinical urgency is actually increased in poorly controlled **Diabetes Mellitus**, as the risk of rapid **retinopathy progression** is much higher.

Question 64: A 46-year-old man attends for an NHS Health Check. He smokes 15 cigarettes daily, drinks 28 units of alcohol weekly, and has a BMI of 31 kg/m². Blood pressure is 138/86 mmHg. Fasting blood tests show: total cholesterol 6.2 mmol/L, HDL 0.9 mmol/L, non-HDL 5.3 mmol/L, HbA1c 41 mmol/mol, eGFR 78 ml/min. His QRISK3 score is 18%. Considering the hierarchy of intervention priorities, which lifestyle modification should be the primary focus?

A. Alcohol reduction to within recommended limits
B. Smoking cessation with pharmacological support (Correct Answer)
C. Weight loss through dietary modification and exercise
D. Dietary changes to reduce cholesterol levels
E. Blood pressure reduction through salt restriction

Explanation: ***Smoking cessation with pharmacological support*** - Smoking cessation is considered the **highest priority** intervention because it offers the largest and most immediate **absolute risk reduction** for cardiovascular events compared to other lifestyle factors. - NICE guidelines emphasize that for high-risk patients (QRISK3 >10%), **combination therapy** (NRT or Varenicline) should be proactively offered to maximize the chances of successful quitting. *Alcohol reduction to within recommended limits* - While the patient consumes **28 units/week** (double the recommended 14 units), the direct impact on **QRISK3 reduction** is less significant than stopping smoking. - Excessive alcohol contributes to **hypertension** and weight gain, but it is not ranked as the primary modifiable contributor to cardiovascular mortality in this hierarchy. *Weight loss through dietary modification and exercise* - A BMI of **31 kg/m²** indicates obesity, but weight loss interventions typically result in slower, more modest reductions in **CV risk** compared to the immediate benefits of cessation. - While essential for long-term health and preventing **Type 2 Diabetes** (HbA1c is currently 41), it remains secondary to smoking in urgent risk management. *Dietary changes to reduce cholesterol levels* - Although the **non-HDL cholesterol (5.3 mmol/L)** is elevated, the QRISK3 score of 18% suggests that pharmacological intervention (Statins) alongside diet is likely needed. - Dietary change alone typically reduces cholesterol by only **10–15%**, which is insufficient to match the risk reduction achieved by **stopping smoking**. *Blood pressure reduction through salt restriction* - The blood pressure of **138/86 mmHg** is high-normal/Grade 1 hypertension, but salt restriction provides a relatively minor drop in systolic pressure. - Managing hypertension is crucial, but addressing the **highly pro-thrombotic** and atherosclerotic nature of smoking takes clinical precedence.

Question 65: A 34-year-old woman attends with her cervical screening result showing hrHPV positive with normal cytology. She is anxious and asks what this means. She is in a long-term monogamous relationship and has had the same partner for 8 years. What is the most appropriate explanation and management?

A. She needs immediate treatment with topical imiquimod cream
B. She should have annual cervical screening for the next 5 years
C. She has precancerous changes requiring urgent colposcopy referral
D. The test indicates recent HPV acquisition suggesting partner infidelity
E. She should be retested at 12 months with hrHPV testing and cytology (Correct Answer)

Explanation: ***She should be retested at 12 months with hrHPV testing and cytology*** - In the primary HPV screening program, a result of **hrHPV positive but normal cytology** mandates a repeat test in **12 months** to allow for natural viral clearance. - Most HPV infections are **transient** and cleared by the immune system; colposcopy is only indicated at this stage if hrHPV persists for two consecutive 12-month repeats or if cytology becomes abnormal. *She needs immediate treatment with topical imiquimod cream* - **Imiquimod** is used for the treatment of **anogenital warts**, not for subclinical cervical hrHPV infection or cervical dysplasia. - Normal cytology indicates there are no visible cellular changes to treat, and the virus itself has no specific medical "cure" other than **immune clearance**. *She should have annual cervical screening for the next 5 years* - This management plan does not align with national screening protocols; the current pathway uses **12-month intervals** for HPV persistence monitoring. - If hrHPV is negative at the 12-month repeat, the patient generally returns to **routine recall** (3 or 5 years depending on age) rather than annual testing. *She has precancerous changes requiring urgent colposcopy referral* - **Normal cytology** specifically indicates that there are currently **no precancerous cells** (dyskaryosis) detected in the sample. - Urgent colposcopy is reserved for clinical suspicion of cancer or high-grade dyskaryosis; HPV positivity alone with normal cells is **low risk** for immediate malignancy. *The test indicates recent HPV acquisition suggesting partner infidelity* - HPV can remain **latent or dormant** for many years or even decades before becoming detectable on a screening test. - A positive result often represents a **reactivation** of an old infection rather than a new acquisition, making it an unreliable indicator of a partner's recent sexual activity.

Question 66: A 57-year-old woman attends for her NHS breast screening mammogram. She has been taking combined HRT (oestrogen and progestogen) for 4 years for menopausal symptoms. She asks whether her HRT use affects the accuracy of mammography. Which statement best explains the effect of HRT on breast screening?

A. HRT increases breast density which may reduce mammographic sensitivity (Correct Answer)
B. HRT increases the false positive rate but does not affect cancer detection
C. HRT should be stopped 6 months before mammography to ensure accuracy
D. HRT has no effect on mammographic breast density or screening accuracy
E. HRT reduces breast density making abnormalities more easily detectable

Explanation: ***HRT increases breast density which may reduce mammographic sensitivity*** - Combined **HRT (estrogen and progestogen)** stimulates glandular tissue, leading to an increase in **mammographic breast density** in about 25-30% of women. - High breast density reduces **mammographic sensitivity** because both dense fibroglandular tissue and potential tumors appear **white (radiopaque)**, potentially masking underlying malignancies. *HRT increases the false positive rate but does not affect cancer detection* - While HRT can increase the **false positive rate** due to benign changes, it definitely impacts **cancer detection** by lowering the sensitivity of the test. - Increased density makes it harder to distinguish between **normal tissue** and a **carcinoma**, leading to more missed diagnoses (false negatives). *HRT should be stopped 6 months before mammography to ensure accuracy* - There is no clinical guideline recommending that HRT be **stopped or paused** prior to routine breast screening mammograms. - Clinical practice focuses on maintaining **symptom control** for the patient while acknowledging the slight reduction in screening accuracy as a known factor. *HRT has no effect on mammographic breast density or screening accuracy* - This is incorrect as **hormonal replacement** has a well-documented physiological effect on the proliferation of **breast epithelium**. - Studies consistently show that **combined HRT** significantly alters the radiographic appearance of the breast, unlike estrogen-only therapy which has a lesser effect. *HRT reduces breast density making abnormalities more easily detectable* - HRT actually has the opposite effect; **estrogen and progesterone** increase the ratio of glandular to fatty tissue, thereby **increasing density**. - **Fatty involution** (decreased density) typically occurs naturally after menopause without HRT, which usually makes mammograms **easier to interpret**.

Question 67: What is the screening interval for cervical screening in women aged 50-64 years in the NHS Cervical Screening Programme in England?

A. Annually
B. Every 3 years
C. Every 5 years (Correct Answer)
D. Every 10 years
E. No routine screening required

Explanation: ***Every 5 years*** - In the **NHS Cervical Screening Programme** in England, women aged **50 to 64** are invited for routine screening every **5 years**. - This extended interval, compared to younger age groups, reflects the slower progression of **HPV-related cervical changes** and a lower risk of rapidly developing high-grade lesions in this demographic. *Annually* - **Annual screening** is not the routine interval for any age group within the NHS Cervical Screening Programme in England. - It is typically reserved for specific **follow-up management** after abnormal results or for individuals with certain high-risk factors. *Every 3 years* - This is the standard screening interval for women aged **25 to 49** within the NHS Cervical Screening Programme. - A shorter interval is used for younger women due to a higher prevalence of **HPV infection** and potentially faster progression of cervical abnormalities. *Every 10 years* - A **10-year interval** is not currently utilized as a routine screening frequency in the NHS Cervical Screening Programme. - Such a long interval would significantly increase the risk of undetected **cervical cancer** development between screens. *No routine screening required* - Routine screening is still **required** for women aged 50-64 years in England to detect cervical abnormalities early. - Screening typically stops at age **65** only if a woman has had adequate negative screening results (e.g., two negative HPV tests after age 50 or three consecutive negative cytology results).

Question 68: A 62-year-old woman attends for discussion of her NHS bowel cancer screening result. Her FIT result is 95 micrograms Hb/g faeces. She has no symptoms and examination is unremarkable. She is on clopidogrel following a TIA 18 months ago. Which of the following factors is most likely to have contributed to her positive FIT result?

A. Daily consumption of red meat
B. Concurrent use of clopidogrel (Correct Answer)
C. Haemorrhoids noted on previous examination
D. Recent upper respiratory tract infection
E. Menstruation at the time of sample collection

Explanation: ***Concurrent use of clopidogrel***- **Clopidogrel** is an **antiplatelet agent** that inhibits platelet aggregation and can increase the risk of **occult gastrointestinal bleeding**.- This increased bleeding risk can lead to the presence of **human haemoglobin** in the faeces, resulting in a positive **Faecal Immunochemical Test (FIT)** result.*Daily consumption of red meat*- The **Faecal Immunochemical Test (FIT)** uses antibodies specific to **human haemoglobin**, making it unaffected by dietary sources of haemoglobin like **red meat**.- This is a key advantage over older **guaiac-based tests**, which required dietary restrictions to avoid false positives.*Haemorrhoids noted on previous examination*- While **haemorrhoids** can cause bleeding, patients are usually advised to defer **FIT sample collection** if they are actively bleeding from haemorrhoids.- The patient is described as having **no symptoms**, making active haemorrhoidal bleeding a less likely explanation for a high FIT result compared to medication-induced occult bleeding.*Recent upper respiratory tract infection*- An **upper respiratory tract infection (URTI)** is localized to the respiratory system and has no physiological mechanism to cause **gastrointestinal bleeding**.- Therefore, an URTI cannot contribute to the presence of **human haemoglobin** in the stool, which is detected by the FIT.*Menstruation at the time of sample collection*- The patient is **62 years old**, indicating she is almost certainly **post-menopausal**.- Consequently, **menstruation** is an improbable cause for a positive FIT result in this age group.

Question 69: A 65-year-old man attends his GP surgery with a letter following his NHS AAA screening ultrasound. The report states: 'Anterior-posterior diameter of infrarenal abdominal aorta: 2.8 cm. No other significant findings.' He is asymptomatic and has well-controlled hypertension. His brother had an emergency AAA repair aged 72. What is the most appropriate management plan?

A. Refer urgently to vascular surgery for outpatient assessment
B. Discharge with advice to re-attend if symptoms develop
C. Arrange repeat ultrasound surveillance in 12 months (Correct Answer)
D. Arrange repeat ultrasound surveillance in 3 months
E. Refer routinely to vascular surgery for operative assessment

Explanation: ***Arrange repeat ultrasound surveillance in 12 months*** - According to the **NHS AAA Screening Programme** guidelines, an infrarenal abdominal aorta measuring **2.5–2.9 cm** is classified as a small aneurysm, necessitating **annual surveillance**. - The patient's aortic diameter of **2.8 cm** falls precisely within this range, requiring monitoring every **12 months** to track any potential growth or progression. *Refer urgently to vascular surgery for outpatient assessment* - **Urgent referral** to vascular surgery is typically indicated for symptomatic aneurysms, rapidly expanding aneurysms (growth >1 cm per year), or those approaching the threshold for elective repair. - This patient is **asymptomatic**, and his aneurysm size does not warrant urgent intervention at this stage. *Discharge with advice to re-attend if symptoms develop* - Discharging the patient is inappropriate as an aortic diameter between **2.5–2.9 cm** indicates an increased risk of developing a clinically significant **AAA**. - These patients require ongoing monitoring within the screening program rather than being discharged and waiting for symptoms to develop. *Arrange repeat ultrasound surveillance in 3 months* - **3-monthly surveillance** is generally reserved for medium-sized aneurysms, typically those measuring **4.5–5.4 cm**, to closely monitor their rapid growth potential. - Applying this frequent surveillance schedule to a **2.8 cm** aneurysm is excessive and not aligned with current clinical guidelines. *Refer routinely to vascular surgery for operative assessment* - **Routine surgical referral** for elective repair is typically recommended when the abdominal aortic aneurysm reaches a diameter of **≥5.5 cm** in men. - An infrarenal aortic diameter of **2.8 cm** is significantly below the threshold for operative assessment, as the risks associated with surgery at this size outweigh the risk of rupture.

Question 70: A 50-year-old man of South Asian ethnicity attends for NHS Health Check. His BP is 136/84 mmHg, BMI 26 kg/m², HbA1c 41 mmol/mol, total cholesterol 5.8 mmol/L, HDL 0.9 mmol/L, and triglycerides 2.8 mmol/L. His QRISK3 score is 8.2%. His brother developed type 2 diabetes at age 45. What is the most appropriate next step in diabetes risk management?

A. Reassure that HbA1c is normal and arrange repeat testing in 5 years
B. Diagnose prediabetes and prescribe metformin for diabetes prevention
C. Refer to NHS Diabetes Prevention Programme and arrange annual HbA1c (Correct Answer)
D. Arrange oral glucose tolerance test to exclude diabetes
E. Advise lifestyle modification only with HbA1c recheck in 3 years

Explanation: ***Refer to NHS Diabetes Prevention Programme and arrange annual HbA1c***- The patient's **HbA1c of 41 mmol/mol** falls within the **prediabetes** range (39-47 mmol/mol), indicating a high risk for type 2 diabetes.- Given the patient's **South Asian ethnicity**, **overweight BMI**, and **strong family history** of type 2 diabetes, referral to the **NHS Diabetes Prevention Programme (NDPP)** and **annual HbA1c monitoring** are the most appropriate management steps. *Reassure that HbA1c is normal and arrange repeat testing in 5 years*- An HbA1c of 41 mmol/mol is **not normal**; it is diagnostic of **prediabetes**, requiring active management.- Waiting **5 years** for repeat testing is inappropriate for a patient with multiple significant risk factors and an already elevated HbA1c. *Diagnose prediabetes and prescribe metformin for diabetes prevention*- While the patient has prediabetes, **metformin** for diabetes prevention is typically considered for individuals with a higher HbA1c (e.g., **≥44 mmol/mol**) or where intensive lifestyle interventions have failed.- The first-line intervention for this level of risk is a **structured lifestyle modification programme** such as the NDPP. *Arrange oral glucose tolerance test to exclude diabetes*- The **HbA1c of 41 mmol/mol** is sufficient to diagnose prediabetes; an **oral glucose tolerance test (OGTT)** is not routinely necessary at this stage.- An OGTT might be considered if the HbA1c result was equivocal or if there were conditions affecting HbA1c accuracy, which is not indicated here. *Advise lifestyle modification only with HbA1c recheck in 3 years*- Simply advising **lifestyle modification** is less effective than a **structured, evidence-based program** like the NDPP for high-risk individuals.- For individuals with prediabetes, **annual HbA1c monitoring** is recommended, not a 3-year interval, to detect progression to diabetes early.

Question 71: A 37-year-old woman attends with her cervical screening result showing hrHPV positive with normal cytology. She had a similar result 3 years ago which resolved at repeat testing 12 months later. She is anxious about persistent infection and asks about vaccination. What is the most appropriate advice regarding HPV vaccination in her situation?

A. HPV vaccination is contraindicated in women with current hrHPV infection
B. HPV vaccination may provide some benefit by protecting against other HPV types not currently present (Correct Answer)
C. HPV vaccination will clear her current hrHPV infection and prevent progression
D. HPV vaccination is only effective if given before any sexual activity and offers no benefit
E. HPV vaccination is not cost-effective in women over 25 years and is not recommended

Explanation: ***HPV vaccination may provide some benefit by protecting against other HPV types not currently present***- Vaccination is not a treatment for **existing infections**, but it can prevent future acquisition of other **high-risk HPV types** included in the vaccine that the patient has not yet encountered.- Most sexually active adults have not been exposed to all the types covered by current **9-valent vaccines**, making private vaccination a viable option for reducing future risk.*HPV vaccination is contraindicated in women with current hrHPV infection*- There is no **clinical contraindication** to receiving the vaccine while currently positive for **hrHPV**; it is safe but simply lacks therapeutic effect for the current strain.- Current infection does not increase the risk of **adverse events** from the vaccine.*HPV vaccination will clear her current hrHPV infection and prevent progression*- The HPV vaccine is **prophylactic**, not therapeutic, and has no proven efficacy in clearing **pre-existing infections** or treating established **CIN lesions**.- Patients must be counselled that the vaccine will not change the management of their current **positive screening results**.*HPV vaccination is only effective if given before any sexual activity and offers no benefit*- While **maximal benefit** is achieved when administered prior to **sexual debut**, benefit still exists for sexually active individuals who remain at risk for new infections.- Even with a history of infection, the vaccine reduces the risk of **re-infection** or acquisition of different **genotypes**.*HPV vaccination is not cost-effective in women over 25 years and is not recommended*- Although not routinely funded by the **NHS** for women over 25, clinical guidelines state individuals can still benefit and may choose to pursue it **privately**.- Recommendations are based on **individual risk assessment** and patient preference rather than a hard age-based exclusion of clinical benefit.

Question 72: A 68-year-old man with a 3.8 cm infrarenal abdominal aortic aneurysm (AAA) detected through NHS screening attends for review. He has COPD with FEV1 48% predicted, ischaemic heart disease with previous MI, and chronic kidney disease stage 3a. He asks whether surgery is recommended. According to current evidence-based guidelines, what threshold diameter would typically prompt consideration of elective repair in this patient?

A. 4.0 cm - repair should be offered now given his comorbidities
B. 4.5 cm - repair threshold is lower in patients with multiple comorbidities
C. 5.0 cm - repair threshold is higher in patients with significant comorbidities
D. 5.5 cm - standard threshold regardless of comorbidity status (Correct Answer)
E. 6.0 cm - repair threshold is higher given his prohibitive surgical risk

Explanation: ***5.5 cm - standard threshold regardless of comorbidity status*** - For men, the standard threshold for elective infrarenal abdominal aortic aneurysm (AAA) repair is **5.5 cm**, as studies demonstrate that the risk of aneurysm rupture significantly exceeds the risk of elective surgical mortality at this size. - The presence of significant comorbidities like **COPD**, **ischaemic heart disease**, and **CKD** does not lower this diameter threshold; rather, they influence the comprehensive assessment of surgical fitness and the choice between **open repair** or **endovascular aneurysm repair (EVAR)**. *4.0 cm - repair should be offered now given his comorbidities* - A **3.8 cm AAA** is classified as a small aneurysm, which is typically managed with **annual ultrasound surveillance** rather than immediate surgical intervention. - The patient's multiple comorbidities would increase the perioperative risk, making surgery for a small, low-risk aneurysm even less justifiable. *4.5 cm - repair threshold is lower in patients with multiple comorbidities* - Current evidence-based guidelines do not support a lower AAA repair threshold in patients with comorbidities; the risk of rupture for a **4.5 cm aneurysm** is still considerably lower than the risks associated with elective surgery. - For aneurysms between **4.5 cm and 5.4 cm**, more frequent surveillance with **ultrasound every 3 months** is generally recommended. *5.0 cm - repair threshold is higher in patients with significant comorbidities* - While **5.0 cm** is often considered the threshold for elective repair in **women** due to their generally smaller aorta and higher rupture risk at smaller diameters, it is not the standard threshold for men. - Comorbidities necessitate careful medical optimization before considering intervention, but they do not typically lead to a *higher* diameter threshold for men to be considered for repair. *6.0 cm - repair threshold is higher given his prohibitive surgical risk* - An AAA of **6.0 cm** or larger presents a very high risk of **rupture**, making the consideration of elective repair more urgent, not a reason to delay or raise the threshold further. - While extremely high surgical risk might lead to a decision to avoid intervention, the standard surveillance and referral threshold for potential repair remains **5.5 cm**, with larger aneurysms increasing immediate risk.

Question 73: A 53-year-old woman attends for results of her NHS breast screening mammogram which shows microcalcifications in the right breast suspicious for ductal carcinoma in situ (DCIS). She asks about the significance of DCIS and whether treatment is necessary. Which of the following statements most accurately reflects the current understanding of DCIS management?

A. DCIS always progresses to invasive breast cancer if untreated and requires immediate mastectomy
B. DCIS represents overdiagnosis in most cases and active surveillance is now standard treatment
C. DCIS has variable natural history; treatment is recommended as approximately 25-50% may progress to invasive cancer (Correct Answer)
D. DCIS is not a true malignancy and requires no treatment or follow-up
E. DCIS never progresses to invasive cancer and hormone therapy alone is sufficient treatment

Explanation: ***DCIS has variable natural history; treatment is recommended as approximately 25-50% may progress to invasive cancer***- **Ductal carcinoma in situ (DCIS)** is a non-invasive breast lesion with a **variable natural history**; a significant proportion (approximately **25-50%**) may progress to invasive breast cancer if left untreated.- Current guidelines recommend **treatment** (typically surgical excision with or without radiation) to reduce the risk of subsequent invasive carcinoma, reflecting its status as a precursor lesion.*DCIS always progresses to invasive breast cancer if untreated and requires immediate mastectomy*- While DCIS carries a risk of progression, it does **not always progress** to invasive cancer; its natural history is variable, and some lesions remain indolent.- **Mastectomy** is not universally required; **breast-conserving surgery** (lumpectomy) followed by radiotherapy is often sufficient, depending on factors like tumor size and grade.*DCIS represents overdiagnosis in most cases and active surveillance is now standard treatment*- While **overdiagnosis** is a recognized concern in breast screening, it's not universally accepted that DCIS represents overdiagnosis in **most cases**, and there's no reliable way to distinguish harmless from progressive lesions.- **Active surveillance** for DCIS is currently being investigated in **clinical trials** (e.g., LORIS, LORD) but is not yet the **standard of care** outside of research settings.*DCIS is not a true malignancy and requires no treatment or follow-up*- DCIS is considered a **pre-invasive malignancy**; it consists of abnormal cells that are confined within the breast ducts but have the potential to become **invasive cancer**.- Due to its potential for progression, DCIS absolutely requires **treatment and follow-up** to prevent or detect any development of invasive disease.*DCIS never progresses to invasive cancer and hormone therapy alone is sufficient treatment*- This statement is incorrect; DCIS is well-established as a **precursor to invasive breast cancer**, particularly **invasive ductal carcinoma**.- **Hormone therapy** (e.g., tamoxifen) may be used as **adjuvant therapy** to reduce recurrence risk in **ER-positive DCIS** but is not a standalone treatment and does not replace the need for local control through surgery.

Question 74: A 46-year-old woman with a BMI of 41 kg/m² attends for weight management review. She has lost 3 kg over 12 weeks following dietary advice and increased physical activity. She requests pharmacological treatment to augment weight loss. Her past medical history includes hypertension controlled with amlodipine and hypothyroidism treated with levothyroxine. What is the most appropriate pharmacological option?

A. Orlistat 120 mg three times daily with meals (Correct Answer)
B. Liraglutide 3 mg once daily subcutaneously
C. Metformin 500 mg twice daily
D. Phentermine 37.5 mg once daily
E. Semaglutide 2.4 mg once weekly subcutaneously

Explanation: ***Orlistat 120 mg three times daily with meals*** - **Orlistat** is the first-line pharmacological treatment for weight loss in primary care for individuals with a **BMI 30 kg/m²** (or 28 kg/m² with comorbidities) who haven't met weight loss goals through lifestyle alone. - It acts as a **pancreatic lipase inhibitor**, preventing the absorption of dietary fats and requiring dietary consultation to manage potential **gastrointestinal side effects**. *Liraglutide 3 mg once daily subcutaneously* - While licensed for weight management, it is typically reserved for **specialist weight management services** (Tier 3) and is not the standard first-line option in primary care. - It is a **GLP-1 receptor agonist** that requires specific criteria for NHS funding, such as presence of non-diabetic hyperglycemia or high cardiovascular risk. *Metformin 500 mg twice daily* - This medication is **not licensed** for weight loss in patients without prediabetes or Polycystic Ovary Syndrome (PCOS). - Although it may cause modest weight reduction as a side effect, it is Primarily used for **glycemic control** and is not indicated here for obesity management. *Phentermine 37.5 mg once daily* - This drug is currently **not licensed** for use in the UK due to historical concerns regarding cardiovascular safety and potential for misuse. - It is a **sympathomimetic amine** and is not a recommended pharmacological option in modern evidence-based guidelines for obesity. *Semaglutide 2.4 mg once weekly subcutaneously* - Similar to liraglutide, this **GLP-1 receptor agonist** is restricted to specialist services and is not routinely initiated in primary care settings under NICE guidance. - While highly effective for weight loss, the protocol dictates that **Orlistat** is used first before proceeding to injectable specialist therapies.

Question 75: A 64-year-old man attends for discussion of his NHS bowel cancer screening faecal immunochemical test (FIT) result showing 78 μg Hb/g faeces. He has no symptoms and his father died from colorectal cancer aged 76. What is the most appropriate management?

A. Repeat FIT in 2 weeks to confirm the result
B. Refer routinely to gastroenterology for colonoscopy
C. Arrange urgent suspected cancer (2-week wait) referral for colonoscopy (Correct Answer)
D. Reassure and arrange repeat FIT in 2 years
E. Arrange CT colonography as first-line investigation

Explanation: ***Arrange urgent suspected cancer (2-week wait) referral for colonoscopy*** - According to **NICE guidelines (NG12)**, any individual with an abnormal **FIT** result from the Bowel Cancer Screening Programme must be referred via the **2-week wait (2WW)** pathway for further investigation. - A **FIT value of 78 μg Hb/g** is significantly above the standard threshold (typically 10-120 μg depending on the region/pathway), indicating a high risk of **occult bleeding** that requires gold-standard evaluation via **colonoscopy**. *Repeat FIT in 2 weeks to confirm the result* - Repeating the test is inappropriate because a single positive **FIT** in a screening context already indicates a high **positive predictive value** for pathology. - This would cause a dangerous and **unnecessary delay** in diagnosing a potential colorectal malignancy. *Refer routinely to gastroenterology for colonoscopy* - Routine referral is unsuitable given the **elevated FIT score**, which mandates an **urgent suspected cancer** pathway to ensure the patient is seen within 14 days. - Screening programs are specifically designed to detect **asymptomatic** pre-cancerous or cancerous lesions where early intervention significantly improves survival. *Reassure and arrange repeat FIT in 2 years* - This approach is incorrect as the patient has already triggered a **positive screening result** which cannot be ignored based on a lack of symptoms. - The **2-year interval** is only for those who return a negative screening result and remain within the eligible screening age range (60-74 in the UK). *Arrange CT colonography as first-line investigation* - **Colonoscopy** remains the first-line investigation in the screening pathway because it allows for both direct visualization and **biopsy** or **polypectomy** during the same procedure. - **CT colonography** is typically reserved for patients who are medically unfit for colonoscopy or where the procedure was **incomplete**.

Question 76: A 31-year-old woman who is 10 weeks pregnant attends for booking. She previously lived in Eastern Europe and has unclear immunisation records. Rubella IgG is negative, hepatitis B surface antigen is negative, and she is blood group O RhD-positive. What is the most appropriate management regarding immunisations?

A. Administer MMR vaccine immediately to protect against congenital rubella syndrome
B. Offer MMR vaccine in the second trimester when organogenesis is complete
C. Advise strict avoidance of rubella contacts and administer MMR postpartum (Correct Answer)
D. Arrange rubella IgG re-testing in 4 weeks to confirm seronegative status
E. Offer rubella immunoglobulin prophylaxis throughout pregnancy

Explanation: ***Advise strict avoidance of rubella contacts and administer MMR postpartum***- The **MMR vaccine** is a **live attenuated vaccine**, which is strictly **contraindicated during pregnancy** due to the theoretical risk of transmission to the fetus.- Management for seronegative women involves counseling on avoiding exposure to rubella and scheduling vaccination in the **immediate postpartum period** to protect future pregnancies.*Administer MMR vaccine immediately to protect against congenital rubella syndrome*- Administering a **live vaccine** in the first trimester is contraindicated because of the potential risk of **fetal infection**.- While inadvertent vaccination usually does not lead to **Congenital Rubella Syndrome (CRS)**, it is never intentionally performed during pregnancy.*Offer MMR vaccine in the second trimester when organogenesis is complete*- **Live vaccines** are contraindicated throughout the **entire duration** of pregnancy, not just during the period of organogenesis.- The woman must wait until she has delivered before receiving the **MMR vaccine** to ensure fetal safety.*Arrange rubella IgG re-testing in 4 weeks to confirm seronegative status*- A **negative Rubella IgG** at the booking visit is a reliable indicator that the patient lacks immunity; routine re-testing is not indicated.- Resources should instead focus on **postpartum immunization** planning and education on avoiding infection.*Offer rubella immunoglobulin prophylaxis throughout pregnancy*- **Rubella immunoglobulin** does not provide reliable protection against infection or prevent fetal transmission if the mother is exposed.- It is not used for **routine prophylaxis** in seronegative pregnant women and is only considered in specific, high-risk exposure scenarios under specialist advice.

Question 77: A 55-year-old man with type 2 diabetes attends for his annual diabetic eye screening appointment but refuses mydriatic drops as he needs to drive home for an important meeting. Non-mydriatic photography is attempted but image quality is insufficient in his right eye due to small pupil size. What is the most appropriate next step?

A. Record screening as adequate based on left eye images only
B. Document refusal and discharge from the screening programme
C. Arrange urgent referral to ophthalmology for slit-lamp examination
D. Rebook screening appointment within 6 weeks with advice about transport arrangements (Correct Answer)
E. Accept images as technically inadequate and arrange review in 12 months

Explanation: ***Rebook screening appointment within 6 weeks with advice about transport arrangements*** - When non-mydriatic photography is **insufficient** due to small pupil size or patient refusal of drops, the standard protocol is to rebook the screening. - This rebooking should occur within **6 weeks**, with clear advice for the patient to arrange **alternative transport** so that **mydriatic drops** can be safely administered for a comprehensive examination. *Record screening as adequate based on left eye images only* - Screening for diabetic retinopathy must be **bilateral** to ensure complete assessment, as retinopathy can be asymmetrical and potentially sight-threatening lesions could be missed in the unexamined eye. - Declaring an incomplete screening as adequate is a significant **clinical safety risk** and falls short of **diabetic eye screening guidelines**. *Document refusal and discharge from the screening programme* - Patients have the right to refuse specific procedures, but this should not automatically lead to **discharge** from a vital, ongoing screening program for a chronic condition. - The appropriate action is to educate the patient about the **risks of vision loss** and facilitate a complete examination through rebooking. *Arrange urgent referral to ophthalmology for slit-lamp examination* - An urgent ophthalmology referral is typically reserved for cases where multiple screening attempts fail due to **physical barriers** (e.g., dense cataracts) or if there are suspected acute pathologies. - In this scenario, the issue is a temporary logistical one (patient needing to drive), not an acute clinical finding, making an urgent referral unnecessary at this stage. *Accept images as technically inadequate and arrange review in 12 months* - Accepting technically inadequate images means a crucial part of the eye is **unexamined** for diabetic retinopathy, leaving the patient at risk of undetected or progressing disease. - Deferring review for 12 months is unsafe as it significantly delays diagnosis and potential treatment for a condition that can cause **irreversible vision loss**.

Question 78: A 42-year-old man attends for lifestyle advice. He drinks 4 pints of lager (5.2% ABV) on Friday and Saturday evenings, and a bottle of wine (750 mL, 13% ABV) on Sunday. He asks if his drinking is within safe limits. What is his weekly alcohol consumption in units?

A. 24 units per week
B. 28 units per week
C. 32 units per week (Correct Answer)
D. 36 units per week
E. 40 units per week

Explanation: ***32 units per week*** - Alcohol units are calculated using the formula: **(Volume in mL × ABV%) / 1000**. 8 pints of lager (4544 mL × 5.2%) equals **23.6 units**, and 750mL of wine (13%) equals **9.75 units**. - The total consumption of **33.35 units** is closest to 32 units, which significantly exceeds the recommended **low-risk limit of 14 units** per week. *24 units per week* - This value underestimates the total by failing to account for either the high **ABV of the lager** or the full volume of the wine bottle. - It incorrectly suggests a level of consumption that is nearly **10 units lower** than the patient's actual intake. *28 units per week* - This total might be reached if using rounded estimates (e.g., 2 units per pint) rather than the **precise volume and ABV** provided in the clinical scenario. - Accurate calculation requires using the standard UK pint volume of **568 mL**, which yields a higher unit count for 5.2% lager. *36 units per week* - This value overestimates the patient's intake based on the provided volumes of **4 pints per night** and one bottle of wine. - It does not align with the standard calculation for **8 pints of 5.2% ABV** lager and a single bottle of 13% wine. *40 units per week* - This choice significantly exceeds the calculated value of **~33 units** and would suggest a higher frequency or volume of drinking than described. - While the patient is participating in **binge drinking**, the mathematical total of his current weekly sessions does not reach this threshold.

Question 79: What is the primary reason the UK National Screening Committee does not recommend routine screening for ovarian cancer in the general population?

A. Ovarian cancer is too rare to justify screening costs
B. No effective treatment is available for early-stage disease
C. Available screening tests lack sufficient sensitivity and specificity to reduce mortality (Correct Answer)
D. Most women with ovarian cancer have identifiable genetic mutations requiring targeted surveillance
E. The test (CA125) is too expensive for population-level screening

Explanation: ***Available screening tests lack sufficient sensitivity and specificity to reduce mortality*** - Randomized controlled trials, such as the **UKCTOCS**, demonstrated that while screening may detect cancer earlier, it does not significantly **reduce mortality**. - Current methods like **CA125** and **transvaginal ultrasound** result in high **false-positive** rates, leading to unnecessary investigations and potentially harmful surgeries. *Ovarian cancer is too rare to justify screening costs* - While not as common as some other cancers, ovarian cancer is a significant cause of **cancer-related death** in women, making it a viable target for screening if an effective test existed. - The decision against screening is based on the **lack of clinical benefit** and mortality reduction, rather than solely the incidence of the disease. *No effective treatment is available for early-stage disease* - **Early-stage (Stage I)** ovarian cancer actually has a high **five-year survival rate** if treated promptly with surgery and chemotherapy. - The primary problem is the **inability to detect** the disease reliably at this treatable stage, not the absence of effective management options. *Most women with ovarian cancer have identifiable genetic mutations requiring targeted surveillance* - Only about **5-15%** of ovarian cancers are associated with mutations like **BRCA1/2** or Lynch syndrome, for which targeted surveillance is recommended. - The vast majority of cases occur **sporadically** in the general population, meaning focusing solely on genetic mutations would miss most patients. *The test (CA125) is too expensive for population-level screening* - The **CA125 blood test** itself is relatively inexpensive; however, the **downstream costs** of investigating numerous **false positives** are substantial. - The primary barrier to screening is the **lack of diagnostic accuracy** and clinical effectiveness in reducing mortality, not the unit cost of the test.

Question 80: A 58-year-old woman attends for her NHS breast screening mammogram. The report shows scattered fibroglandular densities (approximately 40% of breast tissue). She asks what this means for her breast cancer risk and whether additional screening is needed. What is the most appropriate advice?

A. Breast density does not affect cancer risk; routine triennial screening is appropriate
B. Dense breast tissue increases cancer risk modestly but NHS screening intervals remain unchanged (Correct Answer)
C. She should have annual MRI screening in addition to mammography
D. She should have ultrasound screening every 6 months
E. She should be referred to genetics for assessment of familial risk

Explanation: ***Dense breast tissue increases cancer risk modestly but NHS screening intervals remain unchanged*** - High **breast density**, particularly with **fibroglandular tissue**, is an independent, modest risk factor for breast cancer and can also **mask small tumors** on mammograms. - Despite this increased risk, current **NHS Breast Screening Programme** guidelines maintain standard **triennial screening** (every 3 years) for women with scattered fibroglandular densities, without recommending shorter intervals or supplemental imaging. *Breast density does not affect cancer risk; routine triennial screening is appropriate* - This statement is incorrect as higher **breast density** is a well-established, independent **risk factor** for developing breast cancer. - While routine triennial screening is appropriate for this patient, it is crucial to accurately inform her that breast density *does* modestly **increase her risk**. *She should have annual MRI screening in addition to mammography* - **Annual MRI screening** is typically reserved for women at very high risk of breast cancer, such as those with **BRCA gene mutations** or a lifetime risk exceeding 30%. - Scattered fibroglandular densities (40% breast tissue) do not meet the criteria for routine supplemental MRI surveillance in the absence of other high-risk factors. *She should have ultrasound screening every 6 months* - There is no clinical evidence or national guideline supporting **6-monthly ultrasound** screening for asymptomatic women based solely on scattered breast density. - While ultrasound can be a useful adjunct in diagnostic workups for dense breasts, it is not a **standardized primary screening tool** in the UK for women at average risk. *She should be referred to genetics for assessment of familial risk* - Referral to **genetics** for familial risk assessment is indicated by a significant **family history** of breast/ovarian cancer (e.g., multiple affected first-degree relatives, young-onset cancer). - **Mammographic breast density** alone is a common finding and is not a direct indicator for genetic testing or a hereditary cancer syndrome referral.

Question 81: A 60-year-old woman with a 35 pack-year smoking history attends for cardiovascular risk assessment. She quit smoking 6 months ago. Her BP is 138/82 mmHg, BMI 27 kg/m², total cholesterol 6.2 mmol/L, HDL 1.3 mmol/L, and non-HDL 4.9 mmol/L. Her QRISK3 score is 12%. She asks about lung cancer screening as her friend in the United States receives annual CT scans. What is the most appropriate response?

A. Arrange annual low-dose CT chest scan as she meets high-risk criteria
B. Explain that lung cancer screening with CT is not part of the NHS national screening programme (Correct Answer)
C. Refer her to respiratory medicine for consideration of CT screening
D. Arrange a chest X-ray now and annually for the next 5 years
E. Advise CT screening only if she develops respiratory symptoms

Explanation: ***Explain that lung cancer screening with CT is not part of the NHS national screening programme*** - In the UK, a universal **national screening programme** for lung cancer using low-dose CT (LDCT) scans is not currently implemented by the **NHS National Screening Committee**. - While **Targeted Lung Health Checks** are being piloted in specific high-risk areas, routine, nationwide access to LDCT screening for asymptomatic patients is not standard NHS practice. *Arrange annual low-dose CT chest scan as she meets high-risk criteria* - Despite the patient meeting high-risk criteria often used in international trials (e.g., **NLST**), clinicians in UK primary care cannot routinely arrange **low-dose CT (LDCT)** for screening purposes outside of official pilot programs or research. - **NICE guidelines** in the UK do not currently recommend widespread lung cancer screening with CT as a standard primary care intervention for all former heavy smokers. *Refer her to respiratory medicine for consideration of CT screening* - Referral to secondary care for **asymptomatic screening** is inappropriate given that no national program exists, and it would place an unnecessary burden on specialist services. - Respiratory physicians follow the same **national guidelines** which do not currently support ad-hoc CT screening for asymptomatic individuals outside of specific initiatives. *Arrange a chest X-ray now and annually for the next 5 years* - **Chest X-rays** have been proven ineffective in reducing lung cancer mortality when used as a screening tool in multiple large clinical trials. - They are associated with **high false-negative rates** for early-stage disease and contribute to unnecessary **radiation exposure** without a proven screening benefit. *Advise CT screening only if she develops respiratory symptoms* - A CT scan performed for the development of respiratory symptoms is considered a **diagnostic investigation**, not a screening tool, and should follow **Two Week Wait (2WW) cancer referral pathways**. - If symptoms such as **persistent cough** or **haemoptysis** arise, the initial investigation is typically a **chest X-ray**, followed by a diagnostic CT if indicated, not a screening CT.

Question 82: A 74-year-old man attends following a routine blood test which shows a PSA of 6.2 ng/mL. He is asymptomatic with no urinary symptoms and has an unremarkable prostate on digital rectal examination. He asks whether he needs further investigation. What is the most appropriate management?

A. Arrange urgent urology referral for prostate biopsy
B. Repeat PSA in 1 month and refer if persistently elevated
C. Discuss the implications and arrange shared decision-making about further investigation (Correct Answer)
D. Reassure him that PSA elevation is normal at his age and no action needed
E. Start a trial of alpha-blocker therapy and recheck PSA in 3 months

Explanation: ***Discuss the implications and arrange shared decision-making about further investigation***- PSA testing is not part of a formal **screening program** because it can lead to **overdiagnosis** and treatment of non-clinically significant disease, especially in older patients.- Management must involve **shared decision-making**, weighing the elevated PSA against his life expectancy, potential treatment side effects, and his personal preferences.*Arrange urgent urology referral for prostate biopsy*- An **urgent referral** (using the 2-week wait pathway) is often triggered by a PSA > 5.0 ng/mL in this age group, but it should only occur after a thorough discussion of the **risks and benefits**.- Primary care practitioners must first explore the patient's wishes as **prostate biopsy** and subsequent treatments carry significant morbidity that may not benefit a 74-year-old.*Repeat PSA in 1 month and refer if persistently elevated*- While repeating a PSA can rule out transient elevation from **prostatitis** or recent ejaculation, it does not address the fundamental need for **patient counseling** regarding the initial result.- In an asymptomatic patient with an unremarkable **digital rectal examination (DRE)**, the priority is discussing the clinical significance of the current result rather than just delaying the decision.*Reassure him that PSA elevation is normal at his age and no action needed*- A PSA of 6.2 ng/mL is technically above the **age-specific reference range** (usually < 5.0 ng/mL for men in their 70s) and cannot be dismissed as entirely "normal."- Completely ignoring the result fails to provide the patient with the information needed to make an **informed choice** about his health care.*Start a trial of alpha-blocker therapy and recheck PSA in 3 months*- **Alpha-blockers** are used to treat **lower urinary tract symptoms (LUTS)** associated with BPH, but this patient is explicitly described as **asymptomatic**.- Using medication to treat a laboratory value without clinical indication is inappropriate and delays the necessary **diagnostic discussion** regarding possible malignancy.

Question 83: A 26-year-old woman attends for cervical screening. She reports being in a monogamous relationship with a female partner for 3 years. She has never had sexual contact with men and is concerned that cervical screening may not be necessary for her. What is the most appropriate advice regarding cervical screening?

A. She does not need cervical screening as she has no risk of HPV transmission
B. She should attend for routine cervical screening as per national guidelines (Correct Answer)
C. She only needs cervical screening if she develops symptoms
D. She should have cervical screening every 5 years instead of 3 years
E. She should be tested for HPV antibodies before deciding about screening

Explanation: ***She should attend for routine cervical screening as per national guidelines*** - All individuals with a **cervix** aged 25–64 should participate in screening, regardless of their sexual history or orientation, as **Human Papillomavirus (HPV)** can be transmitted between female partners. - Transmission can occur through **skin-to-skin** genital contact, digital-vaginal contact, or the sharing of **sex toys**, making screening essential for women who have sex with women (WSW). *She does not need cervical screening as she has no risk of HPV transmission* - This is a common misconception; while the risk may vary, **HPV transmission** is well-documented between female partners through non-penetrative contact. - Medical guidelines explicitly state that **sexual orientation** should not be used as a reason to opt-out of the screening program. *She only needs cervical screening if she develops symptoms* - Cervical screening is a **preventative tool** designed to detect asymptomatic **pre-cancerous changes** (cervical intraepithelial neoplasia) before they progress to cancer. - Waiting for symptoms, such as **abnormal vaginal bleeding**, often means the disease has already progressed to a later, more dangerous stage. *She should have cervical screening every 5 years instead of 3 years* - Screening intervals are determined by **age and clinical findings**, not by the gender of sexual partners; the standard interval for a 26-year-old is every **3 years**. - Deviating from **national guidelines** based on perceived low risk can lead to missed diagnoses of high-risk HPV strains. *She should be tested for HPV antibodies before deciding about screening* - **Serological testing** for HPV antibodies is not a substitute for cervical screening as it does not indicate current infection or the presence of **cytological abnormalities**. - The screening program relies on **primary HPV DNA testing** from a cervical swab, and an antibody test would provide no actionable information for cancer prevention.

Question 84: A 44-year-old woman with a BMI of 38 kg/m², polycystic ovary syndrome, and gestational diabetes in two previous pregnancies attends for weight management. She has lost 3 kg over 6 months with lifestyle modification. Her fasting glucose is 5.8 mmol/L and HbA1c is 41 mmol/mol. What is her current diabetes risk status and most appropriate preventive management?

A. Low risk; continue lifestyle advice and screen for diabetes every 3 years
B. Moderate risk; arrange annual HbA1c monitoring
C. High risk; refer to NHS Diabetes Prevention Programme even without non-diabetic hyperglycaemia (Correct Answer)
D. Very high risk; commence metformin for diabetes prevention
E. Diabetes likely given risk factors; arrange oral glucose tolerance test

Explanation: ***High risk; refer to NHS Diabetes Prevention Programme even without non-diabetic hyperglycaemia*** - Patients with a history of **gestational diabetes (GDM)** are at significantly increased risk for Type 2 diabetes and qualify for the **NHS Diabetes Prevention Programme (NDPP)** regardless of whether their current results show non-diabetic hyperglycaemia. - Despite her **HbA1c being 41 mmol/mol** (below the pre-diabetes threshold of 42) and normal fasting glucose, her multiple risk factors including **obesity (BMI 38)**, **PCOS**, and recurrent GDM necessitate intensive lifestyle intervention. *Low risk; continue lifestyle advice and screen for diabetes every 3 years* - This patient is not low risk; a history of **gestational diabetes** carries a seven-fold lifetime risk of developing Type 2 diabetes and classifies her as high risk. - Screening every 3 years is insufficient; patients with previous GDM require **annual HbA1c monitoring** for life according to guidelines. *Moderate risk; arrange annual HbA1c monitoring* - While annual monitoring is correct for someone with a history of GDM, classifying her as only "moderate risk" and omitting referral to an **intensive lifestyle intervention** (NDPP) ignores her substantial cumulative risk factors. - This approach fails to provide the most effective preventive strategy by not addressing her **obesity** and **PCOS comorbidities** aggressively. *Very high risk; commence metformin for diabetes prevention* - **Metformin** is generally reserved for patients where lifestyle interventions have failed, or who have rising **HbA1c levels** within the pre-diabetic range (42-47 mmol/mol), or specific high-risk groups. - Current clinical guidelines prioritise **structured lifestyle programmes** (diet and physical activity) over pharmacological intervention for initial primary prevention. *Diabetes likely given risk factors; arrange oral glucose tolerance test* - Her **HbA1c (41 mmol/mol)** and **fasting glucose (5.8 mmol/L)** are currently within normal ranges, indicating that diabetes is not currently present or "likely" based on these objective measures. - An **Oral Glucose Tolerance Test (OGTT)** is typically used for diagnosing GDM during pregnancy or if results are borderline for diabetes, but it is not the initial preventive management step when current screening results are normal.

Question 85: A 67-year-old woman with type 2 diabetes attends for review. Her diabetic eye screening result indicates 'ungradable images - unable to visualise retina due to cataracts'. The report requests referral to ophthalmology. She mentions her vision has gradually deteriorated but she can still manage daily activities. What is the most appropriate management?

A. Routine ophthalmology referral for cataract assessment and retinal examination (Correct Answer)
B. Repeat diabetic eye screening in 3 months after pupil dilation
C. Urgent ophthalmology referral within 2 weeks due to diabetes
D. Discharge from diabetic eye screening as cataracts prevent adequate screening
E. Refer to optometry for refraction and cataract assessment first

Explanation: ***Routine ophthalmology referral for cataract assessment and retinal examination*** - When **diabetic eye screening** images are **ungradable** due to **cataracts**, a **clinical retinal examination** by an ophthalmologist is essential to assess for **diabetic retinopathy**. - The patient's **gradual vision deterioration** and ability to manage daily activities suggest a **routine referral** is appropriate, as there are no signs indicating an urgent, sight-threatening condition like **proliferative diabetic retinopathy**. *Repeat diabetic eye screening in 3 months after pupil dilation* - **Cataracts** cause a physical **media opacity** that typically cannot be overcome by **pupil dilation** alone, making repeat screening unlikely to yield gradable images. - Delaying a proper **ophthalmology assessment** for three months could lead to a missed or progression of **diabetic retinopathy**, which is crucial for early management. *Urgent ophthalmology referral within 2 weeks due to diabetes* - An **urgent referral (within 2 weeks)** is typically reserved for acute, sight-threatening conditions such as **proliferative diabetic retinopathy**, sudden vision loss, or symptoms indicating retinal detachment. - This patient's **gradual vision loss** and stable daily activities, despite ungradable images, do not meet the criteria for an urgent referral pathway. *Discharge from diabetic eye screening as cataracts prevent adequate screening* - Discharging a patient with **diabetes** from **eye screening** is inappropriate as they remain at a high, lifelong risk for developing or progressing **diabetic retinopathy**. - Instead, if digital screening is not possible, the patient should transition to **ophthalmology surveillance** to ensure regular clinical assessment of their retina. *Refer to optometry for refraction and cataract assessment first* - While optometrists can identify **cataracts**, the primary concern following a failed diabetic eye screen is a comprehensive **medical retinal examination** by an ophthalmologist to rule out or manage **diabetic retinopathy**. - A direct **ophthalmology referral** ensures the patient receives the appropriate specialized assessment and management planning, including potential **cataract surgery** to enable future screening.

Question 86: A 35-year-old man presents requesting a general health check. He has no symptoms and takes no regular medication. His father developed hypertension at age 60. The patient runs regularly and maintains a healthy diet. His BMI is 24 kg/m², blood pressure 118/76 mmHg. He asks for blood tests 'to check everything is okay'. What is the most appropriate approach?

A. Arrange full blood count, renal function, liver function, lipids, HbA1c, and thyroid function
B. Explain that routine health checks for asymptomatic adults without risk factors are not recommended (Correct Answer)
C. Offer NHS Health Check as he is over 40 years old
D. Arrange lipid profile and HbA1c only as these are recommended screening tests
E. Arrange cardiovascular risk assessment and blood tests if QRISK3 >10%

Explanation: ***Explain that routine health checks for asymptomatic adults without risk factors are not recommended*** - For **asymptomatic adults** under the age of 40 with no significant risk factors, routine "general health checks" or a battery of screening blood tests are not supported by **evidence-based guidelines**. - Indiscriminate testing in low-risk individuals can lead to **overdiagnosis**, false positives, and unnecessary patient anxiety without providing a clear clinical benefit. *Arrange full blood count, renal function, liver function, lipids, HbA1c, and thyroid function* - Performing a broad panel of tests in this patient would violate **stewardship of resources** and increase the risk of finding clinically insignificant abnormalities. - There is no clinical indication for **FBC, LFTs, or TFTs** in an asymptomatic 35-year-old with a healthy lifestyle and normal BMI. *Offer NHS Health Check as he is over 40 years old* - The **NHS Health Check** program is specifically designed for adults aged **40 to 74 years**; this patient is only 35 years old and therefore ineligible. - The patient's father developed hypertension at 60, which does not count as **premature cardiovascular disease** (usually defined as occurring before age 60), thus not triggering early screening. *Arrange lipid profile and HbA1c only as these are recommended screening tests* - Lipids and HbA1c are not recommended as **universal screening tools** for healthy, normotensive 35-year-olds without secondary risk factors like obesity or high-risk ethnicity. - Screening for **Type 2 Diabetes** and dyslipidemia in the UK is primarily delivered via the targeted **NHS Health Check** for patients 40 and over. *Arrange cardiovascular risk assessment and blood tests if QRISK3 >10%* - Primary prevention **QRISK3 assessment** is typically indicated for patients aged 40 to 84 or those with specific risk factors such as **Type 1 Diabetes** or chronic kidney disease. - Since the patient is only 35 and has a **healthy BMI** and normal blood pressure, a formal QRISK3 calculation is not routinely required or indicated.

Question 87: A 49-year-old woman attends for discussion about her recent NHS breast screening mammogram which showed scattered fibroglandular densities. She has read online that dense breast tissue increases cancer risk and asks whether she needs additional screening with ultrasound or MRI. What is the most appropriate response based on current NHS screening policy?

A. Arrange supplemental breast ultrasound at next screening in 3 years
B. Refer for breast MRI screening if she has additional risk factors
C. Explain that breast density does not affect cancer risk, only mammogram interpretation
D. Reassure that standard mammographic screening remains appropriate; supplemental imaging is not routinely offered based on density alone (Correct Answer)
E. Advise annual mammography instead of 3-yearly due to increased density

Explanation: ***Reassure that standard mammographic screening remains appropriate; supplemental imaging is not routinely offered based on density alone***- Under current **NHS Breast Screening Programme (NHSBSP)** policy, breast density is not used as a standalone criterion for supplemental screening with ultrasound or MRI.- While dense tissue can mask lesions, evidence does not yet support that additional screening based on density alone improves **mortality outcomes** within the UK population screening model.*Arrange supplemental breast ultrasound at next screening in 3 years*- Routine **supplemental ultrasound** is not provided by the NHS for high-density tissue due to concerns regarding a high rate of **false positives**.- The priority remains the **standard 3-yearly mammogram** unless the patient is classified within a specific high-risk group (e.g., genetic predisposition).*Refer for breast MRI screening if she has additional risk factors*- In the UK, **MRI screening** is strictly reserved for women with a very high lifetime risk (often >30%), such as **BRCA gene carriers** or those with a very strong family history.- Finding **scattered fibroglandular densities** on a mammogram does not trigger an MRI referral without these specific high-risk genetic or hereditary markers.*Explain that breast density does not affect cancer risk, only mammogram interpretation*- This statement is medically incorrect: increased breast density is an **independent risk factor** for developing breast cancer, not just a diagnostic challenge.- It also creates a **masking effect** where white dense tissue can hide white cancerous lesions, making mammograms harder to interpret.*Advise annual mammography instead of 3-yearly due to increased density*- The **NHSBSP** follows a fixed interval of **every 3 years** for women aged 50-70; there is no current provision to increase frequency based on tissue density.- **Annual mammography** is typically reserved for women under 50 who are at increased risk due to family history, rather than density findings in the screening age group.

Question 88: A 52-year-old woman of South Asian ethnicity attends for her NHS Health Check. She has a BMI of 26 kg/m², waist circumference 82 cm, blood pressure 128/78 mmHg, fasting glucose 6.3 mmol/L, HbA1c 43 mmol/mol, total cholesterol 5.1 mmol/L. She has no family history of diabetes. What is her diabetes risk status?

A. Low risk; routine screening in 5 years
B. Moderate risk; repeat HbA1c annually
C. High risk (non-diabetic hyperglycaemia); intensive lifestyle intervention required (Correct Answer)
D. Diabetes diagnosed; commence metformin
E. Impaired fasting glucose only; dietary advice and repeat in 3 years

Explanation: ***High risk (non-diabetic hyperglycaemia); intensive lifestyle intervention required***- The patient's **fasting glucose of 6.3 mmol/L** and **HbA1c of 43 mmol/mol** both fall into the range for **non-diabetic hyperglycaemia (NDH)** or pre-diabetes (fasting glucose 6.1-6.9 mmol/L; HbA1c 42-47 mmol/mol).- Given her **South Asian ethnicity** and elevated **waist circumference (82 cm)**, she is at **high risk** of progressing to Type 2 diabetes, necessitating a referral to an **intensive lifestyle intervention program** such as the NHS Diabetes Prevention Programme.*Low risk; routine screening in 5 years*- Her elevated **fasting glucose (6.3 mmol/L)** and **HbA1c (43 mmol/mol)**, along with her ethnicity and waist circumference, indicate a **significant risk** for diabetes, not a low risk.- **Routine screening in 5 years** is insufficient for someone already showing signs of non-diabetic hyperglycaemia and multiple risk factors.*Moderate risk; repeat HbA1c annually*- While annual HbA1c monitoring is appropriate for NDH, this patient's glycemic values and risk factors (ethnicity, waist circumference) categorize her as **high risk**, which warrants a more active intervention than just monitoring.-

Question 89: A 66-year-old man has completed 12 weeks of varenicline for smoking cessation and reports being smoke-free for 10 weeks. He works as a long-distance lorry driver and is concerned about weight gain since quitting (he has gained 4 kg). He requests to continue varenicline for another 12 weeks to prevent relapse. What is the most appropriate response?

A. Decline extension as standard course is 12 weeks and he has achieved abstinence
B. Prescribe additional 12 weeks of varenicline as relapse prevention in successful quitters (Correct Answer)
C. Switch to nicotine replacement therapy for ongoing maintenance
D. Prescribe orlistat to address weight gain concerns
E. Offer bupropion as alternative to limit post-cessation weight gain

Explanation: ***Prescribe additional 12 weeks of varenicline as relapse prevention in successful quitters*** - According to **NICE guidelines**, patients who have successfully quit smoking after a 12-week course can be offered an additional 12-week course to further reduce the risk of **relapse**. - This patient's concern about **weight gain** and his occupation as a long-distance lorry driver suggest potential triggers for relapse, making extended therapy a clinically sound strategy for long-term **abstinence**. *Decline extension as standard course is 12 weeks and he has achieved abstinence* - While 12 weeks is the standard initial treatment, **NICE guidelines** explicitly support extending varenicline for an additional 12 weeks in **successful quitters** to consolidate the quit attempt. - Declining the request would ignore the patient's expressed concerns about **relapse** and miss an opportunity to enhance long-term cessation success. *Switch to nicotine replacement therapy for ongoing maintenance* - There is no clinical reason to switch to **Nicotine Replacement Therapy (NRT)** when the patient has successfully quit smoking and is tolerating **varenicline** well. - **Varenicline** is a **partial agonist** at the α4β2 nicotinic receptor and is often more effective than NRT monotherapy for maintaining **abstinence**. *Prescribe orlistat to address weight gain concerns* - A **weight gain of 4 kg** is a common and expected side effect of smoking cessation and does not typically meet the criteria for **orlistat**, which is reserved for individuals with a **BMI of 30 kg/m² or higher** (or 27 kg/m² with comorbidities). - The primary focus remains on maintaining **smoking abstinence**, as the health benefits of quitting far outweigh the minor risk associated with modest post-cessation weight gain. *Offer bupropion as alternative to limit post-cessation weight gain* - While **bupropion** can help attenuate post-cessation weight gain, it is inappropriate to switch medications when a patient has successfully quit with **varenicline**. - Introducing a new drug would expose the patient to a different **side effect profile** and contraindications without demonstrating superior efficacy for relapse prevention in this already successful quitter.

Question 90: A 58-year-old man with a BMI of 43 kg/m², type 2 diabetes, hypertension, and obstructive sleep apnoea attends for weight management review. Despite 9 months of intensive lifestyle intervention and maximum tolerated dose of orlistat, his weight has decreased from 142 kg to 138 kg (2.8% weight loss). His HbA1c has increased from 64 to 71 mmol/mol. What is the most appropriate next step?

A. Continue current management and review in 6 months
B. Refer to tier 3 weight management service for consideration of pharmacotherapy or bariatric surgery (Correct Answer)
C. Switch from orlistat to liraglutide for dual diabetes and weight management
D. Increase diabetes medication and continue lifestyle modification
E. Arrange psychological assessment for possible eating disorder

Explanation: ***Refer to tier 3 weight management service for consideration of pharmacotherapy or bariatric surgery*** - The patient's **BMI of 43 kg/m²** and failure to achieve significant weight loss (only 2.8% after 9 months) with intensive lifestyle and orlistat, along with worsening **HbA1c**, meet the **NICE criteria** for referral to specialist (tier 3 or 4) weight management services. - A specialist service can offer a **multidisciplinary assessment** and consider advanced interventions like **bariatric surgery** or other **pharmacotherapy** (e.g., GLP-1 receptor agonists) under expert guidance, which are appropriate given his complex comorbidities like **Type 2 Diabetes** and **Obstructive Sleep Apnea**. *Continue current management and review in 6 months* - **Orlistat** is typically discontinued if at least **5% weight loss** is not achieved within 3 months, making continued current management after 9 months of poor results inappropriate and ineffective. - His worsening **HbA1c** indicates a progressive metabolic issue that requires more aggressive intervention, not a delayed review with an ineffective regimen. *Switch from orlistat to liraglutide for dual diabetes and weight management* - While **liraglutide** (a GLP-1 receptor agonist) is effective for both diabetes and weight loss, the patient's severe obesity (BMI 43 kg/m²) and failure of primary care interventions warrant a comprehensive evaluation by a **tier 3 specialist service**. - A specialist service can provide a holistic approach, considering all suitable pharmacotherapy options and multidisciplinary support, rather than a single medication switch in primary care. *Increase diabetes medication and continue lifestyle modification* - Simply increasing **diabetes medication** addresses the symptom (hyperglycemia) but not the underlying cause of severe obesity, which is driving his metabolic deterioration. - The patient has already undergone **intensive lifestyle modification** for 9 months with minimal success, so continuing this without further escalation is unlikely to be effective in preventing further glycemic decline or achieving meaningful weight loss. *Arrange psychological assessment for possible eating disorder* - There is no specific information in the patient's history, such as **binge eating episodes**, purging, or distorted body image, to primarily suggest an **eating disorder** as the immediate next step. - While psychological support is crucial in weight management, it is typically part of the multidisciplinary assessment within a **tier 3 weight management service**, rather than a standalone assessment for an eating disorder at this stage.

Question 91: A 41-year-old woman presents requesting cardiovascular risk assessment. Her father died aged 46 of myocardial infarction, and her brother was diagnosed with familial hypercholesterolaemia. Her total cholesterol is 8.2 mmol/L, LDL 6.1 mmol/L, triglycerides 1.8 mmol/L. Her QRISK3 score calculates as 8.5%. What is the most appropriate management approach?

A. Start atorvastatin 20 mg as QRISK3 is approaching 10% threshold
B. Do not use QRISK3; offer lipid specialist referral and start high-intensity statin (Correct Answer)
C. Start atorvastatin 80 mg and repeat lipids in 3 months
D. Arrange genetic testing for familial hypercholesterolaemia before treatment
E. Provide intensive lifestyle advice and reassess QRISK3 in 12 months

Explanation: ***Do not use QRISK3; offer lipid specialist referral and start high-intensity statin*** - **QRISK3** is not intended for use and underestimates risk in patients with suspected **familial hypercholesterolaemia (FH)** due to lifelong cholesterol exposure. - This patient meets criteria for suspected FH (Total Cholesterol >7.5 mmol/L and premature family history); management requires **specialist referral** and immediate **high-intensity statin** therapy. *Start atorvastatin 20 mg as QRISK3 is approaching 10% threshold* - **20 mg atorvastatin** is a primary prevention dose for general populations; patients with FH require more potent **high-intensity** regimens. - Relying on the **10% QRISK3 threshold** is inappropriate here as the tool is invalidated for patients with strongly suspected genetic dyslipidemias. *Start atorvastatin 80 mg and repeat lipids in 3 months* - While **80 mg atorvastatin** is the correct high-intensity treatment, this option fails to address the essential requirement for **specialist referral** and cascade testing. - FH management is not limited to statin initiation; it involves **clinical scoring** (Simon Broome) and formal risk assessment by experts. *Arrange genetic testing for familial hypercholesterolaemia before treatment* - **Genetic testing** is often performed by specialists, but pharmacological treatment should not be delayed while awaiting these results. - Immediate **lipid-lowering therapy** is prioritized to reduce the significant risk of premature **myocardial infarction**. *Provide intensive lifestyle advice and reassess QRISK3 in 12 months* - **Lifestyle advice** is insufficient for FH as the condition is driven by genetic defects that prevent adequate clearance of **LDL cholesterol**. - Delaying treatment for 12 months increases the risk of **major adverse cardiovascular events** in a high-risk patient.

Question 92: A 37-year-old woman attends with her cervical screening result showing hrHPV positive with normal cytology (hrHPV+/cytology negative). This is her first hrHPV positive result. She is very anxious about having cancer and requests urgent colposcopy. What is the correct next step according to current NHS Cervical Screening Programme guidelines?

A. Reassure and arrange routine colposcopy within 6 weeks
B. Reassure and invite for repeat hrHPV test and cytology in 12 months (Correct Answer)
C. Arrange urgent colposcopy within 2 weeks due to hrHPV positivity
D. Repeat cervical cytology in 3 months to exclude false negative result
E. Perform hrHPV genotyping to determine if HPV 16/18 present

Explanation: ***Reassure and invite for repeat hrHPV test and cytology in 12 months***- According to **NHS Cervical Screening Programme** guidelines, for a **first-time hrHPV positive** result with **normal cytology**, the recommended next step is to invite the woman for a **repeat hrHPV test and cytology in 12 months**.- This approach allows for the possibility of **spontaneous viral clearance**, as most **HPV infections are transient**, and minimizes unnecessary immediate intervention given the low risk of high-grade disease with normal cytology.*Reassure and arrange routine colposcopy within 6 weeks*- A **routine colposcopy** is not indicated for a first-time **hrHPV positive** result with **normal cytology** as per current NHS guidelines.- Immediate colposcopy is typically reserved for cases with **abnormal cytology** (e.g., moderate dyskaryosis or worse) or for **persistent hrHPV positivity** on follow-up.*Arrange urgent colposcopy within 2 weeks due to hrHPV positivity*- An **urgent colposcopy within 2 weeks** is reserved for women with a strong suspicion of **cervical cancer** based on clinical findings or specific high-grade cytological abnormalities.- **hrHPV positivity** with **normal cytology** does not meet the criteria for an urgent referral, as the immediate risk of cancer is very low.*Repeat cervical cytology in 3 months to exclude false negative result*- A **3-month repeat** for cervical cytology or hrHPV testing is not a standard interval in the current **NHS Cervical Screening Programme** for this scenario.- This interval is too short to observe natural **viral clearance** or significant changes in cytology, making the **12-month follow-up** more appropriate.*Perform hrHPV genotyping to determine if HPV 16/18 present*- While **HPV 16 and 18** are indeed high-risk types, current **NHS screening protocols** do not use immediate genotyping to triage a **first-time hrHPV positive** result with **normal cytology**.- The management pathway is primarily driven by the **cytology result** and the **persistence of the hrHPV infection** over time, rather than immediate genotyping.

Question 93: A 71-year-old woman with type 2 diabetes for 12 years is noted to have missed her last two diabetic retinopathy screening appointments. She explains she doesn't attend because her vision is fine and she sees her optician annually. Her most recent HbA1c is 68 mmol/mol. What is the most important point to explain about diabetic eye screening?

A. Optician examinations cannot replace NHS diabetic eye screening as they don't routinely dilate pupils
B. Diabetic retinopathy causes visual symptoms early, allowing time for intervention
C. Annual screening is only required if HbA1c is suboptimal or duration exceeds 10 years
D. Sight-threatening diabetic retinopathy can develop without symptoms and requires digital retinal photography (Correct Answer)
E. Diabetic eye screening can be deferred if recent cataract surgery was performed

Explanation: ***Sight-threatening diabetic retinopathy can develop without symptoms and requires digital retinal photography***- **Diabetic retinopathy** is notoriously **asymptomatic** in its early, treatable stages, meaning a patient's self-reported "fine vision" is not a reliable indicator of eye health.- Specialized **digital retinal photography** is the gold standard for screening to detect **microaneurysms**, hemorrhages, and exudates before they cause irreversible vision loss.*Optician examinations cannot replace NHS diabetic eye screening as they don't routinely dilate pupils*- While **optician exams** provide general checks, they lack the **standardized grading** and systematic reporting used by the national screening program to monitor progression.- The distinction regarding **pupil dilation** is secondary to the fact that optician records are not integrated into the specialist **diabetic clinical pathway**.*Diabetic retinopathy causes visual symptoms early, allowing time for intervention*- This is medically incorrect; visual symptoms such as **blurring** or **floaters** usually only occur once **maculopathy** or **proliferative disease** has already developed.- Intervention is most effective when the disease is **pre-symptomatic**, making regular screening vital regardless of visual acuity.*Annual screening is only required if HbA1c is suboptimal or duration exceeds 10 years*- All patients with diabetes are at risk; although **poor glycemic control** (HbA1c > 58 mmol/mol) increases risk, screening is mandated for **all individuals** with diabetes from age 12.- Current guidelines require regular screening (usually **annually**) even if the patient has had the condition for less than 10 years.*Diabetic eye screening can be deferred if recent cataract surgery was performed*- **Cataract surgery** does not treat or prevent **diabetic retinopathy**; in fact, the inflammatory stress of surgery can occasionally exacerbate underlying retinal issues.- Patients must remain in the **screening program** regardless of other ophthalmological procedures to monitor for **vascular changes**.

Question 94: A 56-year-old woman attends for discussion about smoking cessation. She smokes 20 cigarettes daily and has a 35 pack-year history. She has tried nicotine replacement therapy twice without success. She has no contraindications to pharmacological treatment. Which medication combination offers the highest quit rates for smoking cessation?

A. Varenicline alone
B. Bupropion alone
C. Nicotine patch plus nicotine gum dual therapy
D. Varenicline plus nicotine patch combination (Correct Answer)
E. Bupropion plus nicotine replacement therapy

Explanation: ***Varenicline plus nicotine patch combination*** - Combining **Varenicline** with a **long-acting nicotine patch** is clinically proven to achieve higher cessation rates than monotherapy by reducing both cravings and withdrawal symptoms. - This approach is particularly effective in heavy smokers with a significant **pack-year history** who have previously failed single-agent therapies. *Varenicline alone* - While **Varenicline monotherapy** is more effective than Bupropion or single-form NRT, it is statistically inferior to its combination with **nicotine replacement therapy (NRT)**. - It acts as a **partial agonist** at the α4β2 nicotinic acetylcholine receptor, but adding a patch provides better relief during the initial cessation phase. *Bupropion alone* - **Bupropion** is an antidepressant that inhibits the reuptake of dopamine and norepinephrine, but it generally has **lower quit rates** compared to Varenicline. - It is often reserved as a second-line option or for patients with specific contraindications to **Varenicline** or with co-morbid depression. *Nicotine patch plus nicotine gum dual therapy* - **Dual NRT** (patch plus a short-acting form like gum) is superior to single NRT but is typically less effective than **Varenicline-based combinations**. - This patient specifically noted a lack of success with previous **NRT attempts**, suggesting a need for a more potent pharmacological intervention. *Bupropion plus nicotine replacement therapy* - The combination of **Bupropion and NRT** provides higher success rates than Bupropion alone but remains less effective than **Varenicline-NRT** regimens. - Recent evidence and guidelines favor Varenicline as the backbone for **combination therapy** in high-dependency smokers.

Question 95: A 69-year-old man attends for discussion of his NHS Health Check results. He has a QRISK3 score of 18%, total cholesterol 6.8 mmol/L, HDL 1.1 mmol/L, blood pressure 148/92 mmHg, BMI 29 kg/m², and HbA1c 41 mmol/mol. He is a non-smoker. What is the most appropriate initial management strategy?

A. Start atorvastatin 20 mg and arrange blood pressure monitoring (Correct Answer)
B. Arrange repeat HbA1c in 3 months and lifestyle advice only
C. Start atorvastatin 80 mg, amlodipine 5 mg, and metformin
D. Provide lifestyle advice and reassess cardiovascular risk in 12 months
E. Refer to cardiology for specialist cardiovascular risk assessment

Explanation: ***Start atorvastatin 20 mg and arrange blood pressure monitoring*** - The patient's **QRISK3 score of 18%** is significantly above the **10% threshold** (NICE guidelines) for initiating primary prevention with a statin, making **atorvastatin 20 mg** the appropriate starting dose. - A clinic blood pressure of **148/92 mmHg** suggests **Stage 1 hypertension**; this needs confirmation with **Ambulatory Blood Pressure Monitoring (ABPM)** or Home Blood Pressure Monitoring (HBPM) before commencing antihypertensive medication. *Arrange repeat HbA1c in 3 months and lifestyle advice only* - An **HbA1c of 41 mmol/mol** is within the normal range, or just at the very upper end of normal (pre-diabetes is typically 42-47 mmol/mol), so repeating it in 3 months is not the immediate priority over managing high cardiovascular risk. - Relying solely on lifestyle advice ignores the patient's **high QRISK3 score (18%)**, which necessitates immediate pharmacological intervention with a statin. *Start atorvastatin 80 mg, amlodipine 5 mg, and metformin* - **Atorvastatin 80 mg** is a higher dose usually reserved for **secondary prevention** or very high-risk primary prevention, not typically as an initial dose for a QRISK3 score of 18%. - **Metformin** is indicated for type 2 diabetes, which the patient does not have (**HbA1c 41 mmol/mol**), and **amlodipine** should not be started without confirmed hypertension via **ABPM/HBPM**. *Provide lifestyle advice and reassess cardiovascular risk in 12 months* - For a patient with a **QRISK3 score of 18%**, delaying pharmacological intervention for 12 months is inappropriate and unsafe, as it leaves them at significant immediate risk of cardiovascular events. - While **lifestyle advice** is crucial, it is insufficient on its own for this level of risk and must be combined with statin therapy. *Refer to cardiology for specialist cardiovascular risk assessment* - The assessment and initial management of cardiovascular risk using tools like **QRISK3** fall within the scope of **primary care**. - Specialist cardiology referral is typically reserved for complex cases, such as suspected **familial hypercholesterolaemia** (e.g., total cholesterol > 7.5 mmol/L or specific family history) or established complex heart disease, which are not indicated here.

Question 96: A 32-year-old woman with learning disabilities attends with her carer for cervical screening. She has capacity to consent but becomes very anxious during speculum examination and the test cannot be completed. What is the most appropriate next step in her management?

A. Document failed attempt and inform her she cannot have screening
B. Arrange repeat attempt in 6 months with practice nurse
C. Offer hrHPV self-sampling as an alternative to speculum examination (Correct Answer)
D. Refer to colposcopy for examination under general anaesthetic
E. Prescribe diazepam for sedation prior to next screening attempt

Explanation: ***Offer hrHPV self-sampling as an alternative to speculum examination*** - This option directly addresses the patient's **anxiety** and inability to tolerate the **speculum examination**, providing an effective and less invasive alternative for cervical screening. - **hrHPV self-sampling** allows individuals, especially those with learning disabilities or severe anxiety, to collect their own sample for HPV testing, promoting **equitable access** to screening.*Document failed attempt and inform her she cannot have screening* - This is an **unacceptable** approach as it denies the patient her right to **preventive healthcare** and fails to make reasonable adjustments for her disability. - Healthcare providers have a duty to ensure **accessible services** and explore all possible alternatives to facilitate screening for vulnerable patients.*Arrange repeat attempt in 6 months with practice nurse* - A simple repeat attempt without addressing the underlying issue of **speculum intolerance** is unlikely to be successful and may exacerbate the patient's **anxiety**. - This approach fails to provide a **patient-centered solution** and is inefficient given the identified barrier.*Refer to colposcopy for examination under general anaesthetic* - **Examination under general anaesthetic (EUA)** is an invasive procedure with inherent risks and is generally reserved for diagnostic or therapeutic interventions, not routine **primary screening**. - This option is **overly aggressive** and disproportionate as a first-line alternative, especially when less invasive and equally effective screening methods are available.*Prescribe diazepam for sedation prior to next screening attempt* - While sedation might reduce anxiety, it carries risks such as **oversedation**, **adverse drug reactions**, and requires careful monitoring, which complicates a routine screening procedure. - Providing **hrHPV self-sampling** is a more empowering, patient-friendly, and non-pharmacological solution that avoids the potential side effects and logistical challenges of sedation.

Question 97: A 63-year-old woman attends for her NHS breast screening appointment. She asks about the frequency of mammographic screening in the NHS Breast Screening Programme. What is the standard screening interval for women aged 50-70 years in England?

A. Annually
B. Every 18 months
C. Every 2 years
D. Every 3 years (Correct Answer)
E. Every 5 years

Explanation: ***Every 3 years*** - The **NHS Breast Screening Programme** in England invites women aged **50 to 70** for mammographic screening at a standard interval of **every three years**. - This interval is designed to balance the **early detection** of breast cancer with minimizing **over-diagnosis** and unnecessary **radiation exposure**. *Annually* - **Annual screening** is not the standard for the general population in the UK due to concerns about increased **false positives** and cumulative **radiation exposure**. - Annual mammograms are typically reserved for women at **very high risk**, such as those with specific genetic mutations like **BRCA1 or BRCA2**. *Every 18 months* - An **18-month interval** is not currently utilized within the UK national breast screening program for any demographic or risk category. - This frequency has not been demonstrated to offer a significant clinical advantage over the established **triennial** (three-yearly) approach for the general population. *Every 2 years* - While a **two-year interval** is common in several other international screening programs, it is not the protocol for the **NHS in England**. - The UK system adheres to its **three-year cycle**, though women over 70 can continue to **self-refer** for screening at the same frequency. *Every 5 years* - A **five-year interval** is considered too extended for effective breast cancer screening, as aggressive cancers could develop and advance significantly between appointments. - This longer frequency would substantially reduce the program's efficacy in identifying **asymptomatic cancers** at an early, more treatable stage.

Question 98: What is the age range for men eligible for NHS Abdominal Aortic Aneurysm (AAA) screening programme in England?

A. All men aged 60-74 years
B. Men aged 65 years invited in the year they turn 65 (Correct Answer)
C. All men aged 50-65 years
D. Men aged 65-70 years
E. All men over 60 years on initial invitation

Explanation: ***Men aged 65 years invited in the year they turn 65***- The **NHS Abdominal Aortic Aneurysm (AAA) screening programme** in England specifically invites all men for a one-off **ultrasound scan** in the year they turn **65**.- This age is chosen to identify clinically significant aneurysms, balancing the **prevalence** of AAA with the **cost-effectiveness** and benefit of early detection to prevent rupture.*All men aged 60-74 years*- This age range is too broad and not specific to the **single invitation** nature of the AAA screening program.- Other screening programs, like **Bowel Cancer Screening**, might use broader age ranges for repeated invitations, but AAA screening is a one-time event at a particular age.*All men aged 50-65 years*- Screening at age 50 is too early, as the **prevalence** of clinically significant AAAs is much lower in this younger cohort, making screening less efficient.- The **NHS AAA screening programme** specifically targets men in their **65th year** to optimize detection rates and clinical benefit.*Men aged 65-70 years*- While men over 65 who missed their initial invitation can **self-refer**, the primary **routine invitation** for the NHS AAA screening is strictly for men in the year they turn **65**.- There isn't a continuous automatic invitation window between 65 and 70; the initial screening is a one-off event.*All men over 60 years on initial invitation*- The initial invitation is precisely targeted at **65 years** of age, not broadly for all men over 60.- Men older than 65 who have not been screened need to **proactively contact** the screening service, as they won't receive an automatic invitation after turning 65.

Question 99: A 70-year-old man with type 2 diabetes for 18 years attends for review. His most recent diabetic retinopathy screening (6 months ago) was graded as R1M1 (background retinopathy and maculopathy). He has now developed blurred vision in his right eye over the past week. Visual acuity is 6/18 in the right eye (previously 6/9) and 6/6 in the left eye. Fundoscopy shows dot and blot haemorrhages consistent with his previous screening result. What is the most appropriate management?

A. Refer urgently to ophthalmology for assessment within 1 week (Correct Answer)
B. Reassure and arrange routine annual diabetic retinopathy screening
C. Optimize glycaemic control and arrange repeat screening in 3 months
D. Refer to optometry for refraction and new spectacles
E. Arrange urgent same-day ophthalmology assessment

Explanation: ***Refer urgently to ophthalmology for assessment within 1 week*** - Any diabetic patient experiencing **acute visual deterioration**, such as this patient's decline from 6/9 to 6/18, requires **urgent specialist review** regardless of previous screening results. - The presence of **M1 (maculopathy)** increases the risk of rapid progression to **diabetic macular oedema**, which can lead to irreversible sight loss if not managed promptly. *Reassure and arrange routine annual diabetic retinopathy screening* - **Routine screening** is only appropriate for asymptomatic patients with stable findings; it is unsafe for a patient with **new-onset blurred vision**. - Waiting for annual screening ignores the **red flag** of a significant drop in **visual acuity**, potentially leading to permanent blindness. *Optimize glycaemic control and arrange repeat screening in 3 months* - While **glycaemic control** is vital for long-term management, it will not address the acute pathology causing the **current vision loss**. - A **3-month delay** is too long for a patient showing active symptoms of **macular involvement**, as treatment efficacy decreases with time. *Refer to optometry for refraction and new spectacles* - This approach incorrectly assumes a **refractive error** rather than addressing the known **diabetic retinopathy** and maculopathy complications. - **Dot and blot haemorrhages** and sudden blurring indicate organic disease that **optometry** cannot treat with glasses. *Arrange urgent same-day ophthalmology assessment* - **Same-day referral** is typically reserved for **sudden-onset sight loss** (e.g., vitreous haemorrhage) or emergencies like **retinal detachment** or acute glaucoma. - While the patient's condition is urgent, a review **within 1 week** is the standard clinical guideline for subacute visual changes in diabetic maculopathy.

Question 100: A 38-year-old man presents for cardiovascular risk assessment. His father died suddenly at age 42 from myocardial infarction, and his paternal grandfather died at age 45 from heart disease. Lipid profile shows: total cholesterol 8.9 mmol/L, LDL 6.8 mmol/L, HDL 1.1 mmol/L, triglycerides 1.8 mmol/L. On examination, he has bilateral Achilles tendon thickening and tendon xanthomata. What is the most appropriate immediate management?

A. Calculate QRISK3 score and start atorvastatin 20mg if >10%
B. Start atorvastatin 80mg and refer to specialist lipid clinic (Correct Answer)
C. Arrange genetic testing for familial hypercholesterolaemia before starting treatment
D. Refer to specialist lipid clinic and defer statin therapy until specialist review
E. Start atorvastatin 20mg and titrate according to response, aiming for 40% reduction in non-HDL cholesterol

Explanation: ***Start atorvastatin 80mg and refer to specialist lipid clinic***- This patient presents with classical features of **familial hypercholesterolaemia (FH)**, including markedly elevated **LDL cholesterol** (6.8 mmol/L), a strong family history of premature **coronary artery disease** (father and grandfather dying at young ages), and diagnostic physical signs such as **Achilles tendon thickening** and **tendon xanthomata**.- **NICE guidelines** recommend immediate initiation of a **high-intensity statin** (e.g., atorvastatin 80mg) to aggressively lower LDL and mitigate the significant **lifetime cardiovascular risk** associated with FH, coupled with a prompt **referral to a specialist lipid clinic** for further management and cascade screening.*Calculate QRISK3 score and start atorvastatin 20mg if >10%*- **QRISK3** and similar cardiovascular risk calculators are designed for the general population and significantly **underestimate** the true risk in patients with established or highly suspected conditions like **familial hypercholesterolaemia**.- The patient's clinical presentation, including markedly elevated **LDL** and **tendon xanthomata**, already indicates an extremely high cardiovascular risk, rendering a QRISK3 calculation unnecessary and a low-dose statin (20mg) inadequate for initial management.*Arrange genetic testing for familial hypercholesterolaemia before starting treatment*- While **genetic testing** is a valuable tool for confirming **familial hypercholesterolaemia** and facilitating **cascade screening** of relatives, it should **not delay** the immediate initiation of life-saving lipid-lowering therapy.- Treatment is commenced based on robust clinical criteria (such as very high LDL and tendon xanthomata), and genetic testing can proceed in parallel without deferring critical intervention.*Refer to specialist lipid clinic and defer statin therapy until specialist review*- Deferring statin therapy is inappropriate and potentially dangerous given the patient's extremely high risk of a **premature cardiovascular event**, highlighted by his father's death at age 42, which is highly indicative of FH.- Primary care should initiate **high-intensity statins** immediately upon clinical suspicion of FH, typically **atorvastatin 80mg**, without waiting for the specialist appointment to avoid delay in crucial risk reduction.*Start atorvastatin 20mg and titrate according to response, aiming for 40% reduction in non-HDL cholesterol*- A starting dose of **atorvastatin 20mg** is standard for primary prevention in the general population but is generally considered insufficient for the aggressive management required in **familial hypercholesterolaemia**.- Patients with FH require **maximal tolerated doses of high-intensity statins** (e.g., atorvastatin 80mg) from the outset to achieve optimal reductions in **LDL cholesterol** and effectively manage their very high lifetime cardiovascular risk.

Question 101: A 59-year-old woman attends for her first NHS breast screening mammogram. She had breast augmentation with silicone implants 15 years ago following mastectomy for benign phyllodes tumour. She is asymptomatic. The screening unit contacts you to say that adequate breast tissue imaging was difficult to obtain due to the implants. What is the most appropriate management?

A. Reassure her that breast screening is not necessary given her benign breast disease history
B. Advise her that mammographic screening is not suitable and she should perform monthly breast self-examination instead
C. Explain that she should have ultrasound screening instead of mammography every 3 years
D. Arrange for her to be recalled to the screening unit for additional imaging techniques including implant displacement views (Correct Answer)
E. Refer her to breast surgery for annual clinical examination as an alternative to mammographic screening

Explanation: ***Arrange for her to be recalled to the screening unit for additional imaging techniques including implant displacement views***- Women with **breast implants** are still eligible for screening; however, implants can obscure tissue, requiring specialized **Eklund (implant displacement) views**.- This technique involves pushing the implant back against the **chest wall** while pulling the breast tissue forward to ensure adequate visualization of the parenchyma.*Reassure her that breast screening is not necessary given her benign breast disease history*- A history of **benign phyllodes tumour** does not eliminate the risk of developing breast cancer in any remaining or contralateral breast tissue.- All women aged **50 to 71** (in the UK) are invited for screening regardless of previous benign diagnoses.*Advise her that mammographic screening is not suitable and she should perform monthly breast self-examination instead*- Mammography remains the **gold standard** for screening even with implants, provided that modified techniques are employed.- **Breast self-examination** alone is not a sufficient substitute for radiological screening and does not reduce breast cancer mortality.*Explain that she should have ultrasound screening instead of mammography every 3 years*- **Ultrasound** is typically used for targeted assessment of symptomatic masses or implant integrity, not as a primary population-based **screening tool**.- Routine screening protocol dictates that specialized mammographic views must be attempted first before considering alternative modalities.*Refer her to breast surgery for annual clinical examination as an alternative to mammographic screening*- **Annual clinical examination** is not a standard replacement for the high-sensitivity detection provided by mammographic imaging.- Screening units have specific internal protocols for **inadequate images**, and the correct pathway is a recall for technical repeats or additional views, not a surgical referral.

Question 102: A 48-year-old man attends for an NHS Health Check. He drinks 6 pints of lager (4.5% ABV) on Friday and Saturday evenings, and 2-3 pints on Wednesday evenings. He scores 12 on the AUDIT (Alcohol Use Disorders Identification Test) questionnaire. He works full-time and reports no social or occupational problems related to alcohol. Liver function tests and gamma-GT are within normal limits. What is the most appropriate intervention at this consultation?

A. Provide simple brief advice about reducing alcohol consumption to lower-risk levels
B. Refer to community alcohol services for specialist assessment and intervention
C. Arrange extended brief intervention focusing on behaviour change techniques over multiple sessions (Correct Answer)
D. Reassure that his drinking is not problematic given normal liver function tests
E. Prescribe thiamine supplementation and arrange follow-up in 2 weeks

Explanation: ***Arrange extended brief intervention focusing on behaviour change techniques over multiple sessions*** - An **AUDIT score of 8-15** indicates **hazardous drinking** (increasing risk), for which NICE guidelines recommend an **extended brief intervention**. - This intervention typically involves **behavior change techniques** and motivational interviewing delivered over several sessions to help the patient reduce consumption. *Provide simple brief advice about reducing alcohol consumption to lower-risk levels* - **Simple brief advice** (5-10 minutes) is generally suitable for patients scoring below 8 on the **AUDIT** scale or for low-level opportunistic screening. - Given his score of 12 and consumption of approx **66 units per week**, a more intensive extended approach is required to be effective. *Refer to community alcohol services for specialist assessment and intervention* - Specialized referrals are typically reserved for patients with an **AUDIT score ≥20** or those showing signs of physical **alcohol dependence**. - This patient lacks social or occupational dysfunction and has normal **gamma-GT**, suggesting he does not yet require intensive specialist services. *Reassure that his drinking is not problematic given normal liver function tests* - Normal **liver function tests (LFTs)** do not exclude significant health risks such as **hypertension**, various **cancers**, and future liver cirrhosis. - The patient is drinking nearly five times the recommended **14 units per week** limit, which constitutes a major health risk regardless of current LFT results. *Prescribe thiamine supplementation and arrange follow-up in 2 weeks* - **Thiamine (Vitamin B1)** is indicated for those at high risk of **Wernicke-Korsakoff syndrome**, usually seen in **dependent drinkers** or the malnourished. - This patient is a hazardous drinker but shows no signs of **malnutrition** or alcohol dependence that would necessitate prophylactic thiamine at this stage.

Question 103: A 24-year-old woman attends requesting cervical screening. She has never had cervical screening before and has just received her first invitation. She mentions she had the HPV vaccination at school when she was 13 years old and asks if she still needs cervical screening. She is sexually active with one partner and uses condoms for contraception. What is the most appropriate advice?

A. She does not require cervical screening due to her HPV vaccination
B. She should proceed with cervical screening as per the invitation (Correct Answer)
C. She should defer cervical screening until age 30 given her vaccination status
D. She only requires cervical screening every 5 years due to her HPV vaccination
E. She should have an initial HPV test only without cytology given her vaccination

Explanation: ***She should proceed with cervical screening as per the invitation***- All women should attend **cervical screening** when invited, and having received the **HPV vaccination** does not change high-risk screening protocols.- While the vaccine protects against the most common **high-risk HPV types** (16 and 18), it does not cover all oncogenic strains that can lead to cervical cancer.*She does not require cervical screening due to her HPV vaccination*- The **HPV vaccine** is complementary to screening and significantly reduces risk, but it does not offer 100% protection against all **cervical cancers**.- Vaccination history is not currently used to exempt patients from national **screening programmes**.*She should defer cervical screening until age 30 given her vaccination status*- In many regions including the UK, the first invitation for screening occurs at **age 25**; deferring would miss the window for early detection of **cervical intraepithelial neoplasia (CIN)**.- There is no medical evidence to support delaying the **primary screening** age based solely on vaccination status at this time.*She only requires cervical screening every 5 years due to her HPV vaccination*- The standard screening interval for women aged 25-49 is **every 3 years**; this frequency remains the same regardless of **vaccination status**.- **Five-year intervals** are typically only implemented for women aged 50-64 or in specific regions using primary HPV testing for all age groups.*She should have an initial HPV test only without cytology given her vaccination*- Modern screening already uses **HPV primary screening**, but **reflex cytology** is automatically performed if HPV is detected to assess for cellular changes.- Clinical protocols for the **screening methodology** are standardized for the general population and are not modified based on a patient’s vaccination history.

Question 104: A 45-year-old woman with a BMI of 42 kg/m² attends for weight management. She has tried multiple commercial diet programmes without sustained success. Her blood pressure is 146/92 mmHg, HbA1c 43 mmol/mol, and she has grade 2 non-alcoholic fatty liver disease on ultrasound. She is motivated to lose weight and asks about pharmacological options. According to NICE guidance, which medication would be the most appropriate first-line pharmacological intervention?

A. Orlistat 120mg three times daily with meals (Correct Answer)
B. Liraglutide 3mg subcutaneous injection daily
C. Naltrexone-bupropion combination therapy
D. Semaglutide 2.4mg subcutaneous injection weekly
E. Phentermine 37.5mg daily

Explanation: ***Orlistat 120mg three times daily with meals*** - According to **NICE guidelines (NG49)**, **Orlistat** is the first-line pharmacological treatment for obesity in patients with a BMI ≥30 kg/m² or ≥28 kg/m² with risk factors (hypertension and NAFLD in this patient). - It functions by inhibiting **gastric and pancreatic lipases**, thereby reducing the absorption of dietary fat by approximately 30%. *Liraglutide 3mg subcutaneous injection daily* - While licensed for weight management, NICE typically restricts its use to **specialist weight management services** for patients with a BMI ≥35 kg/m² and specific comorbidities. - It is generally considered following a trial of lifestyle interventions and is not the primary first-line choice over **Orlistat** in standard primary care settings. *Naltrexone-bupropion combination therapy* - This combination therapy is **not currently recommended** by NICE for routine use in the management of obesity within the NHS. - Its use is limited by concerns regarding **cost-effectiveness** and its clinical place compared to other established treatments. *Semaglutide 2.4mg subcutaneous injection weekly* - While highly effective, NICE guidance specifies its use within **specialist weight management services** for patients with at least one weight-related comorbidity. - It is not positioned as the initial first-line pharmacological intervention in a general primary care weight management pathway. *Phentermine 37.5mg daily* - This medication is **not licensed** for use in the UK for the management of obesity due to concerns over its safety profile and potential for misuse. - Centrally acting stimulants like phentermine have been largely replaced by treatments with more favorable **benefit-risk ratios**.

Question 105: A 28-year-old woman who is 28 weeks pregnant attends for routine antenatal care. Her midwife has documented that her oral glucose tolerance test (OGTT) shows a fasting glucose of 5.8 mmol/L and 2-hour glucose of 8.2 mmol/L. She has a BMI of 34 kg/m², and her father has type 2 diabetes. She feels well with no polyuria or polydipsia. What is the most appropriate immediate management of these results?

A. Diagnose gestational diabetes and refer to joint diabetic-antenatal clinic within 1 week (Correct Answer)
B. Reassure that results are normal for pregnancy and continue routine antenatal care
C. Start metformin 500mg twice daily and review in 2 weeks
D. Advise dietary modification and arrange repeat OGTT in 4 weeks
E. Check HbA1c to confirm the diagnosis before starting treatment

Explanation: ***Diagnose gestational diabetes and refer to joint diabetic-antenatal clinic within 1 week*** - According to **NICE guidelines**, gestational diabetes is diagnosed if the **fasting glucose** is ≥5.6 mmol/L or the **2-hour glucose** is ≥7.8 mmol/L. This patient's values (5.8 and 8.2 mmol/L) meet both criteria. - **Prompt referral** to a joint diabetic-antenatal clinic is crucial for structured education, dietary advice, glucose monitoring, and potential medical management to optimize maternal and fetal outcomes. *Reassure that results are normal for pregnancy and continue routine antenatal care* - These results are clearly **abnormal** and exceed the diagnostic thresholds for **gestational diabetes mellitus (GDM)**. Reassurance would be inappropriate and dangerous. - Failing to diagnose and manage GDM significantly increases risks of **macrosomia**, **pre-eclampsia**, **polyhydramnios**, and **neonatal hypoglycemia**. *Start metformin 500mg twice daily and review in 2 weeks* - Immediate pharmacological intervention is generally not the first line. Initial management involves a trial of **dietary and lifestyle modifications** under specialist guidance. - Medication such as metformin is typically considered if lifestyle changes are insufficient, following **specialist review** and a period of blood glucose monitoring. *Advise dietary modification and arrange repeat OGTT in 4 weeks* - A repeat OGTT is **unnecessary** as the diagnosis of GDM has already been confirmed by the initial abnormal test results. - While dietary modification is part of management, delaying a comprehensive clinical review for 4 weeks is not appropriate and could lead to uncontrolled hyperglycemia impacting fetal development. *Check HbA1c to confirm the diagnosis before starting treatment* - **HbA1c is not recommended** for diagnosing GDM because it lacks sensitivity in pregnancy and reflects average glucose levels over the preceding 2-3 months, not the acute changes of pregnancy. - The **OGTT** is the established gold standard for diagnosing GDM, and further confirmatory testing with HbA1c is not required.

Question 106: A 67-year-old woman attends following her NHS abdominal aortic aneurysm (AAA) screening ultrasound which detected a 4.8 cm infrarenal AAA. She is asymptomatic. She has well-controlled hypertension on ramipril 10mg daily, blood pressure 128/76 mmHg. She stopped smoking 5 years ago (30 pack-year history). She asks about her prognosis and management options. What is the most appropriate management plan?

A. Arrange ultrasound surveillance every 12 months
B. Arrange ultrasound surveillance every 3 months
C. Refer for elective surgical repair within 8 weeks
D. Arrange CT angiography and refer to vascular surgery for consideration of repair (Correct Answer)
E. Arrange urgent surgical repair within 2 weeks

Explanation: ***Arrange CT angiography and refer to vascular surgery for consideration of repair*** - For an **Abdominal Aortic Aneurysm (AAA)** measuring **4.5 - 5.4 cm**, current guidelines recommend referral to a **vascular surgeon** for detailed assessment and consideration of repair. - **CT angiography** is the next diagnostic step to evaluate the anatomy and determine suitability for either **Endovascular Aneurysm Repair (EVAR)** or open surgical repair. *Arrange ultrasound surveillance every 12 months* - **Annual ultrasound surveillance** is typically reserved for small aneurysms measuring **3.0 - 4.4 cm**. - Since this patient's AAA is **4.8 cm**, yearly monitoring is insufficient as the risk of rupture increases significantly above 4.5 cm. *Arrange ultrasound surveillance every 3 months* - **3-monthly surveillance** is generally indicated when the aneurysm reaches **5.0 - 5.4 cm** or if there is documented rapid expansion. - This frequency is used to monitor patients closely before they reach the **5.5 cm threshold** where elective surgery is routinely offered. *Refer for elective surgical repair within 8 weeks* - Immediate booking for elective repair is usually indicated once the AAA reaches **≥ 5.5 cm** in diameter. - At **4.8 cm**, the patient requires specialist **vascular assessment** and imaging first to weigh the risks of surgery against the risk of rupture. *Arrange urgent surgical repair within 2 weeks* - **Urgent repair** within 2 weeks is indicated for **symptomatic** aneurysms (e.g., pain/tenderness) or those showing **rapid expansion** (>1 cm per year). - This patient is **asymptomatic** and her aneurysm size does not meet the criteria for emergency or urgent surgical intervention.

Question 107: A 66-year-old man attends for cardiovascular risk assessment. He has a 10-year QRISK3 score of 12%. He smokes 15 cigarettes daily, has a BMI of 31 kg/m², blood pressure 138/86 mmHg, total cholesterol 5.8 mmol/L, HDL 1.1 mmol/L, and HbA1c 41 mmol/mol. He is reluctant to take medication. Using motivational interviewing techniques, which approach is most likely to effectively support behaviour change?

A. Explain the serious health consequences of smoking and obesity in detail to increase his concern
B. Prescribe atorvastatin and arrange smoking cessation support, emphasising the importance of compliance
C. Explore his own reasons for wanting to be healthy and support him to identify his priority for change (Correct Answer)
D. Advise him that his cardiovascular risk is significant and he should stop smoking and lose weight immediately
E. Provide written information about lifestyle modification and arrange review in 6 months

Explanation: ***Explore his own reasons for wanting to be healthy and support him to identify his priority for change*** - This approach is central to **motivational interviewing**, focusing on **eliciting intrinsic motivation** by understanding the patient's values and goals. - By empowering the patient to identify their own priorities for change, it fosters **autonomy** and commitment, which are key for sustainable **behavior change**. *Explain the serious health consequences of smoking and obesity in detail to increase his concern* - While well-intentioned, this **directive** approach can lead to **resistance** or defensiveness, as it may feel like lecturing rather than collaboration. - **Fear-based tactics** are generally less effective in motivational interviewing than exploring the patient's existing **ambivalence** and readiness to change. *Prescribe atorvastatin and arrange smoking cessation support, emphasising the importance of compliance* - This approach disregards the patient's stated **reluctance to take medication** and is overly prescriptive, undermining the patient's **autonomy**. - Emphasizing compliance without addressing the patient's underlying motivation and barriers often leads to poor adherence and a damaged **therapeutic relationship**. *Advise him that his cardiovascular risk is significant and he should stop smoking and lose weight immediately* - Direct advice, especially when framed as an immediate command, can trigger **psychological reactance** and strengthen the patient's resistance to change. - This approach lacks the **empathy** and collaborative spirit fundamental to motivational interviewing, which aims to work *with* the patient. *Provide written information about lifestyle modification and arrange review in 6 months* - This is a largely **passive** intervention that fails to actively engage the patient in a discussion about their motivations and barriers to change. - While information is important, it is rarely sufficient on its own to drive significant and lasting **behavior change**, especially for complex lifestyle issues.

Question 108: A 30-year-old woman attends for cervical screening. Her hrHPV test is positive, and cytology shows low-grade dyskaryosis. Colposcopy performed 8 weeks later shows acetowhite changes in the transformation zone, and punch biopsies confirm CIN1. She has no symptoms and examination is otherwise normal. She is in a stable relationship and uses the combined oral contraceptive pill. What is the most appropriate management plan?

A. Discharge back to routine 3-yearly cervical screening
B. Arrange repeat colposcopy in 12 months with hrHPV test (Correct Answer)
C. Arrange cold coagulation treatment of the transformation zone
D. Arrange large loop excision of transformation zone (LLETZ) treatment
E. Arrange repeat hrHPV test and cytology in 12 months

Explanation: ***Arrange repeat colposcopy in 12 months with hrHPV test*** - **CIN1** represents **mild dysplasia** and has a high rate of **spontaneous regression**, so conservative management is favored over immediate intervention. - Following a punch biopsy confirming CIN1, current guidelines recommend **cervical surveillance** at 12 months to monitor for persistence or resolution, which includes repeat colposcopy and hrHPV testing. *Discharge back to routine 3-yearly cervical screening* - Routine screening is only appropriate once the patient has tested **hrHPV negative** at a surveillance check. - Discharging the patient now would be unsafe as the presence of **hrHPV and CIN1** requires closer monitoring than the general population. *Arrange cold coagulation treatment of the transformation zone* - **Cold coagulation** is an ablative treatment that is generally unnecessary for biopsy-proven **CIN1**, which often resolves without surgery. - Use of ablative or excisional treatments for low-grade lesions leads to **overtreatment** and potential complications like cervical scarring. *Arrange large loop excision of transformation zone (LLETZ) treatment* - **LLETZ** is usually reserved for **high-grade lesions (CIN2 or CIN3)** or persistent CIN1 that has not resolved over a period of two years. - Immediate LLETZ for CIN1 carries unnecessary risks for **future pregnancy**, such as increased risk of **preterm labor** or cervical incompetence. *Arrange repeat hrHPV test and cytology in 12 months* - While a 12-month follow-up is correct, patients with histologically confirmed CIN1 remaining under colposcopic care necessitate an **integrated assessment** including colposcopy. - Simply performing primary care cytology would be insufficient for a patient who has already entered the **colposcopy pathway** with a proven histological lesion.

Question 109: A 63-year-old man attends for discussion of his NHS bowel cancer screening result. His faecal immunochemical test (FIT) shows a result of 85 micrograms of haemoglobin per gram of faeces. He is asymptomatic with no change in bowel habit, no rectal bleeding, and no weight loss. Abdominal examination is unremarkable. He takes aspirin 75mg daily for secondary prevention following a previous myocardial infarction. What is the most appropriate management?

A. Refer for colonoscopy via the bowel cancer screening programme (Correct Answer)
B. Arrange routine 2-week-wait referral to colorectal surgery
C. Repeat FIT in 2 years as part of routine screening
D. Stop aspirin for 2 weeks and repeat FIT
E. Repeat FIT in 3 months to confirm the result

Explanation: ***Refer for colonoscopy via the bowel cancer screening programme***- For the **NHS Bowel Cancer Screening Programme**, a **FIT result of 85μg/g** is significantly above the threshold (typically ≥10μg/g) that warrants further investigation with colonoscopy.- Since this positive result was obtained through the formal **screening pathway** in an asymptomatic patient, referral should be managed directly by the dedicated **bowel cancer screening programme** for appropriate follow-up. *Arrange routine 2-week-wait referral to colorectal surgery*- The **2-week-wait (2WW) referral pathway** is primarily for **symptomatic patients** presenting to their GP with concerning features, or for GP-requested FITs.- Positive screening results are managed by the specialized **Bowel Cancer Screening Centres**, which have their own system for arranging prompt colonoscopies. *Repeat FIT in 2 years as part of routine screening*- A **FIT result of 85μg/g** is a positive finding indicating significant occult blood loss, requiring urgent investigation, not routine deferral.- Routine biennial screening is only appropriate for individuals with a **negative FIT result**; delaying investigation of a positive result could miss early cancer. *Stop aspirin for 2 weeks and repeat FIT*- Modern **Faecal Immunochemical Tests (FIT)** specifically detect **human haemoglobin** and are generally not affected by medications like low-dose **aspirin**.- Stopping **aspirin** for secondary prevention of a myocardial infarction is associated with **increased cardiovascular risk** and is not indicated for FIT accuracy. *Repeat FIT in 3 months to confirm the result*- A single **positive FIT result** at the screening threshold is sufficient to trigger a referral for colonoscopy; there is no protocol to

Question 110: A 51-year-old woman with type 2 diabetes attends for her annual diabetic retinopathy screening. The report indicates 'R2 - referable retinopathy with venous beading and multiple deep retinal haemorrhages in all four quadrants, but no neovascularisation'. Visual acuity is 6/9 in both eyes. She reports no visual symptoms. Her HbA1c is 76 mmol/mol and blood pressure is 142/88 mmHg. What is the most appropriate action regarding her retinopathy?

A. Refer urgently to ophthalmology for review within 2 weeks
B. Arrange immediate same-day referral to ophthalmology
C. Refer to ophthalmology for review within 6 weeks
D. Refer routinely to ophthalmology for review within 13 weeks (Correct Answer)
E. Intensify glycaemic and blood pressure control and repeat screening in 6 months

Explanation: ***Refer routinely to ophthalmology for review within 13 weeks*** - The clinical description of **venous beading** and **multiple deep retinal haemorrhages** in all four quadrants, without neovascularisation, defines **severe non-proliferative diabetic retinopathy (R2)**. - According to the **NHS Diabetic Eye Screening Programme (DESP) guidelines**, **R2 retinopathy** without active proliferation requires a routine referral to ophthalmology within **13 weeks**. *Refer urgently to ophthalmology for review within 2 weeks* - This timeframe is for **proliferative diabetic retinopathy (R3)**, which is characterized by the presence of **neovascularization**, or clinically significant macular edema (M1). - The patient's report explicitly states **no neovascularization**, making an urgent 2-week referral unsuitable for R2 retinopathy. *Arrange immediate same-day referral to ophthalmology* - An immediate referral is reserved for acute, sight-threatening emergencies such as a **vitreous haemorrhage**, **retinal detachment**, or sudden, severe **vision loss**. - The patient is **asymptomatic** with stable visual acuity (6/9), indicating no immediate sight-threatening emergency. *Refer to ophthalmology for review within 6 weeks* - A **6-week referral** category is not a recognized or standard timeframe within the **UK national diabetic eye screening referral protocols**. - Adhering to established guidelines (13 weeks for R2) ensures appropriate and timely management based on validated risk stratification. *Intensify glycaemic and blood pressure control and repeat screening in 6 months* - While optimizing **HbA1c** and **blood pressure** is vital for overall diabetes management and slowing retinopathy progression, it does not replace the immediate need for specialist ophthalmology review for **referable R2 retinopathy**. - Delaying a specialist referral by merely repeating screening in **6 months** for established severe non-proliferative changes would be inappropriate and could lead to progression or complications.

Question 111: A 64-year-old woman attends for results of her NHS breast screening mammogram. The report states 'M3 - indeterminate/probably benign calcifications detected in the upper outer quadrant of the right breast'. She is asymptomatic and has no palpable abnormality on clinical examination. Her mother had breast cancer diagnosed at age 72. What is the most appropriate next step in her management?

A. Reassure and arrange routine repeat mammography in 3 years
B. Refer to breast clinic for triple assessment within 2 weeks (Correct Answer)
C. Arrange MRI breast imaging to further characterise the lesion
D. Arrange repeat mammography in 6 months
E. Arrange ultrasound-guided core biopsy within 1 week

Explanation: ***Refer to breast clinic for triple assessment within 2 weeks*** - An **M3 mammographic classification** denotes an indeterminate or probably benign finding that requires urgent evaluation to rule out malignancy. - The standard of care for any suspicious screening result is a **triple assessment**, comprising clinical examination, further imaging (magnification views/ultrasound), and potentially a biopsy. *Reassure and arrange routine repeat mammography in 3 years* - Routine 3-yearly screening is only appropriate for **M1 (normal)** or **M2 (benign)** results where no further action is required. - Delaying assessment for an **M3 lesion** carries a significant risk of missing an early-stage cancer. *Arrange MRI breast imaging to further characterise the lesion* - **MRI** is not the first-line investigation for indeterminate calcifications and is usually reserved for specific indications like dense breast tissue or high-risk screening. - Imaging decisions should be made by the specialist team as part of the formal **triple assessment** process. *Arrange repeat mammography in 6 months* - Short-interval follow-up is generally not recommended for **M3 lesions** identified in a screening program; they require immediate definitive assessment. - Managing indeterminate findings through monitoring alone without initial **triple assessment** is unsafe clinical practice. *Arrange ultrasound-guided core biopsy within 1 week* - While a biopsy might be necessary, it should be performed after specialist clinical review and further **mammographic focal/magnification views**. - Specifically for calcifications, a **stereotactic vacuum-assisted biopsy** is often more appropriate than a standard ultrasound-guided core biopsy.

Question 112: A 55-year-old woman with type 2 diabetes for 8 years attends for annual review. Her HbA1c is 58 mmol/mol on metformin alone. She missed her diabetic eye screening appointment last year and did not rebook. She reports no visual symptoms. Visual acuity is 6/6 in both eyes. Fundoscopy shows a few small dot haemorrhages in the left eye but you cannot obtain adequate retinal views. What is the most appropriate management regarding her diabetic retinopathy screening?

A. Arrange urgent ophthalmology referral for suspected diabetic retinopathy
B. Refer back to NHS diabetic eye screening programme and emphasize importance of attendance (Correct Answer)
C. Perform dilated fundoscopy and refer to screening programme if abnormalities confirmed
D. Arrange optical coherence tomography in primary care to assess for macular oedema
E. Reassure that annual screening is unnecessary if visual acuity is normal

Explanation: ***Refer back to NHS diabetic eye screening programme and emphasize importance of attendance*** - The patient has **missed her regular screening programme appointment** and has early signs of **background retinopathy** (dot haemorrhages) which require formal grading and monitoring by specialists. - The **NHS diabetic eye screening programme** utilizes **digital retinal photography** for standardized, high-quality imaging and systematic surveillance, which is superior to individual primary care assessment for managing diabetic retinopathy. *Arrange urgent ophthalmology referral for suspected diabetic retinopathy* - **Urgent ophthalmology referral** is typically reserved for more severe conditions like **proliferative diabetic retinopathy**, suspected **macular oedema** affecting vision, or vitreous haemorrhage. - The patient has normal visual acuity and only minor findings (few dot haemorrhages), which do not warrant an **urgent referral** but rather a systematic screening approach. *Perform dilated fundoscopy and refer to screening programme if abnormalities confirmed* - While performing dilated fundoscopy could reveal abnormalities, it is not a replacement for the structured **diabetic eye screening programme** which offers a more comprehensive and documented assessment with expert grading. - The immediate priority for a patient with missed screening and background changes is re-engagement with the established **screening pathway** rather than a primary care-based diagnostic confirmation. *Arrange optical coherence tomography in primary care to assess for macular oedema* - **Optical coherence tomography (OCT)** is a specialized imaging technique for the retina and is typically performed in **ophthalmology clinics** or dedicated screening centres, not routinely in primary care settings. - There is no clinical indication for OCT at this stage, as the patient has normal **visual acuity** and no reported visual symptoms suggestive of **macular oedema**. *Reassure that annual screening is unnecessary if visual acuity is normal* - This approach is incorrect and dangerous, as **diabetic retinopathy** often progresses silently without affecting **visual acuity** until advanced stages or when **maculopathy** develops. - **Annual diabetic eye screening** is crucial for all diabetic patients to detect retinopathy early, even in the absence of symptoms, and enable timely intervention to prevent irreversible vision loss.

Question 113: A 29-year-old woman who is 12 weeks pregnant attends for discussion of antenatal screening. This is her first pregnancy. She has no significant medical history and no family history of genetic conditions. Her partner is of Afro-Caribbean origin. She asks which genetic conditions are routinely screened for in pregnancy. Which inherited condition is included in the routine NHS antenatal screening programme?

A. Fragile X syndrome
B. Duchenne muscular dystrophy
C. Sickle cell disease (Correct Answer)
D. Cystic fibrosis
E. Haemophilia A

Explanation: ***Sickle cell disease*** - Routine **NHS antenatal screening** in the UK includes screening for **haemoglobinopathies**, specifically **sickle cell disease** and **thalassaemia**, to identify fetuses at risk. - Screening is routinely offered to all pregnant women, often involving a **Family Origin Questionnaire** and blood tests to determine carrier status, especially when the partner is of **Afro-Caribbean origin**. *Fragile X syndrome* - **Fragile X syndrome** is an X-linked condition that is **not part of universal routine antenatal screening** within the NHS. - Screening for this condition is generally only pursued if there is a known **family history** of the syndrome or unexplained developmental delay. *Duchenne muscular dystrophy* - There is **no routine antenatal screening programme** for **Duchenne muscular dystrophy** for all pregnant women in the absence of a relevant family history. - Prenatal diagnosis is typically considered when the mother is a **known carrier** or in cases of elevated maternal serum alpha-fetoprotein with a male fetus. *Cystic fibrosis* - While prevalent, **cystic fibrosis** carrier testing is **not universally offered** as a routine national antenatal screening service for all pregnant women in the UK. - Testing is typically reserved for individuals with a **family history** of cystic fibrosis or if a partner is a known carrier of the gene mutation. *Haemophilia A* - **Haemophilia A**, an X-linked recessive bleeding disorder, is **not included in the standard routine NHS antenatal screening panel**. - Prenatal diagnosis is usually offered if the mother is a **known carrier** or if there is a strong family history suggestive of the condition.

Question 114: A 35-year-old man attends for advice about his lifestyle and health. He drinks 35 units of alcohol weekly, mostly at weekends. He has normal liver function tests and no symptoms. He is considering reducing his alcohol intake. According to current UK Chief Medical Officers' guidelines, what is the recommended maximum weekly alcohol consumption to keep health risks low?

A. No more than 14 units per week spread over 3 or more days (Correct Answer)
B. No more than 21 units per week with at least 2 alcohol-free days
C. No more than 14 units per week with no restriction on distribution
D. No more than 28 units per week spread evenly across the week
E. No more than 21 units per week for men, 14 units for women

Explanation: ***No more than 14 units per week spread over 3 or more days*** - The **UK Chief Medical Officers' (CMO)** guidelines, updated in 2016, recommend that both men and women should not regularly exceed **14 units per week** to keep health risks low. - It is crucial to spread these units over **three or more days** to avoid binge drinking, acute alcohol poisoning, and to allow the liver time to recover. *No more than 21 units per week with at least 2 alcohol-free days* - This recommendation exceeds the current **UK CMO guidelines** of 14 units per week for low-risk drinking. - While having **alcohol-free days** is a good practice, the total weekly intake of 21 units still places individuals at a higher risk of alcohol-related harm. *No more than 14 units per week with no restriction on distribution* - Although **14 units per week** is the correct maximum, the **distribution** of alcohol consumption is a vital part of the guidelines. - Consuming the entire 14 units in one or two sessions, also known as **binge drinking**, significantly increases the risk of accidents, injuries, and acute health issues. *No more than 28 units per week spread evenly across the week* - This amount (28 units) is double the **recommended low-risk limit** set by the UK CMO for both men and women. - Regularly consuming 28 units per week is associated with a substantially **increased risk** of various alcohol-related harms, including liver disease, cardiovascular problems, and certain cancers. *No more than 21 units per week for men, 14 units for women* - This reflects the **previous UK alcohol guidelines**, which were revised in 2016 to a single, lower limit for both sexes. - The updated **2016 guidelines** harmonized the recommendation to 14 units per week for both men and women, based on new evidence regarding cancer risk at lower alcohol levels and to simplify public health messaging.

Question 115: A 61-year-old man attends for results of his NHS bowel cancer screening faecal immunochemical test (FIT). The result shows haemoglobin concentration of 85 micrograms per gram of faeces. He is asymptomatic with no weight loss or change in bowel habit. Abdominal examination is normal. What is the most appropriate management?

A. Repeat FIT test in 3 months to confirm persistence
B. Refer for colonoscopy via the screening programme (Correct Answer)
C. Arrange flexible sigmoidoscopy and review if abnormal
D. Reassure and advise to repeat screening in 2 years
E. Refer urgently via 2-week-wait colorectal cancer pathway

Explanation: ***Refer for colonoscopy via the screening programme*** - In the **NHS Bowel Cancer Screening Programme**, a **Faecal Immunochemical Test (FIT)** result of **85 µg/g** is above the positive threshold (typically ≥40 or ≥120 µg/g) and indicates the presence of occult blood. - A positive FIT necessitates a **full colonic evaluation** via colonoscopy to identify the source of bleeding, which could be colorectal cancer or advanced adenomas, even in asymptomatic individuals. *Repeat FIT test in 3 months to confirm persistence* - Positive screening results must be acted upon promptly and should **not be repeated**, as colorectal lesions may bleed intermittently, potentially leading to a false negative and delayed diagnosis. - Delaying definitive investigation to re-test risks allowing a **potential malignancy** to progress unchecked, worsening prognosis. *Arrange flexible sigmoidoscopy and review if abnormal* - **Flexible sigmoidoscopy** is an incomplete investigation as it only visualizes the distal colon, thereby missing significant pathology in the **proximal or right colon** where cancers or polyps may be present. - The gold standard for investigating a positive FIT result is a **colonoscopy**, which allows for a comprehensive examination of the entire large bowel and enables biopsy or polyp removal. *Reassure and advise to repeat screening in 2 years* - Reassurance is inappropriate because a positive FIT result signifies **occult gastrointestinal bleeding**, which carries a substantial risk of underlying colorectal cancer or advanced adenomas, even without overt symptoms. - The advice to repeat screening in 2 years applies only to individuals with a **negative FIT result**, ensuring periodic monitoring, not diagnostic follow-up. *Refer urgently via 2-week-wait colorectal cancer pathway* - While a positive FIT result warrants urgent attention, individuals identified through the **screening programme** are managed via a dedicated **screening pathway** rather than the symptomatic 2-week-wait (2WW) pathway. - The screening pathway is specifically designed for asymptomatic individuals with positive screening tests, ensuring their prompt access to specialist assessment and colonoscopy within the screening service's defined urgent timelines.

Question 116: A 67-year-old man attends following his NHS abdominal aortic aneurysm screening scan which showed a maximum aortic diameter of 4.8 cm. He is asymptomatic. He has hypertension and takes amlodipine 10 mg daily. His BP today is 142/86 mmHg. He smokes 10 cigarettes daily. What is the most appropriate management?

A. Urgent referral to vascular surgery for consideration of repair
B. Arrange ultrasound surveillance in 3 months and review cardiovascular risk factors
C. Arrange CT angiography and routine referral to vascular surgery (Correct Answer)
D. Arrange ultrasound surveillance in 12 months and optimize medical management
E. Immediate hospital admission for emergency vascular surgical assessment

Explanation: ***Arrange CT angiography and routine referral to vascular surgery*** - An aortic diameter of **4.8 cm** classifies as a **medium abdominal aortic aneurysm (AAA)** (4.5-5.4 cm), for which current guidelines recommend a **routine referral** to a vascular specialist. - **CT angiography** is crucial for detailed anatomical assessment, confirming the diagnosis, and planning for potential future **surgical or endovascular repair**. *Urgent referral to vascular surgery for consideration of repair* - **Urgent referral for repair** is typically reserved for **large aneurysms (≥5.5 cm)**, those showing rapid growth (≥1 cm per year), or symptomatic patients. - This patient's aneurysm is **4.8 cm** and he is **asymptomatic**, so urgent surgical consideration is not indicated. *Arrange ultrasound surveillance in 3 months and review cardiovascular risk factors* - While **3-monthly ultrasound surveillance** is appropriate for **medium AAAs** (4.5-5.4 cm), this option is incomplete as it misses the critical step of **specialist vascular referral**. - For an aneurysm of this size, a vascular specialist needs to assess and discuss the potential for intervention and secondary prevention strategies comprehensively. *Arrange ultrasound surveillance in 12 months and optimize medical management* - **Annual (12-month) ultrasound surveillance** is recommended only for **small aneurysms (3.0-4.4 cm)**. - A 4.8 cm aneurysm carries a higher risk of growth and rupture, necessitating more frequent monitoring than annually, along with specialist assessment. *Immediate hospital admission for emergency vascular surgical assessment* - **Emergency hospital admission** and surgical assessment are reserved for **symptomatic** (e.g., abdominal or back pain) or **ruptured AAAs**. - This patient is **asymptomatic** and the aneurysm size does not warrant emergency intervention.

Question 117: A 46-year-old woman attends for advice about weight management. She has gained 15 kg over 3 years. Her BMI is 34 kg/m² and waist circumference is 96 cm. She has no comorbidities. She tried several commercial diets without sustained success. She asks about pharmacological options for weight loss. What is the most appropriate initial management?

A. Prescribe orlistat and arrange dietitian referral
B. Offer orlistat only if she achieves 2.5 kg weight loss through dietary measures first (Correct Answer)
C. Refer to specialist weight management service for consideration of pharmacological therapy
D. Advise that pharmacological therapy is only indicated if BMI exceeds 35 kg/m²
E. Recommend continued lifestyle measures alone as she has no obesity-related comorbidities

Explanation: ***Offer orlistat only if she achieves 2.5 kg weight loss through dietary measures first*** - According to **NICE guidelines**, orlistat is indicated for a patient with a **BMI ≥30 kg/m²** but should only be started if they have demonstrated commitment by losing at least **2.5 kg** via lifestyle changes. - This ensures that **pharmacological therapy** acts as an adjunct to, rather than a substitute for, essential **behavioral and dietary modifications**. *Prescribe orlistat and arrange dietitian referral* - Immediate prescription is inappropriate because guidelines require a **pre-requisite weight loss** to prove the patient can sustain the necessary caloric deficit. - While **dietetic support** is important, the pharmacological intervention must be gated by the initial **2.5 kg weight loss** milestone. *Refer to specialist weight management service for consideration of pharmacological therapy* - Specialist referral (Tier 3 or 4) is generally reserved for patients with a **BMI ≥40 kg/m²** or **BMI ≥35 kg/m²** with significant comorbidities. - Initial pharmacological management like **orlistat** is typically managed within **primary care** before escalating to specialist services. *Advise that pharmacological therapy is only indicated if BMI exceeds 35 kg/m²* - This statement is incorrect as the threshold for considering **orlistat** is a **BMI ≥30 kg/m²** in those without comorbidities. - Lower thresholds (**BMI ≥28 kg/m²**) apply to patients who have associated risk factors like **type 2 diabetes** or hypertension. *Recommend continued lifestyle measures alone as she has no obesity-related comorbidities* - Although she has no comorbidities, her **BMI of 34 kg/m²** and previous failed attempts at commercial diets make her eligible for **medical intervention**. - Continuing lifestyle measures alone may be insufficient given her history; adding **orlistat** is appropriate once the initial weight loss goal is met.

Question 118: A 58-year-old man with hypertension and type 2 diabetes attends for medication review. He stopped smoking 3 months ago after smoking 25 cigarettes daily for 40 years. His BMI is 32 kg/m² and he does minimal physical activity. His recent HbA1c is 64 mmol/mol and BP is 135/82 mmHg on current medication. Which lifestyle intervention is likely to provide the greatest absolute cardiovascular benefit?

A. Achieving 150 minutes weekly moderate-intensity physical activity
B. Reducing BMI by 10% through dietary modification
C. Maintaining smoking abstinence (Correct Answer)
D. Reducing alcohol intake to within recommended limits
E. Achieving Mediterranean-style diet with reduced saturated fat

Explanation: ***Maintaining smoking abstinence*** - **Smoking cessation** is the single most powerful lifestyle intervention for reducing **cardiovascular risk**, with significant benefits observed rapidly and profoundly. - Given his **heavy smoking history** (40 years, 25 cigarettes/day) and high-risk comorbidities (hypertension, type 2 diabetes), preventing **relapse** in this early post-cessation period offers the greatest immediate and absolute cardiovascular benefit. *Achieving 150 minutes weekly moderate-intensity physical activity* - While regular **physical activity** significantly reduces cardiovascular risk, its absolute benefit is generally less immediate and less impactful than total **smoking cessation** in a patient with a long, heavy smoking history. - It contributes to improved **glycemic control** and blood pressure, but does not reverse the immediate **prothrombotic state** and endothelial dysfunction to the same extent as sustained abstinence from tobacco. *Reducing BMI by 10% through dietary modification* - **Weight reduction** improves metabolic parameters like blood pressure and HbA1c, thus reducing cardiovascular risk over time. - However, the **absolute risk reduction** from a 10% BMI decrease is typically less pronounced and slower to manifest than the profound and rapid benefits of **smoking cessation**, especially in a patient with 50 pack-years of smoking. *Reducing alcohol intake to within recommended limits* - The patient's **alcohol intake** status is not mentioned, making it a less certain or quantified risk factor compared to his extensive smoking history. - While excessive alcohol is detrimental, reducing it to recommended limits generally provides a smaller **absolute cardiovascular benefit** compared to preventing relapse from heavy smoking. *Achieving Mediterranean-style diet with reduced saturated fat* - Adopting a **Mediterranean diet** is an excellent strategy for long-term **cardiovascular health** and risk reduction, improving lipid profiles and inflammation. - However, for a patient who has recently quit a very heavy smoking habit, the **absolute cardiovascular benefit** of maintaining that abstinence far outweighs the benefits gained solely from dietary changes in the short to medium term.

Question 119: What is the upper age limit for routine NHS cervical screening invitation in England?

A. 60 years
B. 64 years (Correct Answer)
C. 70 years
D. 74 years
E. No upper age limit if sexually active

Explanation: ***64 years*** - In England, the **NHS Cervical Screening Programme** routinely invites women and people with a cervix for screening between the ages of **25 and 64**. - After 64, routine invitations cease, but testing may continue if one of the **last three tests** was abnormal or if the individual has **never been screened** or has a history of high-grade abnormalities. *60 years* - This age is incorrect as routine invitations for cervical screening in England extend for four more years, up to **age 64**. - Between ages **50 and 64**, individuals are invited for screening every **5 years** as per current guidelines. *70 years* - This is not the upper age limit for routine cervical screening; **age 70** is more commonly associated with the upper limit for the **NHS Breast Screening Programme**. - Individuals older than 64 with a consistent history of normal results are generally considered at **very low risk** of developing cervical cancer. *74 years* - This age is the upper limit for routine screening in the **NHS Bowel Cancer Screening Programme**, which uses the FIT kit for those aged 60 to 74. - It does not correspond to the routine threshold for **cervical cytological** or **HPV testing** in England. *No upper age limit if sexually active* - While **sexual activity** is the primary risk factor for HPV acquisition, routine population screening is discontinued at 64 based on a **risk-benefit analysis** of long-term screening history and disease incidence. - Regardless of sexual activity, **symptomatic individuals** (e.g., experiencing postmenopausal bleeding or abnormal discharge) of any age must be investigated via a different clinical pathway, not routine screening.

Question 120: A 39-year-old woman who is 20 weeks pregnant attends for routine antenatal care. She declined all screening at booking. She now mentions she has been diagnosed with gestational diabetes following a glucose tolerance test. She asks whether her baby is at increased risk of Down syndrome given her age and new diagnosis. What is the most appropriate response regarding screening?

A. Offer combined first trimester screening even though it is outside the usual timeframe
B. Explain that second trimester serum screening can still be performed up to 20 weeks
C. Offer detailed anomaly ultrasound scan with particular focus on Down syndrome markers
D. Arrange non-invasive prenatal testing as this is now the timeframe for screening
E. Explain that screening for Down syndrome is only available before 20 weeks and has passed (Correct Answer)

Explanation: ***Explain that screening for Down syndrome is only available before 20 weeks and has passed*** - The **quadruple test** (serum screening) must be performed between **14 weeks 2 days and 20 weeks 0 days**; at exactly 20 weeks, the window for this screening is at its very limit or has effectively closed for meaningful action.- Routine screening for trisomies generally consists of the **combined test** (11–14 weeks) or the **quadruple test**, and once this gestational age is surpassed, primary screening options for Down syndrome are no longer routinely available. *Offer combined first trimester screening even though it is outside the usual timeframe* - **Combined screening** relies on **nuchal translucency** measurement and biochemical markers (PAPP-A), which are only valid and accurate between **11 weeks 2 days and 14 weeks 1 day**.- Offering this outside the established timeframe would yield medically inaccurate or unreliable results, as nuchal translucency measurements rapidly lose diagnostic value in the **second trimester**. *Explain that second trimester serum screening can still be performed up to 20 weeks* - While the technical limit for the **quadruple test** is **20 weeks 0 days**, in practical terms, at exactly 20 weeks, the time required for processing, obtaining results, and offering further diagnostic tests (if indicated) makes it generally unfeasible.- Standard guidelines often consider the specific window for initiating a new **quadruple test** effectively closed if a woman presents at or after 20 weeks. *Offer detailed anomaly ultrasound scan with particular focus on Down syndrome markers* - The **20-week anomaly scan** is primarily designed to detect **structural abnormalities** and fetal development, not to serve as a primary screening tool for chromosomal aneuploidies like Down syndrome.- While certain **"soft markers"** for Down syndrome may be observed, these are often non-specific and the scan alone is not considered a sufficient or accurate primary screening method for Trisomy 21. *Arrange non-invasive prenatal testing as this is now the timeframe for screening* - **Non-invasive prenatal testing (NIPT)**, in many public healthcare systems (e.g., NHS), is typically offered as a **contingent test** for women who have received a **"higher-chance" result** from initial screening (combined or quadruple test).- It is not routinely offered as a **primary screening option** at this gestation for women who declined earlier screening, especially in public health services, although it can be accessed privately.

Question 121: A 52-year-old man attends for smoking cessation support. He smokes 30 cigarettes daily and has done so for 35 years. He works as a builder, drinks 40 units of alcohol weekly, and has a BMI of 29 kg/m². His father died from lung cancer at age 68. He is motivated to quit smoking. In addition to smoking cessation, which additional screening intervention should be prioritized?

A. Low-dose CT screening for lung cancer
B. NHS Health Check for cardiovascular risk assessment (Correct Answer)
C. Liver ultrasound for alcohol-related liver disease
D. Chest X-ray to exclude current lung pathology
E. Spirometry to assess for COPD

Explanation: ***NHS Health Check for cardiovascular risk assessment*** - The **NHS Health Check** is a priority screening for adults aged **40–74** without pre-existing vascular disease to assess risk factors such as **smoking, BMI, and alcohol intake**. - This patient exhibits multiple modifiable risk factors (52.5 pack-year history, **BMI of 29**, and **40 units of alcohol/week**) that necessitate immediate **Cardiovascular Disease (CVD)** risk calculation via tools like QRISK. *Low-dose CT screening for lung cancer* - In the UK, the **Targeted Lung Health Check** program using **low-dose CT** is currently recommended for high-risk smokers aged **55–74**. - Although this patient has a significant smoking history, he is only **52 years old** and does not yet meet the current age threshold for this specific screening protocol. *Liver ultrasound for alcohol-related liver disease* - While his alcohol consumption of **40 units/week** is significantly above the recommended **14 units/week**, a liver ultrasound is not a primary screening tool in the absence of clinical symptoms or abnormal labs. - Initial management should focus on **alcohol brief intervention** and **Liver Function Tests (LFTs)** or **FibroScan** if Advanced Liver Fibrosis is suspected. *Chest X-ray to exclude current lung pathology* - **Chest X-ray** is not an effective or recommended tool for **lung cancer screening** due to its low sensitivity in detecting early-stage, treatable malignancies. - It should only be utilized as a diagnostic step if the patient presents with specific **red-flag symptoms** like chronic cough or hemoptysis. *Spirometry to assess for COPD* - **Spirometry** is used to diagnose **COPD** in patients who are symptomatic, but it is not recommended as a routine screening tool for **asymptomatic smokers**. - While he likely has some degree of airflow obstruction, the priority in an asymptomatic patient is addressing the **CVD risk** and achieving **smoking cessation**.

Question 122: A 41-year-old woman presents requesting information about breast cancer screening. Her mother was diagnosed with breast cancer at age 58 and her maternal aunt at age 62. She has no personal history of breast disease and clinical examination is normal. She asks whether she is eligible for early screening. What is the most appropriate initial response?

A. Arrange annual mammography privately until she reaches NHS screening age
B. She meets criteria for referral to genetics service for risk assessment
C. She should commence routine NHS breast screening immediately
D. She does not meet criteria for early screening but should continue breast awareness (Correct Answer)
E. Offer baseline ultrasound scan and review family history at age 45

Explanation: ***She does not meet criteria for early screening but should continue breast awareness*** - Her family history (mother diagnosed at age **58**, maternal aunt at age **62**) falls into the **near-population risk** category and does not meet the threshold for enhanced screening or referral to genetics services, which typically require earlier onset diagnoses or more extensive family history. - The most appropriate advice is to promote **breast awareness** and explain that she will be invited for routine **NHS breast screening** when she reaches the eligible age (typically 50-53). *Arrange annual mammography privately until she reaches NHS screening age* - Suggesting private annual mammography for a woman at near-population risk is not evidence-based and may lead to **unnecessary radiation exposure**, **anxiety** from false positives, and **over-diagnosis** without clear benefit. - Current guidelines do not support private screening for this level of risk, as the harms outweigh the benefits. *She meets criteria for referral to genetics service for risk assessment* - Referral to a **genetics service** usually requires a stronger family history, such as a **first-degree relative** diagnosed with breast cancer under age 40, or multiple cases of early-onset breast/ovarian cancer within the family. - Her family history does not indicate a sufficiently high **hereditary risk** to warrant a genetics referral at this time. *She should commence routine NHS breast screening immediately* - The **NHS Breast Screening Programme** typically invites women for their first mammogram between the ages of **50 and 53**, not at age 41. - Starting routine screening immediately is only indicated for women with a significantly **higher risk** profile, which is not present in this case. *Offer baseline ultrasound scan and review family history at age 45* - An **ultrasound scan** is generally used as a diagnostic tool for specific breast concerns or as an adjunct to mammography for dense breasts, rather than as a primary **screening modality** for asymptomatic women at population risk. - There is no evidence-based guideline to offer a baseline ultrasound or specifically review family history at age 45 in this risk group without new clinical developments.

Question 123: A 73-year-old man attends for review. He received his NHS bowel screening kit but has not returned it. He mentions he had a colonoscopy 7 years ago for rectal bleeding which showed diverticular disease but no polyps or cancer. He feels the screening is unnecessary given his previous investigation. What is the most appropriate advice?

A. Agree that screening is unnecessary given recent normal colonoscopy
B. Advise him to complete the screening kit as previous colonoscopy does not replace screening (Correct Answer)
C. Arrange surveillance colonoscopy instead of faecal immunochemical testing
D. Advise screening is only needed if he develops new symptoms
E. Explain he is now outside the screening age range and will not receive further invitations

Explanation: ***Advise him to complete the screening kit as previous colonoscopy does not replace screening***- A **colonoscopy** performed 7 years ago does not provide lifetime protection or replace the **NHS bowel cancer screening programme**, as new lesions can develop in the interval.- The **Faecal Immunochemical Test (FIT)** is designed to detect **asymptomatic** early-stage cancer and polyps, which may have developed since his last investigation.*Agree that screening is unnecessary given recent normal colonoscopy*- A colonoscopy from 7 years ago is not considered "recent" enough to exclude current pathology, and **diverticular disease** does not protect against malignancy.- Standard guidelines state that screening should continue regardless of previous **symptomatic investigations** unless the patient is currently under a high-intensity surveillance program.*Arrange surveillance colonoscopy instead of faecal immunochemical testing*- **Surveillance colonoscopy** is reserved for high-risk patients with previous **adenomas**, polyps, or inflammatory bowel disease, which this patient does not have.- Arranging a colonoscopy for an asymptomatic patient with a history of only **diverticular disease** is clinically unnecessary and carries higher procedural risks than a **FIT test**.*Advise screening is only needed if he develops new symptoms*- The primary goal of screening is **primary prevention** and the detection of disease in **asymptomatic** individuals to improve survival rates.- Waiting for **symptoms** such as weight loss or change in bowel habits often means the cancer has reached a more advanced, less treatable stage.*Explain he is now outside the screening age range and will not receive further invitations*- In England, the **NHS bowel screening** age range currently includes individuals up to the age of **74**, meaning this 73-year-old is still eligible for routine invitations.- Even after age 74, patients can take the initiative to **self-refer** and request a screening kit every two years, so he should not be told screening is over.

Question 124: A 27-year-old woman attends requesting cervical screening. She last had cervical screening 4 years ago which showed hrHPV negative. She has been in a stable relationship for 2 years and has no symptoms. She is concerned because her new partner has disclosed previous genital warts. What is the most appropriate action regarding cervical screening?

A. Arrange cervical screening now due to new sexual partner
B. Reassure and arrange cervical screening at 5 years from last screen (Correct Answer)
C. Perform cervical screening and test specifically for HPV types 6 and 11
D. Refer to genitourinary medicine for HPV vaccination
E. Arrange colposcopy referral given partner's HPV history

Explanation: ***Reassure and arrange cervical screening at 5 years from last screen***- In the UK, women aged **25-49** are screened every **5 years**; since her last screen was **hrHPV negative** 4 years ago, she is not due for another year.- A **change in sexual partner** or a partner's history of genital warts is not a clinical indication to perform early cervical screening in an asymptomatic patient.*Arrange cervical screening now due to new sexual partner*- Screening intervals are determined by the **hrHPV status** of the previous test and age, not by the frequency or identity of sexual partners.- Performing tests earlier than the **recommended interval** increases the risk of identifying transient infections that would otherwise resolve spontaneously.*Perform cervical screening and test specifically for HPV types 6 and 11*- Cervical screening specifically targets **high-risk HPV (hrHPV)** types that are oncogenic, whereas types **6 and 11** are low-risk types responsible for genital warts.- Testing for low-risk HPV types provides no benefit in **cervical cancer prevention** and is not part of the standard screening protocol.*Refer to genitourinary medicine for HPV vaccination*- The **HPV vaccine** is most effective when given prior to sexual debut, and while it can be given later, a partner's history of warts is not a standard trigger for **catch-up vaccination** at age 27.- The primary concern here is the **screening schedule**, and vaccination does not replace or alter the need for routine cervical screening.*Arrange colposcopy referral given partner's HPV history*- **Colposcopy** is a diagnostic tool used for investigating positive hrHPV results or abnormal cytology, neither of which apply to this patient.- **Genital warts** in a partner do not increase the risk of high-grade cervical dysplasia in a way that bypasses standard screening and necessitates direct referral.

Question 125: A 65-year-old woman attends for NHS breast screening. She had a wide local excision with adjuvant radiotherapy for left breast ductal carcinoma in situ 8 years ago. She has been disease-free since completion of treatment. Her last mammogram was 3 years ago. She is otherwise well and takes no regular medications. What is the most appropriate management of her breast screening?

A. Continue routine NHS breast screening every 3 years until age 70 (Correct Answer)
B. Discharge from NHS breast screening and arrange annual symptomatic surveillance mammography
C. Refer to breast surgery for clinical assessment before continuing screening
D. Offer MRI surveillance annually in addition to mammography
E. Extend screening interval to 5 years due to previous treatment

Explanation: ***Continue routine NHS breast screening every 3 years until age 70*** - In the UK, individuals treated for **ductal carcinoma in situ (DCIS)** or invasive cancer typically return to the **NHS Breast Screening Programme (NHSBSP)** after 5 years of specialist follow-up, if they are within the eligible age range. - As she is 65 years old and 8 years post-treatment, she has completed her enhanced surveillance and should continue **3-yearly mammograms** as part of the routine screening program until the upper age limit of 70. *Discharge from NHS breast screening and arrange annual symptomatic surveillance mammography* - **Annual clinical surveillance** is usually provided by hospital teams for the initial 5 years post-diagnosis, not indefinitely or in place of routine screening after this period. - **Symptomatic surveillance** is not a standard program for asymptomatic individuals; patients who are disease-free and beyond 5 years post-treatment should integrate back into population-based screening. *Refer to breast surgery for clinical assessment before continuing screening* - For an asymptomatic patient who has remained **disease-free** for 8 years, a routine referral to **breast surgery** for assessment before continuing screening is unnecessary. - Routine screening is managed by the **NHSBSP**, with referrals to specialists only initiated if a new abnormality is detected during screening. *Offer MRI surveillance annually in addition to mammography* - **Annual MRI surveillance** is typically reserved for women at **very high risk** of breast cancer, such as those with BRCA1/2 mutations or a strong family history, which is not indicated for this case of DCIS. - For most women with a history of DCIS and no other high-risk factors, **mammography alone** remains the primary and sufficient imaging modality for long-term follow-up within a screening context. *Extend screening interval to 5 years due to previous treatment* - There are no guidelines supporting an **extended screening interval** to 5 years for patients with a history of DCIS; the standard **3-year interval** is maintained. - A history of breast cancer or DCIS indicates a slightly **increased lifetime risk** of developing another breast cancer, reinforcing the need for regular, timely screening, not less frequent.

Question 126: A 71-year-old woman with type 2 diabetes for 15 years attends for review. She mentions she has not attended for diabetic retinopathy screening for 3 years as she "forgot about the appointments." Her recent HbA1c is 76 mmol/mol and she has background diabetic retinopathy documented from 4 years ago. She takes metformin, gliclazide, and atorvastatin. Fundoscopy today shows dot and blot haemorrhages bilaterally with several hard exudates temporal to the left macula. What is the most appropriate action regarding her diabetic retinopathy screening?

A. Arrange routine diabetic retinopathy screening appointment within 3 months
B. Refer urgently to ophthalmology for assessment within 1 week
C. Continue annual diabetic retinopathy screening through the screening programme
D. Refer to ophthalmology within 6 weeks for assessment of maculopathy (Correct Answer)
E. Arrange repeat screening in 6 months once glycaemic control improves

Explanation: ***Refer to ophthalmology within 6 weeks for assessment of maculopathy*** - The presence of **hard exudates** temporal to the left macula indicates **diabetic maculopathy**, a sight-threatening condition requiring specialist ophthalmological assessment. - Current guidelines recommend referral to hospital eye services for assessment within **6 weeks** for diabetic maculopathy, due to the risk to central vision. *Arrange routine diabetic retinopathy screening appointment within 3 months* - This action is insufficient because the patient has already demonstrated signs of **diabetic maculopathy**, which constitutes **sight-threatening retinopathy**. - A 3-month delay is inappropriate for an identified maculopathy, which requires a more urgent specialist review to prevent further vision loss. *Refer urgently to ophthalmology for assessment within 1 week* - **Urgent 1-week referral** is typically reserved for more severe, rapidly progressing conditions such as **proliferative diabetic retinopathy** or vitreous hemorrhage. - While serious, the described stable hard exudates near the macula usually fall into the 6-week referral category, rather than an immediate 1-week emergency. *Continue annual diabetic retinopathy screening through the screening programme* - Annual screening is appropriate for patients with **no retinopathy** or mild background changes without macula involvement. - This patient's fundoscopy findings have progressed beyond background retinopathy to **diabetic maculopathy**, necessitating specialist ophthalmic management rather than routine screening. *Arrange repeat screening in 6 months once glycaemic control improves* - While improving the **HbA1c of 76 mmol/mol** (9.1%) is important, it must not delay the assessment and management of existing **diabetic maculopathy**. - Rapid optimization of blood glucose can sometimes lead to a **transient worsening** of retinopathy, making prompt specialist assessment even more critical.

Question 127: A 68-year-old man attends following detection of a 3.2 cm abdominal aortic aneurysm on his NHS AAA screening ultrasound. He is asymptomatic. He has type 2 diabetes, hypertension, and continues to smoke 10 cigarettes daily. His current medications include metformin, ramipril, amlodipine, and atorvastatin. What is the most important lifestyle intervention that will reduce his risk of aneurysm expansion and rupture?

A. Smoking cessation (Correct Answer)
B. Weight reduction to achieve BMI <25 kg/m²
C. Reducing dietary sodium intake to <6g daily
D. Increasing physical activity to 150 minutes weekly
E. Adopting a Mediterranean diet pattern

Explanation: ***Smoking cessation*** - **Smoking** is the most significant modifiable risk factor for the development, growth, and **rupture** of abdominal aortic aneurysms (AAA). - Current smokers exhibit **expansion rates** nearly double those of non-smokers, making cessation the highest priority for slowing disease progression. *Weight reduction to achieve BMI <25 kg/m²* - While **weight management** is beneficial for overall cardiovascular health and metabolic syndrome, it has a weaker correlation with **AAA expansion** than tobacco use. - This patient already has established vascular disease (AAA) and hypertension, where **smoking status** is the more immediate driver of aortic wall degradation. *Reducing dietary sodium intake to <6g daily* - Sodium restriction helps manage **hypertension**, which is a risk factor for AAA development, but it does not independently stop aneurysm growth as effectively as quitting smoking. - Blood pressure control is vital for general **cardiovascular risk**, yet smoking cessation provides a more direct benefit specifically for the **aortic wall stability**. *Increasing physical activity to 150 minutes weekly* - **Exercise** is essential for maintaining arterial health and reducing overall mortality, but it is not specifically proven to prevent **aneurysm rupture** once a 3.2 cm AAA exists. - Physical activity should be encouraged, but it must be secondary to eliminating the **collagen-degrading** effects of cigarette smoke. *Adopting a Mediterranean diet pattern* - The **Mediterranean diet** is excellent for lipid profiles and reducing the risk of myocardial infarction, but it has no specific evidence for reducing **AAA growth rates**. - While part of primary cardiovascular prevention, it does not address the **proteolytic activity** in the aortic wall exacerbated by smoking.

Question 128: A 34-year-old woman who is 10 weeks pregnant with her second child attends for booking. Her first pregnancy 3 years ago was uncomplicated. She declined antenatal screening at that time for personal reasons. She has no family history of genetic conditions. She now wishes to discuss screening options. Which statement regarding combined first trimester screening for Down's syndrome, Edwards' syndrome and Patau's syndrome is correct?

A. It should be performed between 11+2 and 14+1 weeks gestation (Correct Answer)
B. It includes measurement of nuchal translucency, beta-hCG, and alpha-fetoprotein
C. A high-risk result (≥1 in 150) automatically leads to amniocentesis
D. It has a detection rate of approximately 99% for Down's syndrome
E. Crown-rump length must be between 35-70 mm for accurate nuchal translucency measurement

Explanation: ***It should be performed between 11+2 and 14+1 weeks gestation*** - The **combined test** for Down's, Edwards', and Patau's syndromes is optimally performed within this specific gestational window. - This timeframe, typically corresponding to a **crown-rump length (CRL)** of **45mm to 84mm**, ensures accurate measurement of **nuchal translucency** and biochemical markers. *It includes measurement of nuchal translucency, beta-hCG, and alpha-fetoprotein* - The combined first-trimester screening includes **nuchal translucency**, **free beta-hCG**, and **PAPP-A (Pregnancy-Associated Plasma Protein-A)**. - **Alpha-fetoprotein (AFP)** is a component of the second-trimester quadruple screen, not the first-trimester combined screening. *A high-risk result (≥1 in 150) automatically leads to amniocentesis* - A high-risk result indicates a higher probability, but diagnostic procedures like **amniocentesis** or **CVS (Chorionic Villus Sampling)** are always optional and require informed parental decision. - If diagnostic testing is chosen in the first trimester, **CVS** is typically performed, whereas **amniocentesis** is usually performed from 15 weeks gestation onwards. *It has a detection rate of approximately 99% for Down's syndrome* - The combined first-trimester screening typically has a detection rate of **85-90%** for Down's syndrome. - A detection rate of approximately **99%** is more characteristic of **Non-Invasive Prenatal Testing (NIPT)**, which screens cell-free fetal DNA. *Crown-rump length must be between 35-70 mm for accurate nuchal translucency measurement* - For an accurate **nuchal translucency (NT)** measurement, the **crown-rump length (CRL)** of the fetus should be between **45mm and 84mm**. - A CRL outside this range can lead to inaccurate NT results and may necessitate alternative screening methods.

Question 129: A 43-year-old man with severe mental illness (schizophrenia) attends for his annual physical health check. He takes olanzapine 15 mg daily and has gained significant weight over the past year. His BMI is now 34 kg/m², BP 148/92 mmHg, and blood tests show HbA1c 48 mmol/mol, total cholesterol 6.2 mmol/L, HDL 0.9 mmol/L, and triglycerides 3.8 mmol/L. He smokes 15 cigarettes daily. According to the Lester UK Adaptation of the Positive Cardiometabolic Health Resource, what is the recommended frequency for monitoring metabolic parameters in patients on antipsychotic medication after the first year?

A. Every 3 months
B. Every 6 months
C. Annually (Correct Answer)
D. Every 2 years
E. Only if symptomatic

Explanation: ***Annually***- The **Lester UK Adaptation** guidelines recommend **annual monitoring** of metabolic parameters for patients on antipsychotic medication *after the first year* of treatment.- This systematic review includes assessing **BMI**, **blood pressure**, **HbA1c**, and **lipid profile** to mitigate the increased cardiovascular risk associated with these medications.*Every 3 months*- This frequency is typically reserved for the **initial phase** (first 12 weeks) of starting a new antipsychotic to detect rapid metabolic changes.- While crucial for early detection, it is not the recommended *long-term* monitoring frequency *after the first year* according to the **Lester Tool**.*Every 6 months*- Monitoring **every 6 months** is not the standardized long-term frequency recommended by the **Lester UK Adaptation** for patients *after the first year* on antipsychotics.- While some high-risk patients might benefit from this, the routine guideline emphasizes a comprehensive **annual physical health review**.*Every 2 years*- This interval is far too infrequent given the high risk of **metabolic syndrome** and **cardiovascular disease** associated with second-generation antipsychotics like **olanzapine**.- Delaying checks to every 2 years would result in missing critical windows for managing evolving **dyslipidaemia** or **impaired glucose regulation**.*Only if symptomatic*- Metabolic complications like **hypertension**, **hypercholesterolaemia**, and **diabetes** are often **asymptomatic** until significant damage has occurred.- Proactive and systematic screening, rather than reactive monitoring based on symptoms, is essential for early intervention and prevention of **cardiovascular morbidity**.

Question 130: A 49-year-old woman attends with her NHS breast screening invitation letter. She had a benign fibroadenoma excised 10 years ago and is now concerned about radiation exposure from mammography. She asks whether the benefits of screening outweigh the harms. Which statement most accurately represents the evidence regarding breast screening in the NHS programme?

A. For every 10,000 women screened for 20 years, approximately 40 breast cancer deaths are prevented (Correct Answer)
B. Approximately 1 in 4 screen-detected breast cancers represents overdiagnosis
C. Screening reduces breast cancer mortality by approximately 50% in those who attend
D. The false positive rate requiring further assessment is less than 2%
E. Radiation exposure from screening causes approximately 10 breast cancer cases per 10,000 women screened

Explanation: ***For every 10,000 women screened for 20 years, approximately 40 breast cancer deaths are prevented*** - According to the **Marmot Review**, inviting 10,000 women for screening over 20 years prevents approximately **43 breast cancer deaths**, which is statistically significant. - This data forms the primary evidence for the **benefit-to-harm ratio** communicated to patients in the NHS screening programme leaflets. *Approximately 1 in 4 screen-detected breast cancers represents overdiagnosis* - Evidence suggests that approximately **3 out of every 4** screen-detected cases are clinically significant, meaning overdiagnosis occurs in about **19%** of cases (roughly 1 in 5). - **Overdiagnosis** refers to detecting cancers that would not have caused symptoms or death within a patient's lifetime, leading to unnecessary treatment. *Screening reduces breast cancer mortality by approximately 50% in those who attend* - Systematic reviews indicate that screening leads to a relative **reduction in mortality** of approximately **20%**, not 50%. - While substantial, it is crucial not to **overestimate benefit** when providing balanced information for informed consent. *The false positive rate requiring further assessment is less than 2%* - The actual **recall rate** for further assessment (false positives) in the NHS programme is approximately **4-7%**. - False positives can cause significant **psychological distress** and anxiety, which is considered a primary harm of the screening process. *Radiation exposure from screening causes approximately 10 breast cancer cases per 10,000 women screened* - The risk of **radiation-induced cancer** is very low, estimated to cause fewer than **5 additional cases** per 10,000 women screened. - The benefits of detecting existing cancers and **preventing deaths** far outweigh the minimal risk associated with the small dose of radiation in mammography.

Question 131: A 57-year-old man attends for an NHS Health Check. He works night shifts as a security guard and admits to minimal physical activity. His BMI is 32 kg/m², BP 136/84 mmHg, and he has impaired fasting glucose at 6.3 mmol/L. HbA1c is 43 mmol/mol. His QRISK3 score is 9%. He is keen to reduce his diabetes risk. According to NICE guidance, which intervention has the strongest evidence for preventing progression to type 2 diabetes in people with non-diabetic hyperglycaemia?

A. Metformin 500 mg twice daily
B. Structured lifestyle modification programme targeting 5-7% weight loss (Correct Answer)
C. Low-carbohydrate diet with carbohydrate intake <130g daily
D. Orlistat 120 mg three times daily
E. Intensive exercise programme of 300 minutes moderate activity per week

Explanation: ***Structured lifestyle modification programme targeting 5-7% weight loss*** - Landmark trials like the **Diabetes Prevention Programme (DPP)** demonstrate that intensive lifestyle changes reduce the risk of progressing to **Type 2 Diabetes** by approximately 58%. - **NICE guidelines** recommend referring patients with non-diabetic hyperglycaemia to structured programmes that combine **dietary changes** and increased **physical activity**. *Metformin 500 mg twice daily* - Although effective, pharmacological intervention with **metformin** typically shows a lower risk reduction (approx. 31%) compared to structured lifestyle changes. - It is usually reserved for patients whose **HbA1c** is rising or failing to improve despite intensive lifestyle interventions, or those with an **HbA1c** ≥ 44 mmol/mol. *Low-carbohydrate diet with carbohydrate intake <130g daily* - While a **low-carbohydrate diet** can assist with glycaemic control, the evidence for a specific carbohydrate threshold is less robust than for **overall weight loss**. - NICE emphasizes a **balanced diet** and total energy deficit rather than specific macronutrient exclusion for the prevention of diabetes. *Orlistat 120 mg three times daily* - **Orlistat** is a weight-loss medication that may indirectly reduce diabetes risk, but it is not recommended as a primary prevention strategy for **non-diabetic hyperglycaemia**. - Its use is specifically targeted at **obesity management** rather than being the first-line intervention for glucose regulation. *Intensive exercise programme of 300 minutes moderate activity per week* - The recommended target for diabetes prevention is generally **150 minutes** of moderate-intensity activity per week, and exercise alone is less effective than **combined diet and exercise**. - **Structured programmes** focus on multifaceted lifestyle changes rather than just high-volume physical activity to ensure sustainable **weight loss**.

Question 132: A 36-year-old woman attends with her cervical screening result showing hrHPV positive but cytology negative (hrHPV+/cytology-). This is her first cervical screening test since age 25 when her result was normal. She is asymptomatic and has no history of abnormal cervical cytology. She is in a stable relationship and uses the combined oral contraceptive pill. What is the most appropriate management according to current NHS guidelines?

A. Repeat hrHPV test in 12 months (Correct Answer)
B. Repeat hrHPV test in 24 months
C. Refer for urgent colposcopy within 2 weeks
D. Refer for routine colposcopy
E. Return to routine recall in 3 years

Explanation: ***Repeat hrHPV test in 12 months*** - For individuals who test positive for **high-risk HPV (hrHPV)** but have **negative cytology**, the current NHS guideline is to repeat the test in **12 months** to allow time for the infection to clear spontaneously. - This is the first step in the **non-referral pathway**, as many HPV infections are transient, especially in women under the age of 50. *Repeat hrHPV test in 24 months* - A **24-month** interval is not the standard immediate follow-up for a first-time **hrHPV+/cytology-** result in this age group. - This timeframe is typically associated with second-year follow-ups of persistent HPV under specific circumstances or older screening intervals. *Refer for urgent colposcopy within 2 weeks* - **Urgent 2-week colposcopy** is reserved for cases where screening suggests **invasive cancer** or a clinical suspicion of malignancy based on physical examination. - There is no clinical indication for urgency here, as the **cytology is negative** and the patient is asymptomatic. *Refer for routine colposcopy* - Routine **colposcopy** is indicated if the **hrHPV** test is positive and **cytology is abnormal** (dyskaryosis), or if **hrHPV** persists for 12 or 24 months even with negative cytology. - Referring immediately after a single negative cytology result would lead to unnecessary invasive procedures for infections that likely clear naturally. *Return to routine recall in 3 years* - **Routine recall** is only appropriate if the primary **hrHPV test is negative**, as a negative HPV test indicates a very low risk of developing cervical cancer before the next screen. - Returning to routine screening while **hrHPV positive** would be unsafe, as it ignores a potentially persistent infection that requires monitoring.

Question 133: A 54-year-old woman attends for smoking cessation support. She smokes 18 cigarettes daily and has a 35 pack-year history. She is motivated to quit and requests pharmacological support. She has previously tried nicotine replacement therapy patches without success. She has a history of well-controlled depression managed with citalopram and has no other medical conditions. What would be the most appropriate pharmacological option to offer?

A. Varenicline
B. Bupropion
C. Nicotine replacement therapy (NRT) combination with patches and short-acting NRT (Correct Answer)
D. Increase citalopram dose and advise behavioural support only
E. Nortriptyline

Explanation: ***Nicotine replacement therapy (NRT) combination with patches and short-acting NRT*** - Given previous failure with **NRT patches alone**, combining a **long-acting NRT** (patch) with a **short-acting NRT** (e.g., gum, lozenge, spray) is a highly effective next step, as per **NICE guidelines**. - This approach addresses both constant cravings and acute urges, often providing efficacy comparable to varenicline but with a **superior safety profile**, especially important for a patient with a history of well-controlled depression. *Varenicline* - While **varenicline** (a **partial nicotine receptor agonist**) is very effective, it can have **neuropsychiatric side effects** and its use might require closer monitoring in patients with a history of depression, even if well-controlled. - Current guidelines often suggest optimizing NRT first, especially when a patient has already shown familiarity with NRT, before moving to agents like varenicline. *Bupropion* - **Bupropion** is contraindicated or should be used with extreme caution in patients taking **SSRIs like citalopram** due to a significantly increased risk of **seizures** and potential drug interactions affecting antidepressant levels. - Its mechanism as a **norepinephrine-dopamine reuptake inhibitor** differs from direct nicotine replacement, and its side effect profile makes it less suitable given the patient's current medication. *Increase citalopram dose and advise behavioural support only* - **Citalopram** is an antidepressant and has **no direct role** in aiding smoking cessation; increasing its dose is not indicated for this purpose and would not address the nicotine dependence. - While **behavioural support** is crucial, the patient specifically requested **pharmacological support**, and neglecting this by only advising behavioural support would be insufficient and inappropriate. *Nortriptyline* - **Nortriptyline**, a **tricyclic antidepressant**, is considered a **second-line** or off-label option for smoking cessation, typically reserved for when first-line options like NRT or varenicline are contraindicated or have failed. - It carries a higher risk of **anticholinergic side effects** and cardiotoxicity compared to NRT, making it less appropriate as an initial choice for this patient.

Question 134: A 59-year-old man attends for cardiovascular risk assessment as part of the NHS Health Check programme. He has no previous medical history and takes no medications. His father had a myocardial infarction at age 68. Examination reveals BMI 28 kg/m², BP 142/88 mmHg, and xanthelasma around both eyes. Blood tests show total cholesterol 8.2 mmol/L, HDL 1.0 mmol/L, non-HDL 7.2 mmol/L, and fasting glucose 5.4 mmol/L. His QRISK3 score is calculated at 18%. Which diagnosis should be considered and investigated further before initiating standard statin therapy?

A. Hypothyroidism
B. Familial hypercholesterolaemia (Correct Answer)
C. Type 2 diabetes mellitus
D. Nephrotic syndrome
E. Cholestasis

Explanation: ***Familial hypercholesterolaemia***- A total cholesterol **>7.5 mmol/L** or non-HDL cholesterol **>5.9 mmol/L** in an adult mandates clinical suspicion for **Familial hypercholesterolaemia (FH)** according to NICE guidelines.- The presence of **xanthelasma** and a high QRISK score in a patient with severely elevated lipids requires formal assessment using **Simon Broome** or **Dutch Lipid Clinic** criteria before starting standard therapy.*Hypothyroidism*- While **hypothyroidism** is a secondary cause of hyperlipidaemia, it is typically excluded with a **TSH test** but does not explain the specific threshold-based suspicion for FH in this context.- It generally causes a mild to moderate elevation in cholesterol rather than the severe primary elevation seen in this patient.*Type 2 diabetes mellitus*- This patient's **fasting glucose of 5.4 mmol/L** is within the normal range, effectively ruling out a diagnosis of **Type 2 diabetes**.- Diabetes is more commonly associated with **hypertriglyceridemia** and low HDL rather than isolated severe cholesterol elevation.*Nephrotic syndrome*- **Nephrotic syndrome** can cause secondary hyperlipidaemia due to increased hepatic lipoprotein synthesis, but there is no mention of **oedema** or proteinuria here.- It remains a differential for secondary lipid elevation but is less likely than a primary genetic lipid disorder given the clinical presentation.*Cholestasis*- **Cholestasis** can lead to elevated cholesterol levels due to decreased biliary excretion, but it would typically present with **jaundice** or pruritus.- There are no symptoms or signs of **liver disease** or biliary obstruction provided in the clinical history to support this diagnosis.

Question 135: A 50-year-old woman of Ashkenazi Jewish heritage attends requesting genetic testing for hereditary breast cancer. Her sister was diagnosed with breast cancer at age 41 and subsequently found to carry a BRCA1 mutation. The patient is anxious about her own risk. She has no personal history of cancer and clinical examination is normal. What is the most appropriate next step in her management?

A. Arrange BRCA1 genetic testing directly through the GP
B. Reassure and arrange annual mammography through the NHS Breast Screening Programme
C. Refer to clinical genetics service for assessment and cascade testing (Correct Answer)
D. Prescribe tamoxifen for chemoprevention
E. Refer to breast surgery for discussion of prophylactic mastectomy

Explanation: ***Refer to clinical genetics service for assessment and cascade testing*** - The patient has a **first-degree relative** with a confirmed **BRCA1 mutation** and is of **Ashkenazi Jewish heritage**, indicating a high likelihood of a pathogenic variant. This warrants a formal **genetic risk assessment** and **pre-test counseling**. - A referral to a **specialist clinical genetics service** ensures appropriate interpretation of results, discussion of implications for family members (**cascade testing**), and tailored surveillance/risk reduction strategies. *Arrange BRCA1 genetic testing directly through the GP* - **Germline genetic testing** for hereditary cancer syndromes is complex and requires specialized **pre-test and post-test counseling** that GPs are not typically equipped to provide. - Without proper **genetic counseling**, misinterpretation of results or inadequate support can lead to significant psychological distress and inappropriate medical decisions. *Reassure and arrange annual mammography through the NHS Breast Screening Programme* - Given the strong family history and known **BRCA1 mutation** in a first-degree relative, the patient is at **high risk** and requires more intensive surveillance than routine screening. - Standard **NHS Breast Screening** is insufficient; high-risk individuals require **enhanced surveillance protocols**, potentially including annual MRI, which are managed by specialized genetics services or high-risk clinics. *Prescribe tamoxifen for chemoprevention* - **Chemoprevention** with agents like **tamoxifen** is only considered after a formal **genetic risk assessment** confirms a high lifetime risk of breast cancer and is discussed with the patient after they understand the benefits and risks. - Prescribing **tamoxifen** without confirming the patient's genetic status and completing a comprehensive risk-benefit discussion is premature and not evidence-based. *Refer to breast surgery for discussion of prophylactic mastectomy* - **Prophylactic mastectomy** is a major surgical intervention reserved for individuals with **confirmed high genetic risk** (e.g., BRCA1/2 mutation carriers) and after extensive counseling by a multidisciplinary team. - Referring for surgery before the patient's **genetic status** is confirmed and a thorough risk assessment by a **genetics service** is conducted is premature and inappropriate.

Question 136: A 44-year-old woman with a BMI of 36 kg/m² attends for weight management review. Over the past 3 months, she has attempted dietary modification and increased physical activity but has only lost 1 kg. She has no contraindications to pharmacological intervention. Her HbA1c is 41 mmol/mol. She requests information about medication to help with weight loss. Which medication would be most appropriate to consider as first-line pharmacological treatment?

A. Metformin 500 mg twice daily
B. Orlistat 120 mg three times daily with meals (Correct Answer)
C. Liraglutide 3.0 mg subcutaneous injection daily
D. Semaglutide 2.4 mg subcutaneous injection weekly
E. Bupropion-naltrexone combination

Explanation: ***Orlistat 120 mg three times daily with meals*** - The patient's **BMI of 36 kg/m²** and failure of lifestyle modifications for 3 months meet the criteria for **first-line pharmacological treatment** for weight loss, as per guidelines (e.g., NICE). - **Orlistat** works as a **gastrointestinal lipase inhibitor**, reducing the absorption of dietary fat, making it an appropriate initial choice when no contraindications exist and HbA1c is normal. *Metformin 500 mg twice daily* - **Metformin** is primarily indicated for **Type 2 Diabetes Mellitus** or **pre-diabetes**; the patient's HbA1c of 41 mmol/mol indicates she is **non-diabetic** and does not require metformin for glycemic control. - Although it can lead to some weight loss, it is **not licensed** as a first-line agent for weight management in individuals without diabetes. *Liraglutide 3.0 mg subcutaneous injection daily* - While effective for weight loss, **Liraglutide** (at the 3.0 mg dose) is generally reserved for use within **specialist weight management services** (e.g., Tier 3/4) and is not considered a first-line primary care option. - It is typically considered for patients with higher BMI thresholds or specific comorbidities, often after initial interventions like orlistat or lifestyle changes have been explored. *Semaglutide 2.4 mg subcutaneous injection weekly* - **Semaglutide** (at 2.4 mg for weight management) is a potent GLP-1 receptor agonist; however, its use is usually restricted to patients with a **BMI of 35 kg/m² or more with at least one weight-related comorbidity**, or a BMI of 30 kg/m² with specific criteria, and initiated by **specialist services**. - It is not typically the first-line pharmacological treatment in primary care for a patient who does not meet these more stringent criteria or require specialist initiation. *Bupropion-naltrexone combination* - The **bupropion-naltrexone combination** is not currently recommended as a first-line agent for routine weight management by key national guidelines (e.g., NICE) in the UK. - It carries a different side effect profile, including potential **neuropsychiatric adverse effects**, making it less favorable than established first-line treatments like orlistat for this patient.

Question 137: A 61-year-old woman attends for discussion of her NHS bowel cancer screening result. Her faecal immunochemical test (FIT) shows a result of 85 micrograms haemoglobin per gram of faeces. She has no gastrointestinal symptoms and examination is unremarkable. She has well-controlled hypertension and takes ramipril. What is the threshold result that requires referral for colonoscopy in the NHS Bowel Cancer Screening Programme?

A. ≥10 micrograms Hb per gram faeces (Correct Answer)
B. ≥40 micrograms Hb per gram faeces
C. ≥150 micrograms Hb per gram faeces
D. ≥100 micrograms Hb per gram faeces
E. ≥200 micrograms Hb per gram faeces

Explanation: ***≥10 micrograms Hb per gram faeces*** - In the **NHS Bowel Cancer Screening Programme**, the specific threshold for a positive **Faecal Immunochemical Test (FIT)** result requiring urgent colonoscopy referral is **≥10 µg Hb/g**. - This threshold is sensitive enough to detect **colorectal cancer** and **advanced adenomas** in asymptomatic individuals within the screening age range. *≥40 micrograms Hb per gram faeces* - This value is higher than the official **NHS screening cutoff**, potentially missing significant pathology if used as a referral gatekeeper. - Although some clinical pathways for **symptomatic** patients use different variations, the national screening standard remains **10 µg Hb/g**. *≥150 micrograms Hb per gram faeces* - This level is significantly higher than the standard threshold and would result in many **false negatives** for early-stage malignancy. - A result of 150 µg Hb/g indicates a high likelihood of colorectal pathology, but the screening programme triggers action at a much lower level to ensure **early detection**. *≥100 micrograms Hb per gram faeces* - Some **FIT** assays previously used higher cut-offs in different jurisdictions, but the **Public Health England** guidelines for the screening programme utilize the **10 µg Hb/g** limit. - Using a **100 µg Hb/g** threshold would overlook the majority of patients with high-risk **polyps**. *≥200 micrograms Hb per gram faeces* - This represents a very high concentration of **occult blood** and is not used as a screening threshold as it lacks the necessary **sensitivity** for a population-wide program. - The goal of the **FIT** in screening is to catch lesions before they become symptomatic, which necessitates the lower **10 µg Hb/g** threshold.

Question 138: A 26-year-old woman attends for cervical screening. She mentions that she received the HPV vaccination at school when she was 14 years old and asks if she still needs cervical screening. She has been sexually active since age 19 and is currently in a monogamous relationship. She has no gynaecological symptoms. What is the most appropriate advice?

A. She does not need cervical screening as she was vaccinated
B. She should commence cervical screening now
C. She should wait until age 30 to commence cervical screening
D. She only needs screening if she develops symptoms
E. She should commence cervical screening at age 25 (Correct Answer)

Explanation: ***She should commence cervical screening at age 25*** - In the UK, the **NHS Cervical Screening Programme** invites all individuals with a cervix to begin screening at **age 25**, regardless of their **HPV vaccination status**. - While the vaccine protects against high-risk types like **HPV 16 and 18**, it does not cover all **oncogenic HPV types**, making regular screening essential for early detection. *She does not need cervical screening as she was vaccinated* - **HPV vaccination** significantly reduces the risk of cervical cancer but does not eliminate it entirely, as other **high-risk HPV strains** are not covered by older vaccines. - Screening is still required to identify **pre-cancerous changes** (CIN) caused by non-vaccine HPV types. *She should commence cervical screening now* - At age 26, she is already within the recommended age bracket, but the standard protocol specifies that the first invitation is sent at **age 25**. - Commencing screening earlier than age 25 is not recommended as **transient HPV infections** and minor cell changes are common and usually resolve without clinical significance. *She should wait until age 30 to commence cervical screening* - Waiting until age 30 would miss the critical window for identifying early **dysplastic changes** often found in the 25-29 age group. - Current guidelines mandate screening every **three years** for those aged **25–49** to ensure adequate monitoring. *She only needs screening if she develops symptoms* - Cervical screening is a **preventative tool** designed to detect asymptomatic **precancerous lesions** before they progress to invasive cancer. - Once symptoms like **post-coital bleeding** occur, the focus shifts from screening to **diagnostic investigation** (colposcopy or biopsy).

Question 139: A 66-year-old man attends following his NHS abdominal aortic aneurysm (AAA) screening ultrasound. The scan reveals an infrarenal AAA measuring 4.8 cm in maximum anteroposterior diameter. He is asymptomatic and his blood pressure is 138/82 mmHg. He stopped smoking 3 years ago and takes atorvastatin for hyperlipidaemia. What is the most appropriate management?

A. Discharge with no follow-up required
B. Refer for urgent vascular surgery review within 2 weeks
C. Arrange repeat ultrasound surveillance in 3 months (Correct Answer)
D. Arrange repeat ultrasound surveillance in 12 months
E. Arrange CT angiography and routine vascular surgery referral

Explanation: ***Arrange repeat ultrasound surveillance in 3 months*** - This patient has a **medium-sized abdominal aortic aneurysm (AAA)**, defined as measuring between **4.5 cm and 5.4 cm** in maximum diameter. - According to **NHS AAA screening guidelines**, medium aneurysms require **3-monthly ultrasound surveillance** to monitor for growth and assess the need for intervention. *Discharge with no follow-up required* - Any AAA measuring **3.0 cm or greater** requires ongoing monitoring to assess for growth and reduce the risk of rupture. - A **4.8 cm infrarenal AAA** carries a significant risk of progression, making discharge without follow-up clinically inappropriate and unsafe. *Refer for urgent vascular surgery review within 2 weeks* - Urgent vascular surgery referral is indicated for **large AAAs (≥5.5 cm)**, symptomatic aneurysms (e.g., pain), or those with rapid expansion (e.g., **>1 cm in a year**). - This patient's aneurysm is **4.8 cm** and **asymptomatic**, so it does not meet the criteria for urgent surgical review at this stage. *Arrange repeat ultrasound surveillance in 12 months* - **Annual (12-month) surveillance** is the standard protocol for **small AAAs**, which are defined as measuring between **3.0 cm and 4.4 cm** in diameter. - For a **4.8 cm aneurysm**, a one-year interval is too long and increases the risk of the aneurysm reaching a critical size without timely detection. *Arrange CT angiography and routine vascular surgery referral* - **CT angiography** is typically used for pre-operative planning or when the aneurysm reaches the **5.5 cm threshold** for surgical consideration. - Routine referral and advanced imaging like CT angiography are not indicated for an **asymptomatic medium AAA** that is currently managed under a surveillance program.

Question 140: A 31-year-old woman who is 16 weeks pregnant attends for her anomaly scan appointment. The sonographer identifies that she has not had the combined screening test for Down syndrome and other chromosomal abnormalities (she missed her 12-week appointment). She has no significant medical or family history. What is the most appropriate screening test to offer at this gestation?

A. Quadruple test (AFP, hCG, uE3, inhibin A) (Correct Answer)
B. Non-invasive prenatal testing (NIPT) with cell-free fetal DNA
C. Amniocentesis for definitive karyotyping
D. Combined test with nuchal translucency measurement and serum markers
E. Arrange early anatomy scan for soft markers of chromosomal abnormality

Explanation: ***Quadruple test (AFP, hCG, uE3, inhibin A)***- The **quadruple test** is the screening test of choice for **Down syndrome** and other chromosomal abnormalities in the second trimester, specifically between **14+2 and 20+0 weeks** of gestation.- It measures four biochemical markers (**AFP, hCG, uE3, inhibin A**) and is used when the window for the combined test has passed, as in this case at 16 weeks.*Non-invasive prenatal testing (NIPT) with cell-free fetal DNA*- **NIPT** is a highly sensitive screening test but is typically offered as a **contingent test** for women who receive a high-risk result from initial screening (e.g., combined or quadruple test).- While it can be performed after 10 weeks, it is not currently the standard **first-line screening alternative** offered to the general population in the second trimester after a missed initial screening.*Amniocentesis for definitive karyotyping*- **Amniocentesis** is an **invasive diagnostic procedure**, not a screening test, and carries a small but significant **risk of miscarriage** (approx. 0.5-1%).- It is generally reserved for **confirming chromosomal abnormalities** after an increased risk is identified by screening tests or ultrasound findings, not as an initial screening offer.*Combined test with nuchal translucency measurement and serum markers*- The **combined test** is only valid between **11+2 and 14+1 weeks** because nuchal translucency measurement is no longer accurate or clinically useful beyond this gestational window.- At **16 weeks gestation**, this patient has missed the clinical window for this specific screening modality.*Arrange early anatomy scan for soft markers of chromosomal abnormality*- The **anomaly scan** (usually performed at 18-20 weeks) focuses on **structural defects** rather than being a primary screening tool for chromosomal trisomies.- Relying solely on "soft markers" for initial screening has a lower detection rate and higher **false-positive rates** compared to biochemical screening tests like the quadruple test.

Question 141: A 68-year-old woman attends for diabetic eye screening. She has had type 2 diabetes for 9 years, current HbA1c 58 mmol/mol. The screening report indicates R1 (background diabetic retinopathy) with microaneurysms in both eyes but no maculopathy. She is asymptomatic with no visual symptoms. What is the appropriate follow-up interval for retinopathy screening?

A. Routine annual screening (Correct Answer)
B. Repeat screening in 6 months
C. Urgent referral to ophthalmology within 2 weeks
D. Routine referral to ophthalmology
E. Repeat screening in 3 months

Explanation: ***Routine annual screening***- For patients with **R1 (background retinopathy)** and no evidence of maculopathy, the standard management is surveillance via **annual screening**.- This staging involves **microaneurysms** or small hemorrhages only, which carry a low risk of immediate vision loss and do not require clinical intervention.*Repeat screening in 6 months*- A **6-month interval** is usually reserved for stable **pre-proliferative changes** in specific monitoring programs, not for standard R1 background retinopathy.- Increasing frequency is unnecessary for **microaneurysms** alone, as progression to vision-threatening disease typically occurs over a longer duration.*Urgent referral to ophthalmology within 2 weeks*- Urgent 2-week referrals are strictly indicated for **R3 (proliferative retinopathy)**, characterized by **neovascularization** or vitreous hemorrhage.- This patient is **asymptomatic** and lacks the high-risk features necessary for emergency specialist evaluation.*Routine referral to ophthalmology*- Routine ophthalmology referral is indicated for **M1 (maculopathy)** or **R2 (pre-proliferative)** changes, neither of which are present in this case.- Patients with **R1 level retinopathy** are managed by the diabetic eye screening service rather than hospital clinic specialists.*Repeat screening in 3 months*- A **3-month interval** is not a standard screening frequency and would typically be part of a specialist's intensive monitoring for rapidly progressing disease.- **Background retinopathy** does not warrant such close follow-up since it is the earliest stage of clinical diabetic eye disease.

Question 142: A 56-year-old man with schizophrenia maintained on olanzapine presents for cardiovascular risk assessment. He has gained 18 kg over 2 years, current BMI 34 kg/m². He smokes 15 cigarettes daily. Blood tests show HbA1c 46 mmol/mol, total cholesterol 6.2 mmol/L, HDL 0.9 mmol/L. BP 142/88 mmHg. QRISK3 is 18.5%. What is the most important initial lifestyle intervention for this patient?

A. Referral to tier 3 weight management service for intensive behavioral intervention
B. Smoking cessation with combination nicotine replacement therapy and varenicline
C. Supervised physical activity programme addressing both weight and mental health
D. Therapeutic lifestyle change diet focused on reducing LDL cholesterol
E. Smoking cessation alongside dietary advice to prevent further weight gain (Correct Answer)

Explanation: ***Smoking cessation alongside dietary advice to prevent further weight gain*** - **Smoking** is the single most modifiable risk factor for cardiovascular disease (CVD) in patients with severe mental illness, making **cessation** the highest clinical priority for immediate risk reduction. - Since **smoking cessation** frequently leads to **weight gain**, combining it with **dietary advice** is crucial for patients already experiencing **metabolic disturbance** and weight gain from antipsychotics like **olanzapine**. *Referral to tier 3 weight management service for intensive behavioral intervention* - While the patient has a **BMI of 34 kg/m²**, intensive weight management services are typically secondary to addressing the most significant and immediate modifiable risk factor, which is **smoking**. - Tier 3 services are usually reserved after less intensive interventions have been attempted or for more complex cases, making it not the *most important initial* lifestyle intervention in this context. *Smoking cessation with combination nicotine replacement therapy and varenicline* - **Smoking cessation** is vital, but this option describes a **pharmacological intervention**, not solely a lifestyle one, and specifies a particular combination of drugs that may not be the initial step without further assessment. - This option, while crucial, does not explicitly include the vital component of **dietary advice** to manage the **olanzapine-induced weight gain** and metabolic risks, which is a key consideration for this patient. *Supervised physical activity programme addressing both weight and mental health* - **Physical activity** is highly beneficial for both **weight management** and **mental health** in patients with **schizophrenia** and is an important lifestyle change. - However, its impact on reducing immediate cardiovascular risk, while significant long-term, is not as rapid or substantial as **smoking cessation** in a patient with such a high **QRISK3 score**. *Therapeutic lifestyle change diet focused on reducing LDL cholesterol* - While the patient has **hyperlipidaemia** and a high **QRISK3 score**, a diet solely focused on **LDL cholesterol reduction** does not address the broader metabolic risks (weight gain, pre-diabetes) from **olanzapine**. - More importantly, focusing on a specific dietary component, while beneficial, does not supersede the paramount importance of **smoking cessation** as the *most important initial* lifestyle intervention for overall CVD risk reduction.

Question 143: A 33-year-old woman attends with her cervical screening result showing hrHPV positive with normal cytology. She is anxious about cancer risk and asks what this means. Her previous screening 3 years ago was hrHPV negative. What is the most appropriate management according to current NHS cervical screening protocols?

A. Refer for immediate colposcopy
B. Reassure and invite for routine screening in 3 years
C. Arrange HPV genotyping for types 16 and 18
D. Repeat hrHPV test in 12 months (Correct Answer)
E. Repeat hrHPV test and cytology in 3 months

Explanation: ***Repeat hrHPV test in 12 months***- According to **NHS cervical screening protocols**, when **hrHPV is detected** but **cytology is negative**, the patient must be recalled in 12 months to check for viral persistence.- Most **HPV infections are transient** and clear spontaneously; repeating the test at 12 months allows time for clearance while monitoring those at higher risk of developing persistent infection.*Refer for immediate colposcopy*- **Colposcopy** is indicated if hrHPV is positive and **cytology is abnormal** (reflex cytology shows dyskaryosis) or after **persistent hrHPV** results over 24 months.- Immediate referral for normal cytology would lead to **over-investigation** and unnecessary anxiety for a condition that often resolves without intervention.*Reassure and invite for routine screening in 3 years*- Reassurance is important, but returning to **routine 3-year recall** is unsafe because the presence of hrHPV requires closer monitoring than the general population.- Patients with **hrHPV positive** results remain in the "surveillance" pathway until they are either HPV negative or referred for further diagnostic workup.*Arrange HPV genotyping for types 16 and 18*- While **HPV 16 and 18** are the highest-risk strains, specific genotyping is not currently used as a standalone triage step in the standard **NHS screening algorithm**.- The management pathway is determined by the presence of any **high-risk HPV** subtype combined with reflex **cytology findings**.*Repeat hrHPV test and cytology in 3 months*- A **3-month interval** is too short to allow for natural viral clearance and is not a recognized interval in the screening protocol.- Short-interval repeats are typically reserved for **inadequate samples**, whereas a 12-month wait is the standard for monitoring **cytology-negative/HPV-positive** cases.

Question 144: A 72-year-old man with hypertension and hyperlipidaemia attends for medication review. His QRISK3 score is 28%. He takes ramipril 10mg daily and atorvastatin 80mg at night. He asks what else he can do to reduce his cardiovascular risk. Which dietary modification has the strongest evidence for secondary cardiovascular disease prevention?

A. Mediterranean-style diet rich in olive oil, nuts, fish, and vegetables (Correct Answer)
B. Strict low-carbohydrate ketogenic diet (<50g carbohydrates daily)
C. Vegetarian diet eliminating all meat and fish
D. Low-fat diet with <20% calories from fat
E. Intermittent fasting with 16:8 time-restricted eating

Explanation: ***Mediterranean-style diet rich in olive oil, nuts, fish, and vegetables***- The **Mediterranean diet** has the strongest evidence base for cardiovascular risk reduction, supported by landmark studies like the **PREDIMED trial**, which showed a ~30% reduction in major cardiovascular events.- It emphasizes **monounsaturated fats** (olive oil), **omega-3 fatty acids** (fish/nuts), and **antioxidants** from plant sources, which collectively improve endothelial function and reduce inflammation.*Strict low-carbohydrate ketogenic diet (<50g carbohydrates daily)*- While effective for rapid **weight loss** and glycemic control, there is a lack of long-term evidence regarding its impact on **cardiovascular mortality**.- High intake of **saturated fats** often associated with this diet may adversely affect **LDL-cholesterol** levels in some individuals.*Vegetarian diet eliminating all meat and fish*- Although associated with lower **ischaemic heart disease** risk compared to meat-eaters, the evidence is less robust than that for the Mediterranean pattern, which includes beneficial **oily fish**.- Strict vegetarianism requires careful management to avoid deficiencies (like **Vitamin B12**) and does not inherently guarantee heart-healthy fat choices.*Low-fat diet with <20% calories from fat*- Historically recommended, but large-scale trials have shown that replacing fats with **refined carbohydrates** does not reduce cardiovascular risk.- Modern guidelines favor the **quality of fat** (unsaturated vs. saturated) over a simple reduction in total fat quantity.*Intermittent fasting with 16:8 time-restricted eating*- This approach can help with **weight management** and insulin sensitivity, but it currently lacks large-scale, long-term **cardiovascular outcome trials**.- It is generally considered a tool for **caloric restriction** rather than a specific cardioprotective nutritional intervention.

Question 145: A 47-year-old woman attends requesting early breast screening. Her sister was recently diagnosed with breast cancer at age 51, and her maternal grandmother had ovarian cancer at age 68. She is otherwise well with no breast symptoms. Using NICE guidelines for familial breast cancer, what is the most appropriate initial management?

A. Reassure that she has average population risk and advise routine NHS screening from age 50 (Correct Answer)
B. Refer to breast surgery for immediate mammography
C. Refer to clinical genetics for formal risk assessment
D. Arrange mammography now and annually until age 50
E. Use primary care risk assessment tools and arrange mammography if lifetime risk >17%

Explanation: ***Reassure that she has average population risk and advise routine NHS screening from age 50***- Per **NICE guidelines (CG164)**, this patient has only one first-degree relative diagnosed over age 40 and one second-degree relative with ovarian cancer over age 60, which falls into the **near-population risk** category.- Specialist referral or early screening is not indicated as she does not meet the threshold of having a first-degree relative diagnosed **under age 40** or multiple relatives on the same side of the family diagnosed at young ages.*Refer to breast surgery for immediate mammography*- Immediate referral to **breast surgery** is indicated for patients with **red-flag symptoms** (e.g., lumps, skin changes), but this patient is asymptomatic.- Mammography is not recommended for **average-risk** women outside of the routine **NHS Breast Screening Programme** starting at age 50.*Refer to clinical genetics for formal risk assessment*- **Clinical genetics** referral is reserved for patients meeting "moderate" or "high risk" criteria, such as those with a calculated **lifetime risk >17%** or specific family clusters.- This patient's family history of a sister at age 51 and grandmother at age 68 does not reach the minimum **referral thresholds** for specialist genetic assessment.*Arrange mammography now and annually until age 50*- **Annual mammograms** for women aged 40–49 are only offered to those categorized as having a **moderate risk** (e.g., one first-degree relative diagnosed <40).- Providing additional screening to **average-risk** patients increases the risk of **false positives** and unnecessary anxiety without proven clinical benefit.*Use primary care risk assessment tools and arrange mammography if lifetime risk >17%*- While **primary care tools** (like IBIS or BOADICEA) can be used, this patient's history is clearly below the threshold where formal **lifetime risk calculation** is required to justify early screening.- A **17% lifetime risk** (moderate risk) requires more significant familial clustering than a single relative diagnosed post-menopause and an elderly relative with ovarian cancer.

Question 146: A 53-year-old woman with a BMI of 38 kg/m² and type 2 diabetes attends for weight management review. Despite dietary modification and increased activity over 6 months, she has lost only 2 kg. Her HbA1c is 64 mmol/mol on metformin 1g BD. She asks about weight loss medications. What is the most appropriate pharmacological option to consider first?

A. Orlistat 120 mg three times daily with meals
B. GLP-1 receptor agonist (e.g., semaglutide) (Correct Answer)
C. Phentermine as short-term appetite suppressant
D. Naltrexone-bupropion combination therapy
E. Increase metformin to maximum dose for weight benefits

Explanation: ***GLP-1 receptor agonist (e.g., semaglutide)*** - For patients with **Type 2 Diabetes** and **obesity (BMI 38 kg/m²)**, **GLP-1 receptor agonists** are the most appropriate first-line pharmacological option as they provide significant **weight loss** and improved **glycaemic control (HbA1c 64 mmol/mol)**. - These agents work by enhancing satiety, slowing gastric emptying, and stimulating glucose-dependent insulin secretion, making them highly effective in this clinical scenario. *Orlistat 120 mg three times daily with meals* - **Orlistat** inhibits **gastric and pancreatic lipases**, reducing dietary fat absorption and leading to modest weight loss, but it lacks the robust **glycaemic benefits** of GLP-1 agonists. - Its efficacy is often limited by common gastrointestinal side effects such as **steatorrhea** and flatulence, which can affect adherence. *Phentermine as short-term appetite suppressant* - **Phentermine** is a sympathomimetic appetite suppressant generally intended for **short-term use** (typically <12 weeks) due to potential for **cardiovascular side effects** (e.g., hypertension, tachycardia) and risk of dependence. - It is not suitable for long-term weight management in a patient with **Type 2 Diabetes** and does not provide comprehensive **glycaemic control** benefits. *Naltrexone-bupropion combination therapy* - This combination targets central pathways involved in **appetite and reward**, promoting weight loss, but it is often considered a second-line agent compared to GLP-1 agonists in patients with **Type 2 Diabetes**. - While effective, it typically does not offer the same magnitude of **HbA1c reduction** and established guideline preference as GLP-1 receptor agonists in this specific patient population. *Increase metformin to maximum dose for weight benefits* - The patient is already on **metformin 1g BD**, and while metformin is weight-neutral or can cause mild weight loss, further increasing the dose is unlikely to achieve clinically significant **weight reduction** for a patient with a BMI of 38 kg/m². - Her persistent **HbA1c of 64 mmol/mol** indicates a need for a more potent glucose-lowering and weight-reducing agent beyond maximum metformin monotherapy.

Question 147: A 66-year-old woman with a 45 pack-year smoking history attends after successfully quitting smoking 2 months ago using varenicline. She remains abstinent and asks about lung cancer screening, having read about it online. She has mild COPD (FEV1/FVC 0.68, FEV1 78% predicted) but no respiratory symptoms currently. What is the most appropriate advice?

A. She should have annual chest X-rays through her GP
B. She should have a one-off CT chest now she has quit smoking
C. She is not eligible as she has already quit smoking
D. She is eligible for the NHS targeted lung health check programme (Correct Answer)
E. Lung cancer screening is not currently available through NHS

Explanation: ***She is eligible for the NHS targeted lung health check programme*** - The **NHS Targeted Lung Health Check (TLHC)** program is aimed at individuals aged **55 to 74** who have ever smoked, including those who have recently quit. - Her age (66) and **45 pack-year smoking history** qualify her as high-risk, making her eligible for assessment and potential **low-dose CT (LDCT)** screening. *She should have annual chest X-rays through her GP* - **Chest X-rays** are not recommended for lung cancer screening due to their low **sensitivity** in detecting early-stage lung nodules. - Studies have shown that **annual chest X-rays** do not significantly reduce **lung cancer mortality**, unlike **low-dose CT** screening. *She should have a one-off CT chest now she has quit smoking* - Lung cancer screening through programs like TLHC involves a **systematic risk assessment** rather than an immediate, self-requested "one-off" CT scan. - If deemed high risk, the screening protocol typically involves **serial low-dose CT scans** at specific intervals, not just a single baseline scan. *She is not eligible as she has already quit smoking* - Eligibility criteria for lung cancer screening explicitly include **former smokers**, often those who have quit within the last **15 years**, due to their continued elevated risk. - Quitting only **2 months ago** means her cumulative smoking risk remains significant, making her a prime candidate for screening. *Lung cancer screening is not currently available through NHS* - This statement is incorrect; the **NHS Targeted Lung Health Check** program has been actively rolling out across England since 2019. - The program aims to become a **national screening programme** for lung cancer, demonstrating its current availability and expansion.

Question 148: A 29-year-old woman attends at 8 weeks gestation in her first pregnancy. She had a previous early miscarriage at age 26. She is of white British ethnicity with no family history of haemoglobinopathy. Her booking blood tests show: Hb 108 g/L, MCV 72 fL. Iron studies show ferritin 8 mcg/L. What is the most appropriate next step regarding antenatal screening?

A. Start iron supplementation and proceed with routine antenatal screening only
B. Offer haemoglobinopathy screening with Hb electrophoresis before starting iron (Correct Answer)
C. Check serum B12 and folate before further action
D. Arrange immediate partner screening for haemoglobinopathy
E. Start iron supplementation and arrange Hb electrophoresis simultaneously

Explanation: ***Offer haemoglobinopathy screening with Hb electrophoresis before starting iron***- The patient presents with **microcytic anaemia** (MCV 72 fL) and low **ferritin** (8 mcg/L), which necessitates investigation for underlying **haemoglobinopathies** in pregnancy, regardless of ethnicity. - It is crucial to perform **Hb electrophoresis** *before* starting iron supplementation because severe iron deficiency can cause a **false decrease in HbA2 levels**, which could mask a diagnosis of **beta-thalassaemia trait**. *Start iron supplementation and proceed with routine antenatal screening only*- Although **iron deficiency** is present, starting iron without prior **haemoglobinopathy screening** in a patient with microcytosis can obscure or delay the diagnosis of an underlying genetic condition.- Routine antenatal screening is insufficient when **microcytic anaemia** has already been identified; specific diagnostic tests like Hb electrophoresis are required. *Check serum B12 and folate before further action*- Deficiencies in **vitamin B12** and **folate** typically lead to **macrocytic anaemia** (high MCV), which is not consistent with this patient's **low MCV** of 72 fL.- These tests would not address the primary concern of identifying a potential **haemoglobinopathy**, which is indicated by the microcytic picture. *Arrange immediate partner screening for haemoglobinopathy*- Partner screening is only indicated and useful if the mother is first confirmed to be a **carrier** of a clinically significant **haemoglobinopathy** (e.g., thalassaemia or sickle cell trait).- The initial and most appropriate step is to establish the mother's **carrier status** definitively through her own diagnostic tests. *Start iron supplementation and arrange Hb electrophoresis simultaneously*- While it may seem efficient, commencing **iron supplementation** can quickly alter erythropoiesis and haemoglobin synthesis, potentially impacting the accurate interpretation of the **Hb electrophoresis** results.- Current guidelines emphasize obtaining a baseline **Hb electrophoresis** result prior to initiating **iron therapy** to avoid misdiagnosis, especially regarding **HbA2 levels**.

Question 149: A 40-year-old man attends for an NHS Health Check. He works as a taxi driver, sits for most of the day, and does no regular exercise. His BMI is 27 kg/m², blood pressure 128/82 mmHg, and QRISK3 score 8%. He is keen to reduce his cardiovascular risk. What evidence-based lifestyle intervention has the strongest evidence for cardiovascular disease prevention in this patient?

A. Reducing dietary saturated fat intake to <10% total energy
B. Achieving 150 minutes of moderate-intensity aerobic activity per week (Correct Answer)
C. Weight loss of 5-10% body weight through calorie restriction
D. Increasing daily fibre intake to 30 grams per day
E. Reducing alcohol consumption to within recommended limits

Explanation: ***Achieving 150 minutes of moderate-intensity aerobic activity per week*** - Regular **physical activity** has the most robust evidence for primary prevention of cardiovascular disease (CVD), showing a significant reduction in risk. - For a **sedentary patient** like a taxi driver, physical activity directly improves metabolic health, **blood pressure**, and lipid profiles, independent of other factors. *Reducing dietary saturated fat intake to <10% total energy* - While **reducing saturated fats** and replacing them with polyunsaturated fats lowers lipids, its impact on overall CVD mortality is generally smaller than that of consistent physical activity. - This intervention is a standard part of a healthy diet but is rarely as effective on its own as a multi-modal exercise regimen for primary prevention. *Weight loss of 5-10% body weight through calorie restriction* - Although this patient has a **BMI of 27 kg/m²** (overweight), calorie restriction alone is less effective for long-term CVD risk reduction than increasing **cardiorespiratory fitness**. - Weight loss improves individual risk factors, but exercise provides unique **cardioprotective benefits** and metabolic improvements that diet-induced weight loss alone may lack. *Increasing daily fibre intake to 30 grams per day* - High **fibre intake** is associated with lower cholesterol and improved bowel health, but the evidence for isolated fibre supplementation as the strongest standalone intervention is weaker than for regular exercise. - It serves as a supportive measure in comprehensive **dietary modifications** rather than the primary lifestyle intervention with the strongest evidence base for CVD prevention. *Reducing alcohol consumption to within recommended limits* - While **excessive alcohol** consumption increases CVD risk and blood pressure, reducing consumption does not offer the same comprehensive and robust protection as consistent **aerobic activity**. - There is no indication in the patient's presentation that he is currently exceeding the **recommended alcohol limits**, making it less likely to be the *strongest* evidence-based intervention for *this* patient.

Question 150: A 58-year-old woman attends discussing her recent NHS breast screening result which shows scattered fibroglandular densities and is otherwise normal (M1). She has a strong family history: her mother was diagnosed with breast cancer at age 42, and her maternal aunt at age 38. She asks about additional screening. What is the most appropriate management?

A. Continue with routine NHS breast screening every 3 years
B. Arrange annual mammography through standard NHS services
C. Refer to clinical genetics for risk assessment and consideration of enhanced surveillance (Correct Answer)
D. Arrange MRI breast screening immediately
E. Recommend bilateral prophylactic mastectomy

Explanation: ***Refer to clinical genetics for risk assessment and consideration of enhanced surveillance*** - This patient has a **significant family history** (mother diagnosed at 42, maternal aunt at 38), indicating a potential **moderate to high lifetime risk** of breast cancer. - Referral to **clinical genetics** allows for a formal **risk assessment**, genetic counseling, and potential **genetic testing** (e.g., for BRCA mutations) to guide appropriate **enhanced surveillance** strategies. *Continue with routine NHS breast screening every 3 years* - Routine screening is appropriate for women at **average risk**, but this patient's strong family history places her at a potentially **higher risk**. - This option would fail to identify and manage her elevated risk, potentially delaying the detection of breast cancer if it were to occur. *Arrange annual mammography through standard NHS services* - While **annual mammography** is a form of enhanced surveillance, it should be initiated only after a formal **risk assessment** by clinical genetics or a specialist breast unit. - Ordering it directly without a comprehensive risk evaluation is not the appropriate first step in managing her family history. *Arrange MRI breast screening immediately* - **Breast MRI** is reserved for women identified as being at **very high risk** (e.g., confirmed BRCA carriers or lifetime risk >30%) after a detailed risk assessment. - Prescribing it immediately without a formal risk stratification is premature and not evidence-based for initial management of family history. *Recommend bilateral prophylactic mastectomy* - **Bilateral prophylactic mastectomy** is a drastic measure considered only for women at **extremely high risk** (e.g., confirmed BRCA1/2 mutation) after extensive counseling and shared decision-making. - Recommending such surgery at this stage, before any formal risk assessment or genetic testing, is highly inappropriate.

Question 151: A 25-year-old woman receives her first cervical screening invitation. She had the HPV vaccination at age 13 (full 2-dose schedule). She has had one sexual partner and asks if she still needs screening given her vaccination history. What is the most appropriate advice?

A. She does not require screening as she is fully vaccinated against HPV
B. She should attend for screening as vaccination does not provide complete protection (Correct Answer)
C. She should delay screening until age 30 due to her vaccination status
D. She only requires screening if she develops symptoms
E. She requires screening only if she has multiple sexual partners

Explanation: ***She should attend for screening as vaccination does not provide complete protection*** - Although the **HPV vaccine** covers major high-risk types like 16 and 18, it does not provide immunity against **all oncogenic HPV types** that can lead to cervical cancer. - Regular **cervical screening** remains the standard of care for all eligible women starting at age **25**, regardless of their vaccination or sexual history, to detect pre-cancerous changes. *She does not require screening as she is fully vaccinated against HPV* - Vaccination is **prophylactic** and reduces risk significantly but does not eliminate the possibility of infection from non-covered **high-risk HPV** strains. - Guidelines mandate participation in the **screening programme** to detect pre-cancerous changes that the vaccine might not have prevented. *She should delay screening until age 30 due to her vaccination status* - Current protocols state that the first invitation for screening should occur at age **25** for all women, irrespective of whether they received the vaccine at a younger age. - Delaying screening would increase the risk of missing early **cytological abnormalities** or persistent infections that could progress to malignancy. *She only requires screening if she develops symptoms* - Cervical screening is a **preventative tool** designed to detect asymptomatic abnormalities; waiting for symptoms like **intermenstrual bleeding** indicates a possible advanced stage. - Screening is highly effective precisely because it identifies **pre-invasive lesions** before they become symptomatic or cancerous. *She requires screening only if she has multiple sexual partners* - While having **multiple sexual partners** increases the risk of HPV exposure, any level of sexual activity warrants inclusion in the screening programme. - HPV is extremely common, and even a single partner can transmit **high-risk strains**, making universal screening at age **25** essential for safety.

Question 152: A 62-year-old woman attends for her NHS bowel cancer screening result. Her faecal immunochemical test (FIT) shows a result of 85 micrograms of haemoglobin per gram of faeces. She has no gastrointestinal symptoms and takes no regular medications. Her examination is unremarkable. What is the most appropriate next step?

A. Reassure and advise to participate in next screening round in 2 years
B. Repeat FIT in 3 months
C. Arrange colonoscopy via routine referral
D. Refer for urgent colonoscopy via 2-week wait pathway (Correct Answer)
E. Arrange CT colonography

Explanation: ***Refer for urgent colonoscopy via 2-week wait pathway***- A FIT result of **85 μg/g** is a **positive screening result**, significantly exceeding common thresholds for normal findings and indicating the presence of **occult gastrointestinal bleeding**, necessitating an **urgent assessment** via the **2-week wait pathway**.- **Colonoscopy** is the gold standard investigation, as it allows for direct visualization of the colonic mucosa, **biopsy** of suspicious lesions, and removal of **adenomatous polyps**, which are precursors to colorectal cancer.*Reassure and advise to participate in next screening round in 2 years*- Reassurance is inappropriate because the FIT result is **significantly positive**, indicating the presence of occult blood and a potential high risk of **colorectal malignancy**.- Delaying follow-up for two years ignores a current abnormal screening result and risks allowing a potential tumor to progress to an **advanced stage**, reducing treatment efficacy.*Repeat FIT in 3 months*- There is no clinical indication for a repeat test once a **threshold-positive** result has been established through the screening programme, especially with such a high value.- Repeating the test would introduce an unsafe **diagnostic delay**, as FIT levels can fluctuate even in the presence of an underlying **carcinoma**, and the initial high result is already alarming.*Arrange colonoscopy via routine referral*- Routine referral is insufficient because the screening programme criteria for a positive FIT, especially at this high level, are designed to identify patients at high risk who require a **2-week wait (2WW)** pathway.- Rapid investigation via the 2WW pathway is essential to improve outcomes and survival rates by detecting **bowel cancer** at an earlier, treatable stage, aligning with national guidelines.*Arrange CT colonography*- While **CT colonography** is an alternative for those who cannot undergo or are unfit for a colonoscopy, it is not the first-line diagnostic tool for a positive FIT in an otherwise healthy individual.- It lacks the ability to perform **biopsies** of suspicious lesions or therapeutic interventions like **polypectomy**, meaning any positive findings would still require a subsequent diagnostic colonoscopy.

Question 153: A 65-year-old man attends his first NHS abdominal aortic aneurysm (AAA) screening appointment. The ultrasound shows an aortic diameter of 2.8 cm. He is asymptomatic and has well-controlled hypertension. He asks what happens next. What is the most appropriate management?

A. Discharge from screening programme with no further follow-up required
B. Repeat ultrasound in 3 months
C. Repeat ultrasound in 12 months (Correct Answer)
D. Refer to vascular surgery for consideration of elective repair
E. Arrange CT angiography for further assessment

Explanation: ***Repeat ultrasound in 12 months*** - In the **NHS AAA screening programme**, an aortic diameter between **2.5 cm and 2.9 cm** requires annual surveillance; similarly, aneurysms between 3.0 cm and 4.4 cm also warrant **yearly monitoring**. - This patient's measurement of **2.8 cm** falls into the category of a **small AAA**, necessitating annual follow-up to monitor for any expansion. *Discharge from screening programme with no further follow-up required* - Discharge from the screening programme is only appropriate if the aortic diameter is **less than 2.5 cm**, indicating a normal, non-aneurysmal aorta. - A 2.8 cm measurement is considered a **small aneurysm**, requiring ongoing surveillance due to the potential for growth and future complications. *Repeat ultrasound in 3 months* - **Three-monthly surveillance** is reserved for **medium-sized AAAs**, which are typically defined as having a diameter between **4.5 cm and 5.4 cm**. - A 2.8 cm aorta has a very low risk of rapid expansion or rupture, making such frequent monitoring unnecessary and outside standard guidelines. *Refer to vascular surgery for consideration of elective repair* - **Elective repair** or referral to vascular surgery is generally indicated when the aortic diameter reaches **5.5 cm or greater**. - For a 2.8 cm aneurysm, the risk of rupture is minimal, and surgical intervention is not currently warranted. *Arrange CT angiography for further assessment* - **CT angiography** is typically reserved for **pre-operative planning** for larger aneurysms or in cases where ultrasound is inconclusive, rather than for routine surveillance of small AAAs. - **Ultrasound** is the standard, safe, and cost-effective method for initial screening and ongoing surveillance of abdominal aortic aneurysms.

Question 154: A 67-year-old man with COPD (FEV1 55% predicted) attends for review. He continues to smoke 10 cigarettes daily despite previous cessation advice. His BMI is 24 kg/m². He lives alone and manages his activities of daily living independently. He has had one exacerbation requiring oral antibiotics in the past year. His exercise tolerance is limited to 100 meters on the flat. Regarding pulmonary rehabilitation, which statement best represents the evidence for this intervention in his management?

A. Pulmonary rehabilitation improves exercise capacity and quality of life but has no effect on exacerbation rates or mortality
B. Pulmonary rehabilitation should only be offered after smoking cessation is achieved
C. Pulmonary rehabilitation improves exercise capacity, quality of life, and reduces hospital admissions in those with MRC grade 3-5 breathlessness (Correct Answer)
D. Pulmonary rehabilitation is most effective when combined with long-term oxygen therapy
E. Pulmonary rehabilitation is contraindicated in those with FEV1 >50% predicted

Explanation: ***Pulmonary rehabilitation improves exercise capacity, quality of life, and reduces hospital admissions in those with MRC grade 3-5 breathlessness*** - Pulmonary rehabilitation is a comprehensive intervention involving **exercise training** and **education** that significantly reduces **hospital admissions** and improves **health-related quality of life** in COPD patients. - This patient, with exercise tolerance limited to **100 meters** on the flat, likely falls into **MRC grade 3-4 breathlessness**, making him an ideal candidate for rehabilitation as per guidelines. *Pulmonary rehabilitation improves exercise capacity and quality of life but has no effect on exacerbation rates or mortality* - While its effect on **long-term mortality** is debated, strong evidence supports that pulmonary rehabilitation significantly reduces the frequency and severity of **COPD exacerbations** and subsequent hospitalizations. - It helps break the **cycle of inactivity** and deconditioning, which indirectly lessens the impact and improves recovery from future exacerbations. *Pulmonary rehabilitation should only be offered after smoking cessation is achieved* - **Smoking cessation** is crucial for slowing disease progression in COPD, but it is **not a prerequisite** for initiating pulmonary rehabilitation. - Rehabilitation focuses on improving **functional capacity** and **symptom management**, and its benefits are independent of a patient's current smoking status. *Pulmonary rehabilitation is most effective when combined with long-term oxygen therapy* - **Long-term oxygen therapy (LTOT)** is indicated for patients with **chronic hypoxemia** (PaO2 < 8 kPa or < 6.7 kPa with cor pulmonale) to improve survival, not as a standard adjunct to enhance pulmonary rehabilitation. - The benefits of pulmonary rehabilitation on **exercise tolerance** and **quality of life** are well-established, regardless of the patient's need for supplemental oxygen. *Pulmonary rehabilitation is contraindicated in those with FEV1 >50% predicted* - Referral criteria for pulmonary rehabilitation are primarily based on **functional impairment** and **symptom burden**, specifically **dyspnea** (e.g., MRC grade ≥3), rather than a specific FEV1 threshold. - Patients with **moderate airflow obstruction** (FEV1 50-80% predicted) can still experience significant improvements in exercise capacity and quality of life from rehabilitation if they are symptomatic.

Question 155: A 35-year-old asymptomatic woman attends requesting cervical screening. She has never had cervical screening before. She has been sexually active since age 19 with 4 lifetime partners. She completed the HPV vaccination course at age 14. On checking the system, she has not responded to previous screening invitations. What is the most appropriate advice regarding her screening?

A. She does not require screening as she received HPV vaccination
B. Perform cervical screening now as she is overdue (Correct Answer)
C. Advise screening is only required from age 40 for vaccinated women
D. Recommend starting screening at age 50 given her vaccination status
E. Explain that screening could have been deferred to age 30 but should now commence

Explanation: ***Perform cervical screening now as she is overdue*** - In the UK, **cervical screening** begins at **age 25** for sexually active women; as this patient is 35 and has never been screened, she is significantly overdue. - Her prior **HPV vaccination** does not alter the requirement for routine screening, as it does not protect against all high-risk HPV strains. *She does not require screening as she received HPV vaccination* - The **HPV vaccine** offers protection against the most common high-risk HPV types but does not cover all strains that can cause cervical cancer. - Therefore, all vaccinated women must still adhere to standard **cervical screening** guidelines to detect any potential abnormalities. *Advise screening is only required from age 40 for vaccinated women* - There are no current national guidelines that recommend initiating **cervical screening** at age 40 for vaccinated women. - Delaying screening to this age would miss the critical period between **ages 25-39** when pre-cancerous lesions are most frequently detected. *Recommend starting screening at age 50 given her vaccination status* - Starting **cervical screening** at age 50 is significantly beyond the recommended initiation age and would lead to a substantial delay in detecting potential cervical pathologies. - **Vaccination status** does not justify such a late start, as early detection through screening is crucial regardless of vaccination. *Explain that screening could have been deferred to age 30 but should now commence* - Current UK national guidelines specify that **cervical screening** commences at **age 25**, not age 30, for all eligible women. - Regardless of any hypothetical deferrals, the patient is currently **35 years old** and has never been screened, making immediate action necessary.

Question 156: A 48-year-old woman who smokes 25 cigarettes daily attends for smoking cessation support. She has tried to quit three times previously using nicotine replacement therapy (NRT) patches with short-term success only. She is motivated to quit and has set a quit date in 2 weeks. She has no contraindications to pharmacotherapy. Which approach is most likely to result in successful long-term smoking cessation?

A. Varenicline plus behavioural support (Correct Answer)
B. Nicotine replacement therapy patches plus behavioural support
C. Bupropion plus behavioural support
D. Behavioural support alone with no pharmacotherapy
E. Combination NRT (patch plus short-acting NRT) plus behavioural support

Explanation: ***Varenicline plus behavioural support*** - **Varenicline** is a **partial agonist** at the **α4β2 nicotinic acetylcholine receptors**, providing the highest long-term quit rates compared to other monotherapies. - Clinical guidelines recommend this approach as a **first-line therapy**, especially when previous attempts with single forms of **Nicotine Replacement Therapy (NRT)** have failed. *Nicotine replacement therapy patches plus behavioural support* - The patient has already failed to quit three times using **NRT patches**, demonstrating that this **monotherapy** is insufficient for her level of dependence. - While effective compared to placebo, single-form NRT is clinically **less effective** than varenicline or combination NRT strategies. *Bupropion plus behavioural support* - **Bupropion** is an antidepressant that doubles the chances of quitting, but head-to-head trials show it is **inferior to varenicline**. - It is a suitable alternative but typically reserved for patients who have **contraindications** or a preference against varenicline. *Behavioural support alone with no pharmacotherapy* - While **behavioural support** is a vital component of cessation, it has significantly **lower success rates** when used without pharmacological assistance in heavy smokers. - Pharmacotherapy is essential here to manage physical **withdrawal symptoms** and the neurobiological reward associated with smoking 25 cigarettes daily. *Combination NRT (patch plus short-acting NRT) plus behavioural support* - **Combination NRT** (e.g., patch plus gum) is more effective than single NRT, but meta-analyses generally place **varenicline** as the most potent option for long-term success. - It is a viable alternative, but given the patient's history and lack of contraindications, **varenicline** remains the preferred evidence-based recommendation.

Question 157: A 55-year-old man with type 2 diabetes attends for diabetic retinopathy screening. The screening report indicates background diabetic retinopathy (R1) in both eyes with referrable maculopathy (M1). His visual acuity is normal at 6/6 bilaterally and he has no visual symptoms. His HbA1c is 64 mmol/mol and blood pressure 136/84 mmHg. What is the most appropriate management of his screening result?

A. Routine annual diabetic eye screening
B. Refer to ophthalmology for assessment within 6 weeks (Correct Answer)
C. Refer to ophthalmology for urgent assessment within 1 week
D. Increase screening frequency to 6-monthly
E. Optimize glycaemic and blood pressure control then repeat screening in 3 months

Explanation: ***Refer to ophthalmology for assessment within 6 weeks*** - The presence of **referrable maculopathy (M1)** necessitates a referral to an ophthalmology department even if the patient's **visual acuity** is currently normal (6/6). - Under standard screening guidelines, M1 indicates significant features like **exudates or thickening** near the fovea, requiring specialist assessment within a **6-week timeframe**. *Routine annual diabetic eye screening* - This is inappropriate because the patient has graduated from R0/R1 (no/background retinopathy only) to **M1 (referrable maculopathy)**, which requires intervention or closer monitoring. - Continuing **annual screening** would risk missing the window for potential treatment to prevent permanent vision loss. *Refer to ophthalmology for urgent assessment within 1 week* - **Urgent 1-week referrals** are generally reserved for **proliferative retinopathy (R3a)**, vitreous hemorrhage, or sudden vision loss. - While **M1** is serious, it is typically managed as a **prompt/routine referral** rather than an immediate ophthalmic emergency. *Increase screening frequency to 6-monthly* - **6-monthly screening** is often used for patients with **R2 (pre-proliferative)** changes that do not yet meet referral criteria. - Once a patient is graded as **M1**, they must be bridged from the screening program to **direct ophthalmology care** for detailed assessment like OCT. *Optimize glycaemic and blood pressure control then repeat screening in 3 months* - While **HbA1c optimization** (current 64 mmol/mol) and BP control are vital for slowing progression, they do not replace the need for **specialist referral** once M1 is detected. - Delaying clinical assessment for **3 months** while waiting for metabolic changes is non-compliant with safety guidelines for **maculopathy**.

Question 158: A 42-year-old woman with a family history of breast cancer asks about genetic testing. Her mother was diagnosed with breast cancer at age 38, and her maternal aunt at age 45. Both are alive and well after treatment. The patient is asymptomatic with no breast concerns. Using the National Institute for Health and Care Excellence (NICE) familial breast cancer guidelines, what is the most appropriate initial action?

A. Refer directly to clinical genetics service
B. Arrange bilateral mammography
C. Calculate her lifetime risk and refer to family history clinic if >17% at age 40 (Correct Answer)
D. Reassure as she does not meet referral criteria
E. Offer prophylactic tamoxifen therapy

Explanation: ***Calculate her lifetime risk and refer to family history clinic if >17% at age 40*** - According to **NICE guidelines (CG164)**, the primary care management for asymptomatic women with a family history involves a formal **risk assessment** using validated tools like **IBIS** or **BOADICEA**. - A **lifetime risk of 17% to 30%** (moderate risk) or above justifies referral to a **specialist family history clinic** for further evaluation and management. *Refer directly to clinical genetics service* - This action is premature; patients should typically be assessed in a **specialist breast family history clinic** first to determine if they meet the threshold for genetic testing. - Referral to clinical genetics is usually reserved for those with a high probability (often **>10%**) of carrying a **pathogenic mutation** like BRCA1 or BRCA2. *Arrange bilateral mammography* - Routine **mammography** in primary care is not indicated for asymptomatic women under the age of 50 unless they are part of a specific **specialist surveillance program**. - The sensitivity of mammography is reduced in younger women due to **increased breast density**, making it an inappropriate first-line tool in this context. *Reassure as she does not meet referral criteria* - Simple reassurance is incorrect because two relatives diagnosed under age 50 constitutes a **moderate family history**, requiring formal risk calculation. - Ignoring this history would miss the opportunity for **enhanced surveillance** or chemoprevention if her calculated risk is indeed elevated. *Offer prophylactic tamoxifen therapy* - While **tamoxifen** can be used for breast cancer risk reduction, it is initiated by **specialists** in a secondary or tertiary care setting after a thorough risk-benefit discussion. - Primary care clinicians do not initiate **chemoprevention**; their role is to identify and refer patients who may benefit from it based on their **lifetime risk score**.

Question 159: A 70-year-old man is diagnosed with an abdominal aortic aneurysm (AAA) measuring 4.8 cm during his NHS AAA screening appointment. He is asymptomatic, normotensive, and a non-smoker having quit 5 years ago. He takes atorvastatin 20mg for hyperlipidaemia. What is the most appropriate surveillance interval for this patient according to the NHS AAA Screening Programme?

A. Repeat ultrasound in 6 months
B. Repeat ultrasound in 1 year
C. Repeat ultrasound in 3 months (Correct Answer)
D. Urgent vascular surgery referral for consideration of repair
E. CT angiography followed by 3-monthly ultrasound

Explanation: ***Repeat ultrasound in 3 months***- According to the **NHS AAA Screening Programme**, an aneurysm measuring **4.8 cm** falls into the **medium AAA** category (4.5 - 5.4 cm).- For aneurysms in this size range, surveillance scans are recommended every **3 months** to monitor for potential rapid expansion.*Repeat ultrasound in 6 months*- A **6-month interval** is not a standard surveillance period within the **NHS AAA Screening Programme** guidelines.- Standard intervals are typically **annual** for small AAAs or **3-monthly** for medium AAAs.*Repeat ultrasound in 1 year*- **Annual ultrasound surveillance** is reserved for **small AAAs**, defined as those measuring **3.0 - 4.4 cm**.- Since this patient's aneurysm is **4.8 cm**, an annual interval would be insufficient and could miss significant growth towards the **surgical threshold (≥ 5.5 cm)**.*Urgent vascular surgery referral for consideration of repair*- **Surgical referral** is generally indicated for AAAs reaching **≥ 5.5 cm** in diameter, or those showing rapid expansion (e.g., > 1 cm per year).- At **4.8 cm**, the risks associated with elective surgical repair typically outweigh the risk of rupture, making surveillance the appropriate initial approach.*CT angiography followed by 3-monthly ultrasound*- **CT angiography** is primarily used for **pre-operative planning** of AAA repair, not for routine surveillance of unoperated aneurysms.- **Ultrasound** is the preferred method for surveillance due to its non-invasiveness, lower cost, and absence of **ionizing radiation**.

Question 160: A 32-year-old man presents with concerns about his alcohol consumption. He drinks approximately 45 units per week, predominantly on Friday and Saturday evenings. He works full-time and has not experienced any alcohol-related health problems or social consequences. His liver function tests are normal. He is motivated to reduce his intake. Which brief intervention approach is most evidence-based for this patient?

A. Advise immediate abstinence and refer to specialist alcohol services
B. Use FRAMES approach: Feedback, Responsibility, Advice, Menu of options, Empathy, Self-efficacy (Correct Answer)
C. Prescribe naltrexone to reduce cravings
D. Arrange weekly follow-up appointments for the next 3 months
E. Refer to Alcoholics Anonymous

Explanation: ***Use FRAMES approach: Feedback, Responsibility, Advice, Menu of options, Empathy, Self-efficacy***- The **FRAMES approach** is an evidence-based brief intervention for patients with **hazardous drinking** who are motivated to reduce their intake, fitting this patient's profile (45 units/week without dependence or severe consequences).- It empowers the patient by providing **feedback** on risks, emphasizing **responsibility**, offering **advice** and a **menu of options**, showing **empathy**, and building **self-efficacy**, leading to sustained reductions in alcohol consumption.*Advise immediate abstinence and refer to specialist alcohol services*- **Immediate abstinence** and **specialist referrals** are generally reserved for patients with **alcohol dependence**, significant withdrawal risk, or severe alcohol-related health/social problems, which are not present here.- This approach is often too intensive for an individual with **hazardous drinking** who is motivated to reduce, rather than stop, alcohol intake completely.*Prescribe naltrexone to reduce cravings*- **Naltrexone** is a medication primarily indicated for treating **alcohol dependence** by reducing cravings and the pleasurable effects of alcohol, usually as part of a comprehensive treatment plan.- This patient presents as a **hazardous drinker** without evidence of dependence or severe cravings, making pharmacological intervention premature at this stage.*Arrange weekly follow-up appointments for the next 3 months*- While follow-up is beneficial, **weekly appointments** for three months represent an intensive level of care, which may be excessive for a patient with **hazardous drinking** and no immediate complications.- **Brief interventions** typically involve fewer, focused sessions, and a less intensive follow-up schedule might be more appropriate initially, escalating if needed.*Refer to Alcoholics Anonymous*- **Alcoholics Anonymous (AA)** is a self-help group primarily for individuals with **alcohol dependence** who are seeking to achieve and maintain abstinence.- This patient is motivated to **reduce** his intake and does not present with features of dependence that would necessitate referral to AA at this initial assessment.

Question 161: A 58-year-old woman attends her first invitation for breast screening. She is anxious after reading about overdiagnosis and questions the benefit of mammography. She has no breast symptoms and no family history of breast or ovarian cancer. Her mother had breast cancer diagnosed at age 72. Which statement most accurately represents the current evidence for breast screening in her age group?

A. Screening reduces breast cancer mortality by approximately 20% but may lead to overdiagnosis in 10-15% of screen-detected cancers (Correct Answer)
B. Screening reduces breast cancer mortality by approximately 50% with minimal overdiagnosis
C. Screening has no proven mortality benefit but improves quality of life through early detection
D. Screening reduces breast cancer mortality by approximately 40% but 30% of screen-detected cancers represent overdiagnosis
E. Screening reduces all-cause mortality by approximately 20% in women aged 50-70

Explanation: ***Screening reduces breast cancer mortality by approximately 20% but may lead to overdiagnosis in 10-15% of screen-detected cancers*** - Current consensus and large meta-analyses demonstrate a **20% reduction in mortality** for women in the 50-70 age group through mammography. - **Overdiagnosis**, where a screen-detected cancer would never have caused clinical disease, is a recognized harm estimated at **10-15%** of cases. *Screening reduces breast cancer mortality by approximately 50% with minimal overdiagnosis* - A **50% mortality reduction** is an overestimation and does not reflect modern evidence or survival improvements from better treatment. - Claiming **minimal overdiagnosis** ignores significant clinical data regarding the detection of indolent lesions like DCIS. *Screening has no proven mortality benefit but improves quality of life through early detection* - Multiple randomized controlled trials have confirmed a **statistically significant breast cancer-specific mortality benefit** from screening. - Early detection often involves **anxiety and invasive procedures**, so quality of life is not always improved for those overdiagnosed. *Screening reduces breast cancer mortality by approximately 40% but 30% of screen-detected cancers represent overdiagnosis* - A **40% mortality reduction** is significantly higher than the evidence-based estimates used in the UK breast screening programme. - While some controversial studies suggest a **30% overdiagnosis rate**, the widely accepted figure for informed consent is closer to **10-15%**. *Screening reduces all-cause mortality by approximately 20% in women aged 50-70* - Screening reduces **disease-specific mortality** (breast cancer deaths) rather than **all-cause mortality**, which includes all other causes of death. - Because breast cancer accounts for only a fraction of total female deaths, the impact on **overall mortality** is not statistically observable in these trials.

Question 162: A 45-year-old woman with a BMI of 33 kg/m² attends for weight management advice. She has tried multiple diets without sustained success. She has no other comorbidities. Her blood pressure is 128/82 mmHg, fasting glucose 5.2 mmol/L, and lipid profile is normal. She walks 30 minutes three times weekly. What is the minimum initial weight loss target you should discuss with her?

A. 2-3% of initial body weight
B. 5-10% of initial body weight (Correct Answer)
C. 10-15% of initial body weight
D. 15-20% of initial body weight
E. Achieve BMI <30 kg/m²

Explanation: ***5-10% of initial body weight***- This is the recommended **initial weight loss target** as it is achievable and produces **clinically significant health benefits**, including improvements in blood pressure, lipid profile, and glycemic control.- A **5-10% weight loss** can reduce the risk of progressing to type 2 diabetes and improve overall cardiovascular health. *2-3% of initial body weight*- A **2-3% weight loss** is often considered too modest to provide substantial and sustained **health benefits** in individuals with obesity.- While easier to achieve, it may not sufficiently impact associated comorbidities or significantly improve **metabolic markers**. *10-15% of initial body weight*- While a **10-15% weight loss** offers greater health benefits, setting it as an initial target can be **overly ambitious** for many patients.- Such aggressive initial goals can lead to **frustration** and reduce long-term adherence to weight management programs. *15-20% of initial body weight*- A **15-20% weight loss** is typically a goal for more intensive interventions like bariatric surgery or specialized medical weight loss programs.- It is generally **unrealistic** as an initial target for lifestyle changes and could be **demotivating** for patients. *Achieve BMI <30 kg/m²*- While a BMI below 30 kg/m² is a desirable outcome, directly aiming for a specific **BMI threshold** can be less effective as an initial target.- Percentage-based weight loss goals are often more **motivating** because they focus on achievable progress from the individual's starting point.

Question 163: A 28-year-old pregnant woman at 11 weeks gestation attends for her booking appointment. She declines the combined screening test for Down syndrome (nuchal translucency and serum markers). She asks about other screening options available. Which single test should be offered as an alternative?

A. Cell-free fetal DNA testing
B. Quadruple test at 16 weeks (Correct Answer)
C. Non-invasive prenatal testing (NIPT)
D. Amniocentesis at 15 weeks
E. Detailed anomaly scan at 20 weeks

Explanation: ***Quadruple test at 16 weeks***- In the NHS Fetal Anomaly Screening Programme, the **quadruple test** is the standard alternative screening for women who decline or miss the **combined test window** (11+2 to 14+1 weeks).- It is performed between **15+0 and 20+0 weeks** and measures four biochemical markers: **AFP, hCG, uE3, and Inhibin-A**.*Cell-free fetal DNA testing*- While highly sensitive, **cell-free DNA** is not currently offered as a routine first-line screening option in the standard NHS pathway.- It is generally reserved as a secondary screening tool for women who receive a **high-risk result** from the combined or quadruple tests.*Non-invasive prenatal testing (NIPT)**- **NIPT** is functionally identical to cell-free DNA testing and is not the standard alternative to the booking screening in the public health protocol.- It serves as a more accurate screen to reduce the need for **invasive diagnostic procedures** but is not offered primary to all patients.*Amniocentesis at 15 weeks*- This is a **diagnostic test**, not a screening test, and is associated with a small **risk of miscarriage** (approximately 0.5-1%).- Diagnostic testing is only offered following a high-risk screening result or if there are specific known **genetic risks**.*Detailed anomaly scan at 20 weeks*- The **mid-pregnancy anomaly scan** is designed to identify structural abnormalities such as **spina bifida** or cardiac defects.- It is not an effective or primary screening tool for chromosomal conditions like **Down syndrome** (Trisomy 21).

Question 164: A 65-year-old man attends for NHS Health Check. His cardiovascular risk score (QRISK3) is calculated as 18%. He has no known cardiovascular disease. His total cholesterol is 6.2 mmol/L, HDL 1.1 mmol/L, blood pressure 138/84 mmHg, and HbA1c 41 mmol/mol. He is a non-smoker with BMI 27 kg/m². According to NICE guidance, which intervention should be offered first?

A. Arrange carotid Doppler ultrasound
B. Commence atorvastatin 20mg once daily (Correct Answer)
C. Commence aspirin 75mg once daily
D. Lifestyle advice on diet and exercise with review in 3 months
E. Start amlodipine 5mg once daily for blood pressure

Explanation: ***Commence atorvastatin 20mg once daily*** - This patient has a **QRISK3 score of 18%**, which is significantly above the **10% threshold** for offering statin therapy for **primary prevention of cardiovascular disease** according to **NICE guidelines**. - **Atorvastatin 20mg** is the recommended **first-line statin** for this purpose, aimed at reducing **lipid levels** and overall cardiovascular risk. *Arrange carotid Doppler ultrasound* - **Carotid Doppler ultrasound** is typically indicated for patients with symptoms suggestive of **carotid artery disease**, such as **transient ischemic attacks (TIAs)** or **stroke**, to assess for **carotid stenosis**. - It is **not recommended** as a routine screening tool for asymptomatic individuals based solely on a high **QRISK3 score** for primary prevention of CVD. *Commence aspirin 75mg once daily* - **NICE guidance** no longer recommends **aspirin** for the **primary prevention** of cardiovascular disease due to the increased risk of **gastrointestinal bleeding** and other adverse events outweighing the small benefits. - **Aspirin 75mg** is primarily used for **secondary prevention** in patients with established cardiovascular disease (e.g., post-MI, stroke). *Lifestyle advice on diet and exercise with review in 3 months* - While **lifestyle modifications** (diet, exercise) are fundamental for cardiovascular health, they are **insufficient as the sole intervention** for a patient with a **QRISK3 score of 18%**. - **NICE guidelines** explicitly state that drug treatment (statin) should be **offered immediately** alongside lifestyle advice for individuals at this level of risk, rather than waiting for a review. *Start amlodipine 5mg once daily for blood pressure* - This patient's blood pressure is **138/84 mmHg**, which falls within the high-normal range but is generally **below the threshold for initiating pharmacological treatment** for hypertension in primary prevention according to **NICE guidelines**. - **Lifestyle advice** would be the initial recommendation for blood pressure at this level, with ongoing monitoring, rather than immediate medication.

Question 165: A 38-year-old woman presents requesting cervical screening. Her last cervical sample was taken 4 years ago and showed borderline nuclear changes with negative high-risk HPV testing. She has had no abnormal bleeding or discharge. She has had the same male partner for 5 years. Examination reveals a healthy-looking cervix with no lesions. What is the most appropriate management?

A. Arrange repeat cervical screening in 6 months
B. Reassure and advise routine recall in 1 year
C. Offer HPV vaccination followed by screening in 3 months
D. Perform cervical screening now (Correct Answer)
E. Refer for colposcopy

Explanation: ***Perform cervical screening now*** - In the UK cervical screening programme, women aged **25-49** are screened every **3 years**; since her last test was 4 years ago, she is currently overdue. - A previous result showing **borderline nuclear changes** but **negative hrHPV** testing dictates a return to **routine recall**, rather than early surveillance or colposcopy. *Arrange repeat cervical screening in 6 months* - There is no clinical indication for **early recall** at 6 months because the patient is already past her **3-year routine interval**. - Six-month follow-up is typically reserved for follow-up after **treatment for CIN** or previous **hrHPV-positive** results. *Reassure and advise routine recall in 1 year* - Waiting another year would lead to a **5-year interval** between screenings, which exceeds the recommended 3-year frequency for her age group. - Immediate testing is necessary to maintain the safety and efficacy of the **screening schedule**. *Offer HPV vaccination followed by screening in 3 months* - **HPV vaccination** is not used as a clinical intervention to dictate the timing of routine screening for those already at the screening age. - Routine screening should not be delayed or advanced based on vaccination status, as the **screening protocol** remains the same regardless. *Refer for colposcopy* - **Colposcopy** is only indicated if the screening reveals **high-risk HPV** or significant cytological abnormalities (like high-grade spans). - Since her previous result was **hrHPV negative**, she remained at low risk, and there is currently no lesion or symptom to justify an urgent referral.

Question 166: A 52-year-old woman with type 2 diabetes mellitus attends for her annual review. She has a BMI of 31 kg/m². Her HbA1c is 58 mmol/mol. She currently takes metformin 1g twice daily. She smokes 15 cigarettes per day and drinks 25 units of alcohol weekly. Her blood pressure is 142/88 mmHg. Which lifestyle intervention would provide the greatest cardiovascular risk reduction for this patient?

A. Weight reduction of 5-10% body weight
B. Smoking cessation (Correct Answer)
C. Reduction of alcohol intake to <14 units per week
D. Increase physical activity to 150 minutes moderate intensity per week
E. Adoption of a Mediterranean-style diet

Explanation: ***Smoking cessation***- **Smoking cessation** is the single most impactful lifestyle intervention for reducing **cardiovascular risk**, offering a rapid and substantial risk reduction (e.g., approximately **50% reduction** in risk within one year of quitting).- In patients with **Type 2 Diabetes**, smoking significantly exacerbates **atherosclerosis**, causes **endothelial dysfunction**, and increases prothrombotic states, making its elimination the highest priority for risk mitigation.*Weight reduction of 5-10% body weight*- While beneficial for improving **insulin sensitivity**, lowering **HbA1c**, and reducing blood pressure, weight loss typically results in a smaller magnitude of **cardiovascular event reduction** (around 15-20%) compared to smoking cessation.- Although an important goal for overall metabolic health, its immediate and absolute impact on cardiovascular mortality is not as profound as discontinuing **tobacco use**.*Reduction of alcohol intake to <14 units per week*- Reducing high alcohol intake (25 units/week) to recommended limits helps in improving **blood pressure control** and reducing **caloric intake**, which positively impacts cardiovascular health.- The cardiovascular risk reduction from alcohol moderation is notable (estimated 20-30%) but does not supersede the overwhelming benefit of quitting **smoking** in a high-risk individual.*Increase physical activity to 150 minutes moderate intensity per week*- Regular **physical activity** improves lipid profiles, **glycemic control**, and blood pressure, reducing cardiovascular risk by approximately **20-30%**.- While crucial for long-term health and disease management, the absolute reduction in **mortality and morbidity** provided by exercise alone is generally less than that achieved by eliminating **smoking**.*Adoption of a Mediterranean-style diet*- A **Mediterranean-style diet** is associated with significant reductions in major cardiovascular events (e.g., a **30% reduction** in stroke and myocardial infarction) due to its emphasis on whole foods and healthy fats.- Despite its proven benefits for **metabolic health** and primary prevention, it still provides a less dramatic immediate risk reduction than the complete cessation of exposure to **tobacco smoke**.

Question 167: A 60-year-old woman attends for her NHS bowel cancer screening results. Her faecal immunochemical test (FIT) result shows 85 micrograms of haemoglobin per gram of faeces. She is asymptomatic with no change in bowel habit, no weight loss, and no family history of colorectal cancer. Her abdominal examination is unremarkable. What is the most appropriate next step in her management?

A. Reassure and repeat FIT in 2 years
B. Refer for colonoscopy within 2 weeks (Correct Answer)
C. Arrange CT colonography
D. Repeat FIT in 3 months
E. Refer routinely to gastroenterology

Explanation: ***Refer for colonoscopy within 2 weeks*** - In the **NHS Bowel Cancer Screening Programme**, a **FIT result of 85 μg/g** is significantly above the threshold for positivity (often ≥10 μg/g or a higher action threshold) and requires urgent investigation. - A **colonoscopy** is the **gold-standard investigation** for a positive screening test, as it allows for direct visualization, **biopsy** of suspicious lesions, and removal of **precancerous polyps** within a **2-week wait** pathway.*Reassure and repeat FIT in 2 years* - This approach is only appropriate for participants with a **negative FIT result** (below the threshold). - Delaying investigation for a positive test by 2 years would significantly increase the risk of missing a **colorectal malignancy**.*Arrange CT colonography* - While used in some clinical pathways, it is not the **first-line investigation** for a positive screening FIT unless the patient is unfit for a colonoscopy. - Unlike colonoscopy, **CT colonography** does not allow for immediate biopsy or **polypectomy**, necessitating a second procedure if abnormalities are found.*Repeat FIT in 3 months* - There is no role for repeating a **positive FIT**; any single result above the threshold demands definitive investigation. - Repeating the test leads to a **delayed diagnosis** and ignores the established evidence that a single positive result is predictive of pathology.*Refer routinely to gastroenterology* - Screening-positive patients must be managed via the **fast-track 2-week wait (2WW)** pathway to ensure timely cancer diagnosis. - A **routine referral** is inappropriate because the probability of finding cancer or high-risk adenomas is high enough to justify urgent secondary care assessment.

Practice by Chapter

Lifestyle interventions

Practice Questions

UK screening programmes

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free

Screening & Prevention — MCQs

Screening & Prevention — MCQs

On this page